

# Sheffield Hallam University

*Effects of the periodontal pathogens Porphyromonas gingivalis and Tannerella forsythia on platelets*

ANDREWS, Alexander

Available from the Sheffield Hallam University Research Archive (SHURA) at:

<http://shura.shu.ac.uk/24343/>

## A Sheffield Hallam University thesis

This thesis is protected by copyright which belongs to the author.

The content must not be changed in any way or sold commercially in any format or medium without the formal permission of the author.

When referring to this work, full bibliographic details including the author, title, awarding institution and date of the thesis must be given.

Please visit <http://shura.shu.ac.uk/24343/> and <http://shura.shu.ac.uk/information.html> for further details about copyright and re-use permissions.



# Effects of the Periodontal Pathogens *Porphyromonas gingivalis* and *Tannerella forsythia* on Platelets

Alexander M Andrews

A thesis submitted in partial fulfilment of the requirements of Sheffield Hallam

University for the degree of Doctor of Philosophy

December 2018

# Candidate declaration

I hereby declare that:

1. I have not been enrolled for another award of the University, or other academic or professional organisation, whilst undertaking my research degree.
2. None of the material contained in the thesis has been used in any other submission for an academic award.
3. I am aware of and understand the University's policy on plagiarism and certify that this thesis is my own work. The use of all published or other sources of material consulted have been properly and fully acknowledged.
4. The work undertaken towards the thesis has been conducted in accordance with the SHU Principles of Integrity in Research and the SHU Research Ethics Policy.
5. The word count of the thesis is 35,000.

Name	Alexander Michael Andrews
Date	December, 2018
Award	Doctor of Philosophy
Faculty	Health and Wellbeing
Director(s) of Studies	Dr Prachi Stafford

## Abstract

Cardiovascular disease (CVD) accounts for ~17.7 million deaths annually, worldwide. Although several key risk factors including smoking, diet and obesity have been identified, these account for only 40-50% of all cases. Historically, poor oral hygiene and the chronic oral condition, periodontitis, characterised by gum bleeding and tooth loss has been implicated in the aggravation of CVD. It has been postulated that in cases of periodontitis, oral bacterial pathogens including *Porphyromonas gingivalis* and *Tannerella forsythia* can access the vascular system during gum bleeding and inflammatory responses within the periodontal pocket and subsequently contribute to atherosclerosis through interactions with platelets. This study aims to determine how periodonto-pathogens interact with platelets and contribute to CVD, specifically atherosclerosis.

Here it is demonstrated that the CHR-288-11 megakaryocytic-like cells can be utilised through a series of methodologies to study the pathogenic effects of periodontal pathogens on platelets and megakaryocytic cells. *In vitro* *P. gingivalis*, but not *T. forsythia*, is able to interact with platelets by inducing both platelet activation and aggregation. *P. gingivalis* is able to initiate platelet activation through intracellular calcium mobilisation that leads to the release of both alpha and dense granules, independent of bacterial outer membrane protein OMPA. *P. gingivalis* NCTC 11834, but not ATCC W50, actively associates and interacts with integrin  $\alpha_2\beta_1$  inducing strain dependent platelet aggregation and could suggest a role for bacterial fimbriae within platelet interactions.

Taken collectively, this data suggests that *P. gingivalis* could contribute to CVD and atherosclerosis through interactions with platelets following invasion of the vasculature. Interestingly, direct interactions between bacterial cells and platelets, as well as bacterial genetics and virulence, appear key to the extent of platelet response and could highlight novel risk factors for future patient treatments.

# Acknowledgments

I would like to take this opportunity to thank Sheffield Hallam University for providing both the opportunity and funding to undertake this PhD project.

I would especially like to thank my supervisor Dr Prachi Stafford for her ongoing support and encouragement throughout the entirety of my time at Sheffield Hallam University. I would also like to thank Dr Sarah Haywood-Small and Professor Tom Smith for all their contributions.

A special mention to Joseph, Laura, Matthew, my parents John and Zoe, and especially Lucy who provide the small things that make the big things happen.

# Table of contents

Candidate declaration.....	i
Abstract.....	ii
Acknowledgments.....	iii
Table of contents.....	iv
List of figures.....	xi
List of tables.....	xv
Abbreviations.....	xvi
Chapter 1: Introduction.....	1
1.1    Introduction Part I: Periodontitis and the oral microbiome.....	2
1.1.1    The oral microbiota.....	2
1.1.2    Oral biofilm formation.....	3
1.1.3    Subgingival biofilm and periodontal disease.....	6
1.1.4    Pathogenic bacterial species.....	9
1.1.4.1 <i>Porphyromonas gingivalis</i> .....	9
1.1.4.2 <i>Tannerella forsythia</i> .....	15
1.2    Introduction Part II: Platelets.....	17
1.2.1    Megakaryocytes and platelet production.....	17
1.2.2    Platelet morphology and ultrastructure.....	19
1.2.2.1    The open canalicular system.....	19
1.2.2.2    The dense tubular system.....	21
1.2.2.3    Alpha granules, dense granules and lysosomes.....	21

1.2.3	Platelet receptors .....	23
1.2.4	Platelet integrins/glycoproteins .....	26
1.2.4.1	Integrin $\alpha$ IIb $\beta$ 3/GPIIb/IIIa .....	28
1.2.4.2	Integrin $\alpha$ 2 $\beta$ 1/GPIa .....	30
1.2.4.3	GPIb-IX-V .....	31
1.2.5	Platelets in haemostasis.....	33
1.2.5.1	The intrinsic pathway.....	34
1.2.5.2	The extrinsic pathway .....	35
1.2.5.3	The common pathway .....	35
1.2.6	Platelet adhesion, aggregation and plug formation.....	36
1.2.7	The roles of platelet within innate and adaptive immunity .....	37
1.3	Introduction Part III: Periodontitis and cardiovascular disease.....	38
1.3.1	The systemic impact of periodontitis .....	38
1.3.2	Periodontal infection and atherosclerotic vascular disease .....	40
1.4	Research rationale and Thesis aims .....	44
Chapter 2: Materials and methods .....		45
2.1	Materials .....	46
2.2	Antibodies .....	47
2.3	Bacterial Strains and Mutants.....	49
2.4	Bacterial Growth .....	50
2.4.1	Long Term Bacterial Storage .....	50
2.5	Megakaryocytic Cell Culture and Differentiation.....	51
2.5.1	Megakaryocyte Cell Line CHR-288-11.....	51

2.5.2	Cell Passaging .....	51
2.5.3	Cryopreservation of Cells .....	51
2.5.4	CHRF-288-11 Differentiation .....	52
2.5.5	Cell Counting .....	52
2.6	Platelet Isolation.....	52
2.6.1	Blood collection .....	53
2.6.2	Platelet rich plasma preparation .....	53
2.6.3	Platelet poor plasma preparation .....	53
2.6.4	Modified Tyrode's Buffer .....	53
2.7	Phenotypic Analysis Methods .....	54
2.7.1	Antibiotic Protection Assays .....	54
2.7.2	Immunofluorescent Microscopy .....	55
2.7.2.1	Phenotypic characterisation of CHRF-288-11 differentiation .....	55
2.7.2.2	Phenotypic evaluation of bacterial challenge on differentiated CHRF-288-11 cells .....	56
2.7.2.3	Visualisation of platelets challenged with perio-pathogens .....	57
2.7.3	Electron microscopy .....	58
2.7.3.1	2.8.3.1 White's Saline .....	58
2.7.3.2	Electron microscopy of platelet/perio-pathogen interactions .....	58
2.7.4	Flow cytometry .....	59
2.7.4.1	Relative expression of platelet markers by CHRF-288-11 cells.....	59
2.7.4.2	Phenotypic analysis of platelet/perio-pathogen interactions .....	60
2.7.5	Enzyme linked immunosorbent assays (ELISAs).....	61

2.7.5.1	Development of a cell-based ELISA .....	61
2.7.5.2	Recombinant protein-based ELISA .....	62
2.8	Platelet Function Methodology .....	63
2.8.1	Platelet Aggregation .....	63
2.8.1.1	Agonist preparation .....	63
2.8.1.2	Platelet inhibitors .....	64
2.8.1.3	Light transmission aggregometry .....	64
2.8.2	Platelet Calcium Mobilisation .....	65
2.8.3	Platelet Granule Release Quantitation by Enzyme-linked Immunosorbent Assay (ELISA) .....	66
2.9	Statistical Analysis .....	66
Chapter 3: Characterisation of an <i>in vitro</i> cellular model to study platelet-periodontal pathogen interactions.....		
		67
3.1	Introduction .....	68
3.2	Aims .....	69
3.3	Results.....	70
3.3.1	Optimisation of CHRF-228-11 differentiation .....	70
3.3.2	Periodontal pathogen invasion and adhesion of CHRF-288-11 cells .....	75
3.3.3	Analysis of CHRF-288-11 interactions with periodontal pathogens by immunofluorescent microscopy .....	82
3.3.3.1	Analysis of CHRF-288-11 mTOR expression following incubation with periodontal pathogens .....	82
3.3.3.2	Analysis of CHRF-288-11 integrin $\beta$ 3 expression following incubation with periodontal pathogens .....	87

3.3.4	Flow cytometric analysis of megakaryocytic/platelet markers following <i>P. gingivalis</i> challenge .....	92
3.3.5	Development of a cell-based ELISA for immunophenotyping of CHRF-288-11 cells following periodontal pathogen challenge .....	94
3.3.5.1	Is <i>P. gingivalis</i> association and interaction with CHRF-288-11 dependent on the multiplicity of infection?.....	96
3.4	Discussion.....	100
3.5	Summary.....	107
Chapter 4: Can periodontal pathogens interact with and induce platelet aggregation? .....		108
4.1	Introduction .....	109
4.2	Aims .....	110
4.3	Results.....	111
4.3.1	Platelet aggregation with wildtype <i>P. gingivalis</i> and <i>T. forsythia</i> .....	111
4.3.2	Investigation of the effect of bacterial virulence on platelet aggregation in induced by <i>P. gingivalis</i> .....	113
4.3.3	Investigation of aggregation induced by <i>T. forsythia</i> mutants .....	115
4.3.4	Investigations into the effect of bacterial viability on platelet aggregation .....	116
4.4	Discussion.....	119
4.5	Summary.....	125
Chapter 5: Development and characterisation of a multicolour flow cytometry panel .....		126

5.1	Introduction .....	127
5.2	Aims .....	129
5.3	Method development and gating strategy.....	130
5.3.1	Panel selection.....	130
5.3.2	Flow cytometer instrument configuration.....	131
5.4	Results.....	136
5.4.1	Antibody optimisation .....	136
5.4.2	Gating strategy .....	138
5.5	Adaptation of stimulated population.....	140
5.6	Discussion.....	144
5.7	Summary.....	147
Chapter 6: The effect of periodontal pathogens on platelet function and protein expression .....		148
6.1	Introduction .....	149
6.2	Aims .....	150
6.3	Results.....	151
6.3.1	Analysis of platelet- <i>P. gingivalis</i> interactions by immunofluorescence microscopy.....	151
6.3.2	Investigation of platelet aggregates by electron microscopy.....	157
6.3.3	Analysis of platelet activation and bacterial association by flow cytometry .....	161
6.3.4	Induction of calcium mobilisation by periodontal pathogens .....	167

6.3.5	Investigations into platelet degranulation by <i>P. gingivalis</i> .....	171
6.3.6	Does the secretome of <i>P. gingivalis</i> induce platelet aggregation?.....	173
6.3.7	Investigation of platelet receptor inhibitors on <i>P. gingivalis</i> induced platelet aggregation .....	177
6.3.7.1	The effect of Toll-like receptor inhibitors on <i>P. gingivalis</i> induced platelet aggregation .....	177
6.3.7.2	The effects of integrin $\alpha_2\beta_1$ and $\beta_3$ inhibitors on <i>P. gingivalis</i> -induced platelet aggregation .....	180
6.3.8	Development of a recombinant protein-based ELISA for the detection of <i>P.gingivalis</i> -platelet integrin interactions .....	186
6.4	Discussion.....	188
6.5	Summary.....	198
Chapter 7: General discussion and future directions .....		199
7.1	Introduction .....	200
7.2	The use of CHRF-288-11 cells as an <i>in vitro</i> platelet model .....	200
7.3	Development of a multiparameter flow cytometry panel .....	201
7.4	Periodontal pathogens and platelet interactions .....	202
7.5	Future Directions.....	203
Bibliography.....		210
Ethical approval .....		256
Copyright licences.....		257

## List of figures

Figure 1.1 Tooth, a cross section of an adult human molar. ....	2
Figure 1.2 Model of biofilm formation on the tooth surface.....	5
Figure 1.3 Periodontal disease progression.. ....	7
Figure 1.4 Bacterial complexes of the oral microbiome.....	8
Figure 1.5 The cell lineage of megakaryocytes. ....	17
Figure 1.6 Representation of the 24 prototypical mammalian integrins.. ....	27
Figure 1.7 The structure of integrin $\alpha\text{IIb}\beta\text{3}$ .....	29
Figure 1.8 The GPIb-IX-V complex. ....	32
Figure 1.9 The intrinsic, extrinsic and common pathways of the coagulation cascade. ....	34
Figure 1.10 Schematic representation of the potential role of periodontal pathogens in atherosclerotic vascular disease progression. ....	42
Figure 3.1 CHRF-288-11 differentiation with 10 ng/ml of PMA.....	71
Figure 3.2 CHRF-288-11 differentiation using 50 ng/ml of PMA.....	72
Figure 3.3 Analysis of megakaryocytic protein expression following CHRF-288-11 differentiation.....	74
Figure 3.4 Invasion of CHRF-288-11 cells by <i>P. gingivalis</i> NCTC 11834. ....	76
Figure 3.5 <i>P. gingivalis</i> invades differentiated CHRF-288-11 cells. ....	77
Figure 3.6 CHRF-288-11 cellular invasion by <i>T. forsythia</i> ATCC 43037.....	78
Figure 3.7 Invasion of differentiated CHRF-288-11 cells by <i>T. forsythia</i> ....	79
Figure 3.8 Bacterial adhesion and invasion of CHRF-288-11 cell by periodontal pathogens.....	81
Figure 3.9 The effect of <i>P. gingivalis</i> invasion on mTOR expression in CHRF-288-11 cells. ....	83

Figure 3.10 Determination of mTOR expression following exposure to <i>T. forsythia</i> in CHRF-288-11 cells. ....	84
Figure 3.11 <i>P. gingivalis</i> decreases mTOR expression in differentiated CHRF-288-11 cells. ....	85
Figure 3.12 Effect of <i>T. forsythia</i> invasion on mTOR expression in differentiated CHRF-288-11 cells.....	86
Figure 3.13 The effect of <i>P. gingivalis</i> invasion on integrin $\beta$ 3 expression in CHRF-288-11 cells.....	88
Figure 3.14 Relative integrin $\beta$ 3 expression following exposure to <i>T. forsythia</i> ATCC 43037.....	89
Figure 3.15 The effect of <i>P. gingivalis</i> invasion on integrin $\beta$ 3 expression by differentiated CHRF-288-11 cells.....	90
Figure 3.16 <i>T. forsythia</i> increases $\beta$ 3 expression in differentiated CHRF-288-11 cells..	91
Figure 3.17 Quantitation of megakaryocytic surface marker expression following challenge with <i>P. gingivalis</i> using flow cytometry. ....	93
Figure 3.18 Analysis of bacterial association and integrin expression by a cell-based ELISA.....	95
Figure 3.19 Specific periodontal pathogen interaction with differentiated CHRF-288-11 cells.. ....	97
Figure 3.20 The effect of MOI on periodontal pathogen induced integrin expression in differentiated.....	99
Figure 4.1 Induction of platelet aggregation by wildtype (WT) periodontal pathogens. ....	112
Figure 4.2 The effect of virulence associated proteins on platelet aggregation.. ....	114
Figure 4.3 Platelet aggregation by <i>T. forsythia</i> WT strain and mutants.....	115

Figure 4.4 The effect of bacterial viability on platelet aggregation. s.....	118
Figure 5.1 Reagent titrations.....	137
Figure 5.2 Platelet gating strategy.....	139
Figure 5.3 Representative revised gating strategy of platelet isolation.....	140
Figure 5.4 Isolation of pathogen associated platelets.....	142
Figure 5.5 Comparative histograms of platelet activation following exposure to <i>P. gingivalis</i> .). .....	143
Figure 6.1 <i>P. gingivalis</i> localises and associates with platelets.....	152
Figure 6.2 The effect of <i>P. gingivalis</i> on platelet integrin $\beta$ 1 expression.. .....	153
Figure 6.3 The effect of <i>P. gingivalis</i> on platelet integrin $\beta$ 3 expression. ....	154
Figure 6.4 Platelet aggregate phenotyping by immunofluorescence microscopy.....	156
Figure 6.5 Phenotypic analysis of platelet aggregates by scanning electron microscopy (SEM).....	158
Figure 6.6 Visualisation of platelet aggregates by transmission electron microscopy (TEM).....	160
Figure 6.7 Detection of wild-type periodontal pathogen-platelet association by flow cytometry. ....	162
Figure 6.8 Expression of platelet activation markers following association with <i>P. gingivalis</i> .....	163
Figure 6.9 The role of <i>P. gingivalis</i> outer membrane protein A (OMPA) in platelet association.....	165
Figure 6.10 <i>P. gingivalis</i> outer membrane protein (OMP) deficient mutants induce platelet activation.....	166
Figure 6.11. Platelet calcium mobilisation is induced by wild type periodontal pathogens.....	168

Figure 6.12 Platelet calcium mobilisation is induced by OMPA deficient <i>P. gingivalis</i> mutants.....	170
Figure 6.13 Induction of platelet degranulation by wild type <i>P. gingivalis</i> .....	172
Figure 6.14 Platelet aggregatory response following exposure to <i>P. gingivalis</i> culture supernatant.....	174
Figure 6.15 <i>P. gingivalis</i> LPS as a platelet agonist.....	176
Figure 6.16 The effect of Toll-like receptor inhibitors on <i>P. gingivalis</i> induced platelet aggregation.....	178
Figure 6.17 The effects of Toll-like receptor inhibitors on <i>P. gingivalis</i> -platelet interactions.....	179
Figure 6.18 Representative aggregation plots following incubation with integrin $\beta_3$ inhibitor.....	181
Figure 6.19 Representative aggregation plots following incubation with integrin $\alpha_2\beta_1$ inhibitor.....	182
Figure 6.20 Effects of integrin $\beta_3$ inhibitor on <i>P. gingivalis</i> NCTC 11834 induced platelet aggregation.....	184
Figure 6.21 Effects of integrin $\alpha_2\beta_1$ inhibitor on <i>P. gingivalis</i> NCTC 11834 induced platelet aggregation.....	185
Figure 6.22 Detection of <i>P-gingivalis</i> -integrin binding by recombinant protein-based ELISA.....	187
Figure 7.1 Circular representation of the <i>P. gingivalis</i> NCTC 11834, ATCC 381 and ATCC W50 genomes.....	207

## List of tables

Table 1.1 Platelet granules and their primary functions..	22
Table 1.2 Major platelet receptors and their ligands/agonists.....	25
Table 1.3 Theoretical mechanisms proposed to how explain periodontal disease may have a systemic impact. ....	39
Table 2.1 Manufacturers and suppliers. ....	46
Table 2.2 Bacterial specific antibodies used within this study.....	47
Table 2.3 Primary antibodies used throughout this study.....	48
Table 2.4 Secondary antibodies used throughout this study. ....	48
Table 2.5 Bacterial strains and mutants used within this study..	49
Table 2.6 Platelet inhibitors. ....	64
Table 5.1 Flow cytometer instrument configuration.....	132
Table 5.2 Commercial reagents used.....	133
Table 5.3 Representative compensation matrix. ....	134

## Abbreviations


Adenosine diphosphate	ADP
Bicinchoninic acid	BCA
Bovine serum albumin	BSA
Brain heart infusion broth	BHI
Colony forming units	CFU
Dimethyl sulfoxide	DMSO
Enzyme-linked immunosorbent assay	ELISA
Epoxypropane	EPP
Ethylenediaminetetraacetic acid	EDTA
Fastidious anaerobic agar	FA
Foetal bovine serum	FBS
Fura-2-acetoxymethyl ester	Fura-2/AM
Heat killed	HK
Hexamethyldisilazane	HEX
Immunofluorescence	IF
Interleukin 1 $\beta$	IL-1 $\beta$
Lipopolysaccharide	LPS
Lipopolysaccharide	LPS
Lithium dodecyl sulphate	LDS
Multiplicity of infection	MOI
N-acetylmuramic acid	NAM
Optical density	O.D.
Phorbol 12-myristate 13-acetate	PMA
Phosphate-buffered saline	PBS
Platelet factor 4	PF4
Platelet poor plasma	PPP
Platelet rich plasma	PRP
Room temperature	RT
Scanning electron microscopy	SEM
Sodium dodecyl sulphate	SDS
Toll-like receptor	TLR
Transmission electron microscopy	TEM
Tris Buffered Saline	TBS
Tris Buffered Saline with Tween	TBST
Tryptic Soy Broth	TSB
Von Willebrand factor	VWF
Wild-type	WT

# **Chapter 1: Introduction**

## 1.1 Introduction Part I: Periodontitis and the oral microbiome

### 1.1.1 The oral microbiota

During gestation, a human infant remains essentially sterile but during birth, immediately acquires microbial communities from the birth canal and surrounding environment (Perez-Muñoz *et al.*, 2017). It is these pioneering bacterial colonies that form the human microbiome resulting in symbiotic relationships that inhabit various areas of the human body, including the skin, digestive tract and the mouth (Costello *et al.*, 2012). The oral cavity, provides distinct microbial habitats including the tongue, cheek, lip and oesophagus, as well as specific localised areas such the gingiva and the enamel (Xu *et al.*, 2015) (Figure 1.1).



**Figure 1.1 Tooth, a cross section of an adult human molar.** A structural, anatomical depiction of the human tooth, showing some areas of biofilm inhabitation such as the enamel and gingiva. (Encyclopaedia Britannica, 2013)


In healthy individuals, the human oral cavity is heavily colonised by a magnitude of microorganisms including bacteria, fungi, viruses and archaea (Winkelhoff *et al.*, 1986; Mager *et al.*, 2003; Wade, 2013). To date, around 700 bacterial species are known to form the complex structure of the human oral microbiota, although it has been hypothesized that a large number are yet to be identified due to lack of successful *in vitro* cultivation (Avila, Ojcius and Yilmaz, 2009). These diverse, polymicrobial, communities that inhabit the oral cavity exist predominantly as biofilms and function as a co-ordinated, fully metabolic society on every surface of the mouth including the teeth, gums, tongue and saliva (Marsh, 2004).

### **1.1.2 Oral biofilm formation**

Biofilms can be defined as dynamic, complex biological systems that house multiple microorganisms providing a protected mode of growth, allowing cells to both survive in hostile environments and diverge to inhabiting new niches (Hall-Stoodley, Costerton and Stoodley, 2004). The first observation of biofilms was made by van Leeuwenhoek, who over 300 years ago described the vast array of 'animalcules' within dental plaques using primitive microscopy (Donlan, 2002). A general theory however, was not developed until 1978, stating that the majority of bacteria grow in biofilms that are adherent to surfaces, enclosed in an extra-cellular polymeric substance matrix and that differ profoundly from their planktonic (floating) counterparts (Costerton, Geesey and Cheng, 1978).

Contrary to initial thoughts, oral biofilm formation is not a simple, uniform process but rather a sequence of complex developmental phases consisting of five stages (Hall-Stoodley, Costerton and Stoodley, 2004). Stages one and two are generally termed as

the association of transient bacteria which is followed by adhesion. Stages three and four are identified as the aggregation of cells into micro-colonies followed by their subsequent growth and maturation. The fifth stage describes a return to the mobile, transient phase following significant bacterial disturbance (Hall-Stoodley, Costerton and Stoodley, 2004). Within the mouth the initial stage which consists of transient bacteria, termed 'early colonisers', pioneer the colonisation process, in hopes of altering the habitat so that it is suitable for other species to populate (Socransky and Haffajee, 2005). These specific early colonisers have the unique ability to adhere to oral surfaces such as the host epithelial cells of the cheeks and gums, other established bacterium or bacterial fragments as well as the salivary pellicle; the latter being a selective, protective barrier between the tooth surface and the oral environment, consisting of host proteins, peptides and other organic molecules (Kolenbrander *et al.*, 1993; Li *et al.*, 2003; Black *et al.*, 2004). A selection of early colonising bacteria (Figure 1.2), depicts the interactions between bacteria and specific adhesion receptors within the salivary pellicle including agglutinins, mucins, phospho-proteins, proline-rich proteins and specific enzymes such as alpha-amylase, known bacterial interactions within the biofilm are also highlighted (Kolenbrander, Andersen, David, *et al.*, 2002). Of the early colonisers, between 47-90% of the cultivatable species consist of *Streptococci* with the remainder population constituting of other genera including *Actinomyces*, *Veillonella* and *Neisseria* (Palmer *et al.*, 2003; Li *et al.*, 2004).




**Figure 1.2 Model of biofilm formation on the tooth surface.** Early colonisers are shown to interact with receptors on the salivary pellicle. Co-aggregation between the early colonisers, *Fusobacterium nucleatum* as well as later colonisers such as *Porphyromonas gingivalis* and *Treponema denticola* are also illustrated. (Kolenbrander, Andersen, David, *et al.*, 2002)

After initial colonisation, further bacterial species can become established within the biofilm through coaggregation; a process which allows cell-to-cell recognition and adhesion between genetically different bacteria, through facilitating mediators called adhesins (Figure 1.2) (Kolenbrander *et al.*, 2006). One such example is the late coloniser *Fusobacterium nucleatum* which is able to coaggregate intergenetically with all known types of oral bacterial species (Gibbons and Nygaard, 1970; Kolenbrander *et al.*, 2010).

### **1.1.3 Subgingival biofilm and periodontal disease**


In healthy individuals, the oral microbiota generally consists predominantly of commensals or non-pathogenic bacteria such as *Streptococci* , *Actinomyces* and *Veilonella* (Jenkinson and Lamont, 2005). However, within a diseased state, the formation of a dysbiotic biofilm together with an increase in the pathogenic bacterial load leads to periodontal diseases, which encompasses any disorder of the tissues surrounding and supporting the teeth (the periodontium) and can affect up to 90% of the global population (Pihlstrom, Michalowicz and Johnson, 2005). Currently, whilst it is well-established that pathogenic bacteria are prevalent within periodontal diseases, the initial trigger or underlying cause which initiates this increase in pathogenic load and results in a diseased state remains to be elucidated. It is currently unclear whether this is a consequence of changes in one or more bacterial species, or whether it is initiated by the host, locally or systemically (Socransky and Haffajee, 2005).

Periodontal disease usually refers to the common inflammatory conditions of gingivitis and periodontitis. Gingivitis, the mildest form, is highly prevalent, effecting between 50-90% of the global population and is easily reversible through routine oral care (Albandar and Rams, 2002). Periodontitis, the chronic inflammatory form of the disease, is characterised by the destruction of the periodontium and surrounding connective tissues, with severe cases resulting in alveolar bone loss and loss of teeth (Lamont *et al.*, 1995; Pihlstrom, Michalowicz and Johnson, 2005). The progression of gingivitis to advanced periodontitis is shown in Figure 1.3.



**Figure 1.3 Periodontal disease progression.** Progression of periodontal disease is measured by the level of inflammation, gum recession and the progressive loss of both connective and bone tissue. The disease has two main classifications: the acute condition, gingivitis and the chronic condition, periodontitis (Hajishengallis, 2015).

Studies conducted by Socransky and colleagues (1998) have shown that several bacterial complexes are associated with either periodontal health or disease. With regard to periodontitis, three bacterial species have been termed the 'red-complex' of perio-pathogens due to their involvement with the disease (Figure 1.4). These gram negative, anaerobic, red complex pathogens; *Porphyromonas gingivalis*, *Tannerella forsythia* and *Treponema denticola* have been associated with periodontal disease with *P. gingivalis* being reported as the keystone pathogen in periodontitis (Lamont *et al.*, 1995; Socransky *et al.*, 1998; Darveau, 2010).



**Figure 1.4 Bacterial complexes of the oral microbiome.** Microbial complexes of the subgingival biofilm including *P. gingivalis*, *T. forsythia* and *T. denticola* termed as the 'red complex'. Bacterial species are colour coded into groups that represent the microbial complexes that exist in clusters within the subgingival plaque. Adapted from Socransky *et al.*, (1998).

Regardless of the initial trigger, 'red complex' pathogens such as *P. gingivalis* are able to integrate within developing biofilms by utilizing certain levels of metabolic cooperation and compatible adhesins provided by early colonizing bacteria (Holt and Ebersole, 2005). It is the growing availability of these factors provided by localised tissue degradation and further bacterial colonisation that drives the increasing population and complexity of the gram-negative, anaerobic bacterial populations resulting in the bacterial community moving from a commensal environment and producing a phenotypical shift to a diseased state (Ruby and Barbeau, 2002; Jenkinson and Lamont, 2005). The progression of periodontal disease from a mild gingivitis state to the chronic, inflammatory state of periodontitis is the consequence of several cycles of tissue destruction caused by the combined impact of the now substantial pathogenic bacterial challenge and subsequent localised inflammatory response by the

host; with the bacterial challenge being suppressed by the host immune response before the cycle repeating itself (Wilson and Henderson, 1995).

#### **1.1.4 Pathogenic bacterial species**

It is clear that the development of periodontal disease is reliant on a series of complex host/bacterial interactions with specific keystone pathogens implicated throughout the progression of the disease (Socransky et al., 1998; Holt and Ebersole, 2005). Of these fundamental pathogens, both *P. gingivalis* and *T. forsythia* have been reproducibly found in elevated numbers in patients with periodontitis (Byrne et al., 2009; Zhu et al., 2013) and although the pathological mechanisms of these bacteria are still under scrutiny, it is their unique virulence qualities that allows them to evade the host immune system and produce the destructive characteristics of the disease (Hernandez et al., 2011).

##### **1.1.4.1 *Porphyromonas gingivalis***

*Porphyromonas gingivalis* is a rod shaped, Gram-negative, non-motile, asaccharolytic, black pigmented, anaerobic bacteria that can exist with or without fimbriae (Mayrand and Holt, 1988). Within the healthy oral flora, *P. gingivalis* can be found in low abundance contributing <5% of the total bacterial population (Fornng et al., 2000), with this number increasing during the conversion from a symbiotic to a dysbiotic microbiota, through accumulation and proliferation of the bacterium within the dental plaque (Haffajee et al., 1998). Despite the aetiology of periodontitis remaining inconclusive, the underlying presence of *P. gingivalis* within periodontitis, coupled with the pathogen's ability to manipulate the oral bacterial community, has led to the classification of *P. gingivalis* as a 'keystone' pathogen within periodontal disease (Hajishengallis, Darveau and Curtis, 2012). As a survival strategy, *P. gingivalis* is known

to adhere to and invade host cells as well as produce a variety of virulence factors in order to acquire nutrients, proliferate and evade the active surveillance of the immune system (Papapanou *et al.*, 1994; Holt *et al.*, 1999). An overview of these bacterial virulence factors are detailed below.

#### **1.1.4.1.1 Lipopolysaccharide**

Lipopolysaccharide (LPS) is a major component of Gram-negative bacterial cell walls which provides membrane stability and structural integrity to the bacteria (Ulevitch and Tobias, 1999). LPS is also able to stimulate host immune response through interactions with various receptors on the host's cells, initiating host cell activation and the production of innate host defence mediators such as proinflammatory cytokines, adhesion molecules and apoptosis (Caroff and Karibian, 2003; Dauphinee and Karsan, 2006). Bacterial LPS consists of three domains; a hydrophobic domain known as lipid A (or endotoxin), a non-repeating 'core' oligosaccharide and a distal polysaccharide O-antigen that interacts with the external environment (Ogawa and Yagi, 2010). The structural composition of LPS can however vary between bacterial species, for example changes within the fatty acid chain composition and charge, which can significantly vary the stimulation of host response. In the case of *P. gingivalis*, LPS released within outer membrane vesicles (Grenier and Mayrand, 1987) can penetrate periodontal tissues and stimulate innate immunity, thus contributing to the progression of periodontal disease (Moore, Wilson and Kieser, 1986; McCoy *et al.*, 1987). Specifically *P. gingivalis* derived LPS has been shown to interact with various mammalian receptors including; toll-like receptor 2 and 4 within endothelial cells (Darveau *et al.*, 2004), activation of monocytes through interactions with CD14 (Shapira *et al.*, 1994) as well as acting as an antagonist for E-selectin suppressing endothelial cell adhesiveness and promoting bacterial colonisation (Darveau *et al.*, 1995). In addition, LPS derived from

*P. gingivalis* have been shown to vary in profile according to clinical isolates and can affect antibiotic resistance to polymyxin B and colony morphology (Díaz *et al.*, 2015). However, despite the plethora of research focussing on *P. gingivalis* LPS, the underlying roles of LPS as well as the basis of inter-stain LPS variation are yet to be fully established.

#### **1.1.4.1.2 Gingipains**

One of the most studied aspects of *P. gingivalis* virulence are a group of cysteine proteases belonging to the peptidase C25 family, termed gingipains (Eichinger *et al.*, 1999). *P. gingivalis* actively expresses three types of gingipain; the arginine specific gingipain A (RgpA), arginine specific gingipain B (RgpB) and a lysine specific gingipain (Kgp) (Curtis *et al.*, 1999). These 'trypsin like' enzymes are known to cleave polypeptides at the C-terminal of the respective arginine and lysine residues (Li and Collyer, 2011) and accounts for ~85% of the proteolytic activity of *P. gingivalis* (Potempa, Pike and Travis, 1997).

Functionally, the gingipains expressed by *P. gingivalis* have been implicated in a number of bacterial and eukaryotic cell interactions. For example, gingipain activity has been shown to facilitate binding of *P. gingivalis* to extracellular matrix proteins such as fibronectin and collagen (O'Brien-Simpson *et al.*, 2005) as well as bacterial adherence to both epithelial and endothelial cells (Pathirana *et al.*, 2007). All three gingipains have also been shown to be involved in nutrient acquisition through haemolysis (Smalley *et al.*, 2008; N. Li *et al.*, 2010), in haem uptake (Simpson, Olczak and Genco, 2004) and in the disruption of the coagulation system via the degradation of fibrinogen (McAlister *et al.*, 2009) and activation of thrombin and factor IX (Imamura *et al.*, 2001).

Previous work by several groups have also linked gingipain protease activity to the disruption of innate immune response through the degradation of multiple signalling peptides including complement proteins (Popadiak *et al.*, 2007), cell surface receptors CD4 (Kitamura *et al.*, 2002) and CD8 (Kitamura *et al.*, 2002), intracellular adhesion molecule 1 (ICAM-1; Tada *et al.*, 2003), as well as several cytokines including IL-1 $\beta$  (Stathopoulou *et al.*, 2009), IL-6 (Banbula *et al.*, 1999), IL-8 (Uehara *et al.*, 2008) and TNF- $\alpha$  (Calkins *et al.*, 1998).

#### **1.1.4.1.3 Hemagglutinins**

Hemagglutinins are a large class of virulence factors that are highly implicated with bacterial adhesion and nutrient acquisition (Han, Whitlock and Progulske-Fox, 1996; Lee, Hillman and Progulske-Fox, 1996; Shi *et al.*, 1999). *P. gingivalis* is known to express at least eight hemagglutinins, of which a subset has been characterised and are known to be encoded by the group of *hag* genes, *hagA-hagE* (Connolly *et al.*, 2017). Hemagglutinins are known to play key role in the absorption of heme, through erythrocyte binding, the facilitation of gingipain activity and agglutination (Lewis *et al.*, 2006; Olczak *et al.*, 2008), as well as been shown to mediate the adherence to both epithelial (Connolly *et al.*, 2017) and endothelial (Song *et al.*, 2005) cells. Further to this, work by Ito and colleagues (2010) identified that the *hagA* gene mediates co-aggregation between *P. gingivalis* and *Treponema denticola*, suggesting a role for hemagglutinin domains within biofilm formation as well as mammalian cell adhesion.

#### **1.1.4.1.4 Fimbriae**

Fimbriae are thin, proteinaceous filaments that protrude from the outer membrane of bacterial cells (Jonson, Normark and Rhen, 2004) and were first identified on *P. gingivalis* by Yoshimura and colleagues (1984). *P. gingivalis* is known to express two

distinct types of fimbriae encoded by the *fimA* gene, termed long/major fimbriae and the *mfa1* gene, termed short/minor fimbriae (Enersen, Nakano and Amano, 2013). Major fimbriae of *P. gingivalis* can be classified into six types; types I-V and Ib which are dependent on amino terminals and DNA sequences (Nakagawa *et al.*, 2000, 2002). Interestingly the presentation of major fimbriae varies between strains of *P. gingivalis*. Strains such as ATCC 381 and NCTC 11834 are highly fimbriated type I strains whereas strains such as ATCC W50 and W83 have much shorter, sparsely populated, type IV fimbriae (Sojar, Hamada and Genco, 1997). Despite the limited characterisation of *mfa1* expression, both major and minor fimbriae are thought to contribute to both bacterial virulence and the progression of periodontal disease (Nakagawa *et al.*, 2002).

The primary role of *fimA* is to promote bacterial adherence to oral surfaces with *fimA* deficient strains presenting a reduced capacity for both adherence (Hamada *et al.*, 1994) and invasion (Njoroge *et al.*, 1997; Weinberg *et al.*, 1997) of oral epithelial cells. It is also thought that minor fimbriae contribute to the adhesive properties of *P. gingivalis* through the coaggregation of bacterial species, the formation of micro-colonies and resistance to shear forces (Lamont *et al.*, 2002; Lin, Wu and Xie, 2006). Further to this, both the major (Ogawa, Uchida and Hamada, 1994) and minor (Amano *et al.*, 2004) fimbriae have been shown to initiate immune response through the stimulation of inflammatory cytokine production by both monocytes and macrophages including interleukin 1 $\beta$ , interleukin 6, interleukin 8 and tumour necrosis factor  $\alpha$  (Ogawa, Uchida and Hamada, 1994; Amano *et al.*, 2004).

#### **1.1.4.1.5 Outer membrane A-like proteins**

Within *Escherichia coli* and other *Enterobacter* species, the outer membrane protein, OmpA, is a highly abundant protein responsible for several functions including acting as an adhesin, an invasin, an evasin as well as forming an immune target and contributing to biofilm formation (Smith *et al.*, 2007). The two major outer membrane subunits which form the OmpA-like protein within *P. gingivalis* have been shown to share a high degree of similarity to that of the OmpA of *E. coli* and have been proposed to hold similar cellular functions (Nagano *et al.*, 2005). Previous research by Iwami and colleagues (2007) identified that OmpA is crucial for membrane stability of *P. gingivalis* with further work by Murakami and colleagues (2014) suggesting that the individual subunits of OmpA could be responsible for glycoprotein interaction. Recently, the OmpA protein, specifically the A2 subunit, has been shown to contribute to both biofilm formation and host-cell interactions with epithelial cells (Naylor *et al.*, 2016), with the *ompA* genes being upregulated in highly invasive populations of *P. gingivalis* (Suwannakul *et al.*, 2010).

#### **1.1.4.1.6 Adherence and invasion**

As well as virulence factors, *P. gingivalis*, like any bacterial species, possess the ability to interact with cellular surfaces of the host cells to acquire necessary growth factors and ultimately to survive the harsh counter measures produced by the host (Stafford *et al.*, 2012). As part of this survival strategy, *P. gingivalis* can adhere to and invade a variety of host cells and tissues by exploiting cellular pathways to evade the active surveillance of the immune system (Papapanou *et al.*, 1994; Lamont *et al.*, 1995; Deshpande, Khan and Genco, 1998; Dorn *et al.*, 2000). After invasion, both pathogens and host cells remain viable for an extended period of time during which several cytological changes take place (Belton *et al.*, 1999; Simin F Nakhjiri *et al.*, 2001; Tribble

*et al.*, 2006). These cytological changes include; remodelling of the tubulin and actin cytoskeleton (Yilmaz *et al.*, 2003), prevention and manipulation of the apoptosis pathway through transcriptome alterations (Simin F Nakhjiri *et al.*, 2001), secretion of an ATP hydrolysing enzyme (Yilmaz *et al.*, 2008), dysregulation of cellular calcium signalling in the host cells (Izutsu *et al.*, 1996), selective targeting of the MAP kinase pathway (Watanabe *et al.*, 2001) and a down regulation of interleukin 8 expression at both the transcriptional and post-transcriptional level (Darveau *et al.*, 1998).

#### **1.1.4.2 *Tannerella forsythia***

*Tannerella forsythia*, an anaerobic, gram negative bacterium of the *Cytophaga-Bacteroides* family, was originally isolated from the oral cavity and described as *Bacteroides forsythus* by Tanner and colleagues (1986).


To date, whilst the presence of *T. forsythia* in periodontitis is well documented through clinical studies, the virulence factors of the bacterium are not fully characterised (Sharma, 2010). Studies have shown that *T. forsythia* adheres to and invades epithelial cells both *in vivo* (Rudney, Chen and Sedgewick, 2005; Colombo *et al.*, 2007) and *in vitro* (Sabet *et al.*, 2003; Inagaki *et al.*, 2006; Sakakibara *et al.*, 2007). In addition, *T. forsythia* is known to induce enzymatic activity that both protect the bacterium from the innate immune system, whilst also digesting host proteins as a molecular resource (Sharma, 2010). Specifically *T. forsythia* is able to trigger an up-regulation of host metalloproteinases (including MMP- 2, 3, 8, 7, 13 14 (Tervahartiala *et al.*, 2000; Kiili *et al.*, 2002), induce neutrophil recruitment, increase inflammatory response (Jusko *et al.*, 2012; Garred *et al.*, 2016) and degrade host proteins such as collagen, elastin, gelatin and casein (Ksiazek, Mizgalska, Eick, *et al.*, 2015). The pathogen also expresses

endolases which can digest fibronectin and induce pro-inflammatory cytokine production (IL-1 $\beta$ , 6, 8 and TNF- $\alpha$ ) (Lee *et al.*, 2015). Furthermore, *T. forsythia* expresses sialidase enzymes, which cleave the sialic acids contained within host's surface glycoproteins (Sharma, 2010). As well as acting as a sources of macronutrients, this process also aides bacterial adhesion to mammalian cells and promotes biofilm development (Godoy *et al.*, 1993; Thompson *et al.*, 2009; Honma, Mishima and Sharma, 2011). *T. forsythia* has also been shown to directly affect host cell transcription by upregulating the expression of an array of host genes (Bakthavatchalu *et al.*, 2011). Taken together, all of these factors ultimately result in cytopathogenic consequences (Nakajima *et al.*, 2006).

## 1.2 Introduction Part II: Platelets

### 1.2.1 Megakaryocytes and platelet production

Megakaryocytes constitute a highly specialized subset of the haematopoietic stem cell lineage, that through proliferation and terminal differentiation give rise to circulatory platelets (Deutsch and Tomer, 2006). Usually residing within red bone marrow, immature megakaryocytes undertake a series of maturation stages (Figure 1.5) which result in the expansion of cytoplasmic mass, measuring >50-100 nm and polyploidization up to 128N (Tomer, Harker and Burstein, 1988; Patel, Hartwig and Italiano, 2005).



**Figure 1.5 The cell lineage of megakaryocytes.** Diploid megakaryocyte progenitor cells, blast forming units (BFU) and colony forming units (CFU), undertake several genetic replications, through endomitosis before reaching maturity. Adapted from Italiano and Hartwig (2007).

Until recently the bone marrow was thought to be the only location for platelet maturation (Levine *et al.*, 1993). Studies have since demonstrated that megakaryocytes have the ability to migrate out of the red marrow and enter the circulatory system before translocating to the extravascular space of the lung tissue where they undertake platelet biogenesis (Lefrançois *et al.*, 2017). However despite these novel findings, the precise understanding of mass platelet production remains to be elucidated.

It was initially hypothesized that platelets stem from long cytoplasmic protrusions, which extend from megakaryocytes, to form what is termed 'pro platelets' (Radley and Scurfield, 1980) and although other mechanisms were proposed, a modified version of the proplatelet hypothesis provides the most reliable model both *in vivo* and *in vitro* (Italiano *et al.*, 1999; Johnson, Fletcher and Morgan, 2016; Ru *et al.*, 2016). This modified model proposes that during the formation of pro platelet, cytoplasmic extensions act as a cellular highway on which megakaryocytes transfer a plethora of cellular structures and proteins to form the anucleate platelets (Deutsch and Tomer, 2006). For example, platelet proteins such as fibrinogen receptors and von Willebrand factor are synthesised by the megakaryocytes before being conveyed to either the newly formed platelet outer-membrane or are packaged into specialised secretory granules (Richardson *et al.*, 2005). Individual organelles such as alpha/dense granules, lysosomes and mitochondria also migrate from the main cellular body of the megakaryocyte, with ~30% of organelles being in motion at any one time (Richardson *et al.*, 2005). During this process, the pro-platelets extend into the sinusoidal space, where they fragment and detach into individual platelets (Machlus and Italiano, 2013). However the underlying mechanism of how platelets are packaged with the necessary organelles and granules remains to be fully understood.

## **1.2.2 Platelet morphology and ultrastructure**

Platelets are small, discoid, anucleate cells, measuring 2-3  $\mu\text{m}$  that hold a fundamental function within haemostasis (Thon and Italiano, 2012). An adult human maintains approximately one trillion platelets, of which two-thirds are in circulation, with the remaining third reversibly sequestered in the spleen (Thon and Italiano, 2010). Circulatory platelets are maintained for 7-10 days, and as well as being anucleate, platelets contain several distinguishing organelles including the open canalicular system, the dense tubular system, as well as alpha and dense granules (Heijnen and Korporaal, 2017).

### **1.2.2.1 The open canalicular system**

The surface connected open canalicular system (OCS) comprises of a complex series of intracellular membrane channels that form an interconnected membrane store with specific function (Heijnen and Korporaal, 2017). As platelets are anucleate and have a limited RNA stores, platelets have restricted capacity for protein synthesis and rely on protein uptake from the surrounding plasma (Zucker-Franklin, 1981). Proteins such as fibrinogen (Harrison *et al.*, 1989) and tissue factor (Escolar *et al.*, 2008) are endocytosed via the OCS and distributed to the relevant organelles, here the alpha granules within the platelet.

The OCS also functions as a cellular delivery system. During platelet activation both alpha and dense granule stores fuse with the OCS and plasma membrane, allowing their content to be trafficked to the cellular surface which does not only facilitate granule release but is also thought to potentiate the activation process (White and Krumwiede, 1987; Fogelson and Wang, 1996).

As well as acting as a cellular transportation network, the OCS is crucial in maintaining the concentration of adhesion receptor levels on the outer membrane (Sixma, 1986; Escolar, Leistikow and White, 1989), by acting as a storage site for glycoprotein adhesion receptors. For example the glycoproteins GPIIb/IIIa (Cramer *et al.*, 1990) and GPIb (Cramer *et al.*, 1990), are found to be evenly expressed between the outer membrane and the OCS. It is hypothesised that the reserves of adhesion molecules contained within the OCS are trafficked to the membrane during activation to upregulate adhesion receptors available during thrombus formation (Escolar, Leistikow and White, 1989). Despite the OCS not being classified as a completely separate cellular component, it is thought that this intracellular plasma membrane (Escolar, Leistikow and White, 1989) as well as secretory alpha granules (Peters, Michelson and Flaumenhaft, 2012) facilitate the membrane remodelling process during platelet spreading and filopodia formation. Whether the OCS and plasma membrane are able to fuse remains to be fully understood but it has been suggested that the OCS is crucial for platelet activation acting as both cellular storage and enabling trafficking of both granule stores and glycoproteins, regulating platelet adhesion and aggregation (Selvadurai and Hamilton, 2018).

### **1.2.2.2 The dense tubular system**

Circulatory platelets do not contain ribosomal endoplasmic reticulum. To compensate for this, platelets contain the dense tubular system (DTS) which is derived from the parent endoplasmic reticulum of megakaryocytes (White, 1972). The DTS is primarily thought to regulate and store intracellular calcium in a similar way to that of the sarcoplasmic reticulum of striated muscle cells (White, 1972). During platelet stimulation the DTS has been shown to rapidly discharge stored calcium ions and raise cytoplasmic calcium concentrations (Dean, 1984; Ware *et al.*, 1986) thereby facilitating multiple aspects of platelet activation including granule centralisation (Kroll and Schafer, 1989) and regulation of aggregation (Nesbitt *et al.*, 2003).

### **1.2.2.3 Alpha granules, dense granules and lysosomes**

One of the defining characteristics of platelet haemostatic activity is their large granular storage; namely the alpha granules, dense granules and lysosomes which contain a number of biologically active molecules (Rendu and Brohard-Bohn, 2001).

Alpha granules, the most abundant of the granules within platelets (40-80 per platelet), contain both soluble proteins which are released extracellularly, and membrane bound proteins that become expressed on the plasma membrane (Blair and Flaumenhaft, 2009). This proteinous payload is highly involved in platelet adhesion as well as wound healing, vascular remodelling, immune response and inflammation (Heijnen and van der Sluijs, 2015). Dense granules are the second most abundant of the platelet granules and house a variety of haemostatically active molecules that are predominantly responsible for recruiting further platelets to the site of vascular insult (Flaumenhaft, 2013). Further to this, platelets are also known to contain few primary and secondary lysosomes. Although their function is not well studied, it has been

suggested that their enzymatic content is involved in endosomal digestion as observed in nucleated cells (Flaumenhaft, 2013). Key alpha granules, dense granules and lysosomes are detailed in Table 1.1.

<b>Granule</b>	<b>Compound</b>	<b>Function</b>
$\alpha$ granule	Platelet factor 4	Neutralises heparin effect/cytokine
	$\beta$ thromboglobulin	Promotes fibroblast chemotaxis
	Platelet derived growth factor	Mitogen for fibroblast and smooth muscle cells. Chemotaxin for neutrophils
	von Willebrand factor	Adhesion molecule
	Thrombospondin	Promotes platelet-platelet interaction
	Fibronectin	Adhesion of platelets and fibroblasts
	Fibrinogen	Promotes adhesion and coagulation
	Factor V	Promotes coagulation
Dense granules	vascular endothelial growth factor	Vascular remodelling
	ADP	Activation of platelets
	ATP	Source of ADP
	Serotonin	Vasoconstriction
Lysosomes	Calcium	Coagulation
	$\beta$ -galactosidase	Glycoside hydrolase
	Acid phosphatase	Hydrolyses acid phosphatases
	hexosaminidase	Hydrolyses hexosamines

**Table 1.1 Platelet granules and their primary functions.** Adapted from Pallister and Watson (2011).

### **1.2.3 Platelet receptors**

Platelets, like many cells types express a multitude of surface receptors in order to sense and interact with their environment. The major platelet receptors as well as their agonist or ligands are summarised in Table 1.2. Platelet integrins/membrane glycoproteins specific to this thesis are reviewed in more detail within Section 1.2.4.


Receptor Classification	Platelet Receptor	Ligand/Agonist	Physiological Role
Integrins	$\alpha 2\beta 1$ (GPIaIIa, CD49b/61)	Collagen	Platelet adhesion and thrombus stabilisation
	$\alpha 5\beta 1$ (CD49e/61)	Fibronectin	Platelet adhesion
	$\alpha 6\beta 1$ (CD49f/61)	Laminin	Platelet adhesion
	$\alpha L\beta 2$ (CD102, ICAM-2))	Leukocyte function-associated antigen 1 (LFA-1)	Leukocyte adhesion
	$\alpha IIb\beta 3$ (GPIIbIIIa, CD41/61)	Fibrinogen, fibrin, von Willebrand factor, fibronectin, vitronectin and thrombospondin	Promotion of platelet aggregation and platelet-platelet binding
	$\alpha V\beta 3$ (CD51/61)	Vitronectin, fibrinogen, von Willebrand factor, prothrombin and thrombospondin	Platelet adhesion
Selectins	P-selectin (CD62P, GMP-140)	P-selectin glycoprotein ligand-1 (PSGL-1), GPIb-IX-V	Expressed during platelet activation through alpha granule release. Binds to neutrophils and monocytes.
	C-type lectin-like receptor-2 (CLEC-2)	Podoplanins and rhodocytin	Platelet aggregation
Leucine-rich repeat receptors	GPIb-IX-V	von Willebrand factor, thrombin, P-selectin, factor XI, factor XII	Platelet adhesion and aggregation
	Toll-like receptor 2 (TLR2)	Identify various products of bacteria, viruses, protozoa and fungi	Innate immune response and platelet activation
	Toll-like receptor 4 (TLR4)	Identify various products of bacteria, viruses, protozoa and fungi	Innate immune response and platelet activation

Receptor Classification	Platelet Receptor	Ligand/Agonist	Physiological Role
Transmembrane receptors	P2X <sub>1</sub>	Adenosine triphosphate (ATP)	Extracellular calcium influx, platelet activation and aggregation
	P2Y <sub>12</sub>	Adenosine diphosphate (ADP), P2Y <sub>1</sub>	Calcium mobilisation, platelet spreading, granule release, thromboxane production, $\alpha_{IIb}\beta_3$ activation and platelet aggregation
	P2Y <sub>1</sub>	Adenosine diphosphate (ADP), P2Y <sub>12</sub>	Calcium mobilisation, platelet spreading, granule release, thromboxane production, $\alpha_{IIb}\beta_3$ activation and platelet aggregation
Immunoglobulin receptors	GPVI	Collagen	Intracellular calcium mobilisation, cytoskeletal rearrangement, granule release, GPIIb/IIIa activation
	Fc $\gamma$ RIIA (CD32)	Binding of GPVI	Intracellular calcium mobilisation, cytoskeletal rearrangement, granule release, GPIIb/IIIa activation
Prostaglandin receptors	Thromboxane A <sub>2</sub> /prostaglandin H <sub>2</sub>	Thromboxane A <sub>2</sub>	Calcium mobilisation and platelet activation
	Prostacyclin receptor (PGI <sub>2</sub> )	Prostacyclin	Platelet inhibitor, retains platelet resting state
Prostaglandin receptors	Thromboxane A <sub>2</sub> /prostaglandin H <sub>2</sub>	Thromboxane A <sub>2</sub>	Calcium mobilisation and platelet activation
	Prostacyclin receptor (PGI <sub>2</sub> )	Prostacyclin	Platelet inhibitor, retains platelet resting state

**Table 1.2 Major platelet receptors and their ligands/agonists.** Adapted from Saboor and colleagues (2013) and Watson, Morgan and Harrison (2015).

#### **1.2.4 Platelet integrins/glycoproteins**

Glycoproteins are a family of transmembrane adhesion and signalling proteins, which within platelets are fundamental to haemostasis and thrombus formation (Clemetson and Polgár, 1997). Many of the glycoproteins expressed by platelets belong to the supergene family of integrins (Saboor *et al.*, 2013). Mammalian integrins are expressed as heterodimers of non-covalently associated  $\alpha$  and  $\beta$  subunits (Hynes, 2002). There are 18  $\alpha$  subunits and eight  $\beta$  subunits that construct the 24 separate heterodimers shown in Figure 1.6.




**Figure 1.6 Representation of the 24 prototypical mammalian integrins.** The integrin family of proteins are constructed of 24 heterodimers, each containing an  $\alpha$  and  $\beta$  subunit. (Barczyk, Carracedo and Gullberg, 2010).

Platelets are known to express six integrins; namely three  $\beta 1$  associated integrins ( $\alpha 2\beta 1$ ,  $\alpha 5\beta 1$  and  $\alpha 6\beta 1$ ), a further two  $\beta 3$  associated integrins ( $\alpha \text{IIb}\beta 3$  and  $\alpha \text{V}\beta 3$ ) as well as integrin  $\alpha \text{L}\beta 2$  which are summarised in Section 1.2.3 (Table 1.2). In addition to integrins, platelets are also known to express other glycoproteins such as the von Willebrand factor receptor complex, GPIb-IX-V and the collagen receptors GPIV and GPVI (Saboor *et al.*, 2013). Glycoproteins relevant to the work described in this thesis are reviewed in detail, below.

#### **1.2.4.1 Integrin $\alpha \text{IIb}\beta 3$ /GPIIb/IIIa**

Expressing 80,000-100,000 copies, integrin  $\alpha \text{IIb}\beta 3$  (GPIIb/IIIa, CD41/61) is the major integral plasma membrane protein of platelets, accounting for ~17% of the total membrane mass (Wagner *et al.*, 1996a). Like all integrins,  $\alpha \text{IIb}\beta 3$  is a heterodimer and consists of a 1008 amino acid  $\alpha \text{IIb}$  subunit and a 762 amino acid  $\beta 3$  subunit. Each of the subunits consist of a large extracellular region, a single transmembrane spanning region and a short cytoplasmic tail (Bennett, 2005). The extracellular domain of the alpha subunit consists of the N-terminal  $\beta$ -propeller domain, the thigh domain and two calf domains (Xia *et al.*, 2004). The extracellular domain of the  $\beta 3$  subunit is composed of an A domain, PSI domain (plexin/semaphorin/integrin), hybrid domain, four EGF domains and a membrane-proximal  $\beta \text{TD}$  domain (Xiong *et al.*, 2001; Xia *et al.*, 2004). These 12 domains assemble as two cytoplasmic 'tails' and a globular 'head' that is formed by the interaction of the seven-bladed  $\beta$ -propeller of the  $\alpha$ -subunit and the  $\beta \text{A}$  domain (Figure 1.7; Takagi *et al.*, 2002; Xia *et al.*, 2004).



**Figure 1.7 The structure of integrin  $\alpha\text{IIb}\beta\text{3}$ .** The  $\alpha\text{IIb}$  (blue) and  $\beta\text{3}$  (red) subunits depicted in the extended formation. (Bledzka *et al.*, 2013).

Located between the thigh and calf domains is a bending point, referred to as a 'genu' or 'knee'. This genu allows both subunits of the  $\alpha\text{IIb}\beta\text{3}$  integrin to exist in two extreme conformations; a bent resting state or an activated extended state (Takagi *et al.*, 2002). In the bent conformation, the ligand binding site of  $\alpha\text{IIb}\beta\text{3}$  is partially sequestered resulting in a low affinity phenotype, but during platelet activation, this inactive bent integrin extends upwards in a 'switch blade' like motion, opening the head piece into a high affinity state for the ligand (Shimaoka, Takagi and Springer, 2002; Takagi *et al.*, 2002).

$\alpha\text{IIb}\beta\text{3}$  is known to recognise and bind to the amino acid sequence Arg-Gly-Asp (RGD) present on many extracellular matrix proteins including fibrinogen, fibronectin, vitronectin and von Willebrand factor (Bennett, 2005). Although  $\alpha\text{IIb}\beta\text{3}$  is known to contribute to platelet adhesion through interactions with extracellular matrix proteins

such as von Willebrand factor, this integrin holds a predominant role in facilitating platelet aggregation (George, 2000). Following activation and conformational changes in the  $\alpha\text{IIb}\beta\text{3}$  integrin structure, the receptor is able to bind to soluble circulatory fibrinogen, which then acts as bridging molecules between two  $\alpha\text{IIb}\beta\text{3}$  receptors on adjacent platelets (Refaai and Laposata, 2002).

The conformational change undertaken by integrins following platelet activation are often attributed to the process of 'inside-out' signalling. Despite this process not being fully understood, it is known that integrin ligand binding by an external stimulus such as collagen or ADP, induces a series of cellular signalling pathways including activating the protein kinase C pathway and calcium mobilisation (Takagi *et al.*, 2002). This in turn then stimulates integrin activation through 'inside-out' signalling, increasing ligand affinity thus driving platelet aggregation and thrombus formation (Bennett, 2005; Bledzka *et al.*, 2013).

#### **1.2.4.2 Integrin $\alpha\text{2}\beta\text{1}$ /GPIIb/IIIa**


The  $\alpha\text{2}\beta\text{1}$  integrin (GPIIb/IIIa, CD49b/61), expressed at 2000-4000 copies per platelet, is often hailed as the second most important platelet receptor after integrin  $\alpha\text{IIb}\beta\text{3}$  (Clemetson and Clemetson, 2007). The importance of  $\alpha\text{2}\beta\text{1}$  within coagulation was first identified in patients lacking in  $\alpha\text{2}\beta\text{1}$  expression, who present with a mild bleeding disorder and a defective aggregatory response following collagen stimulation (Nieuwenhuis *et al.*, 1985).

The activity of  $\alpha\text{2}\beta\text{1}$  is often discussed with the other major platelet collagen receptor GPVI. Historically it was believed that  $\alpha\text{2}\beta\text{1}$  was solely responsible for collagen adhesion, with GPVI acting as a regulatory mediator of the subsequent platelet aggregation (Jung and Moroi, 1998). However recent advancements have found that

binding of GPVI to collagen generates further inside-out signalling, activating integrin  $\alpha 2\beta 1$  allowing it to also bind to the collagen ligand (Jung and Moroi, 1998, 2000). Interestingly agonists specific to  $\alpha \text{IIb}\beta 3$ -induced platelet aggregation have also been shown to activate integrin  $\alpha 2\beta 1$  increasing its affinity and initiating collagen binding (Jung and Moroi, 2000). Further to this, under sheer flow the  $\alpha 2\beta 1$  collagen receptor is not able to initiate platelet adhesion independently (Sarratt *et al.*, 2005). *In vitro*, platelets depend on the initial tethering of GPIb of the GPIb-IX-V complex, to initiate adhesion before secondary binding activity is undertaken by further collagen binding proteins such as  $\alpha 2\beta 1$  and GPVI, further emphasising the complexity of platelet thrombus formation (Clemetson and Clemetson, 2007).

#### **1.2.4.3 GPIb-IX-V**

The GPIb-IX-V complex is a platelet surface receptor with unique properties regarding structure, function and signalling pathways (López, 1994). The history of GPIb-IX-V begins with the discovery of the congenital bleeding disorder, Bernard-Soulier syndrome (Bernard and Soulier, 1948), in which patients present with an increased bleeding time, thrombocytopenia and extremely large platelets, which was later attributed to a deficiency of GPIb-IX-V expression (López *et al.*, 1998). GPIb-IX-V consists of the following subunits; GPIb $\alpha$  (CD42b $\alpha$ ) disulphide-linked to GPIb $\beta$  (CD42b $\beta$ /CD42c), noncovalently complexed with GPIX (CD42a) and GPV (CD42d) all of which contain leucine-rich repeat regions and are expressed in a ratio of 2:2:2:1 respectively (Figure 1.8) (Andrews, Lopez and Berndt, 1997; López *et al.*, 1998; Berndt *et al.*, 2001).



**Figure 1.8 The GPIb-IX-V complex.** GPIb-IX-V is constructed of the following subunits; GPIb $\alpha$  disulphide-linked to two GPIb $\beta$  subunits which are noncovalently associated with GPIIX and GPV. The N-terminal houses the ligand binding site and leucine-rich repeat regions. (Hadjkacem, Gargouri and Gargouri, 2011).


The 282 amino acid residues within the N-terminal of GPIb $\alpha$  house the binding site for the ligands von Willebrand factor, macrophage-1 antigen (Mac-1), P-selectin,  $\alpha$ -thrombin, clotting factors XI and XIIa, as well as circulatory high-molecular weight kininogen (HMWK; Berndt *et al.*, 2001).

During haemostasis, the predominant function of GPIb-IX-V is adhesion to von Willebrand factor under high shear flow, after which, several signalling pathways are initiated with platelets, resulting in intracellular calcium mobilisation, cytoskeletal rearrangement, degranulation, inside-out activation of  $\alpha$ IIb $\beta$ 3 and ultimately in platelet aggregation (Andrews, Lopez and Berndt, 1997; López *et al.*, 1998; Bodnar *et al.*, 1999; Gu *et al.*, 1999; Berndt *et al.*, 2001). GPIb $\alpha$  is also known to bind  $\alpha$ -thrombin, thereby inducing thrombin dependant platelet aggregation and can bind to factor XI and XIIa which regulates the coagulation cascade (Berndt *et al.*, 2001).

In addition, GPIb-IX-V is also thought to contribute to innate immune response. Interactions between GPIb-IX-V and neutrophil Mac-1 or P-selectin are suggested to facilitate the formation of platelet-leukocyte-endothelial multi-cellular complexes, localising immune response to the site of vascular insult (Cerletti, Evangelista and de Gaetano, 1999; Cerletti, de Gaetano and Lorenzet, 2010).

### **1.2.5 Platelets in haemostasis**

Haemostasis is the process in which, following vessel injury, platelets form a clot which serves to limit the resulting haemorrhage (Rasche, 2001). This process is defined in two stages; primary haemostasis consists of the initial adhesion of platelets to the injured vessel and secondary haemostasis which is often referred to as the coagulation cascade. The original coagulation cascade proposed by Macfarlane (1964) suggested that coagulation was initiated by contact of the blood with foreign substances or damaged tissues. This contact then initiates a series of enzymatic steps in which coagulation factors, generally indicated by roman numerals, act firstly as a substrate and then as an activator or catalyst for the subsequent stages (Macfarlane, 1964). Since then, the majority of these 13 coagulation factors have been shown to circulate within the blood stream as zymogens, before being activated into serine proteases (Davie, Fujikawa and Kiesel, 1991) The exceptions are factors V and VIII which are glycoprotein cofactors as well as factor XIII which is a transglutaminase (Chaudhry and Babiker, 2018). Combined, these factors result in the coagulation cascade which concludes in the conversion of fibrinogen to fibrin and thrombus formation (Chaudhry and Babiker, 2018). The coagulation cascade can be separated into the three distinct extrinsic, intrinsic, and common activation pathways which are detailed in Figure 1.9 and summarised below.



**Figure 1.9 The intrinsic, extrinsic and common pathways of the coagulation cascade.** The intrinsic pathway is activated through contact with a negatively charged surface or through exposure to collagen. The extrinsic pathway is activated through exposure to tissue factor released by damage vessel. Both the intrinsic and extrinsic pathway result in the activation of the common pathway, which through activation of factor X result in the formation of fibrin and a stabilised thrombus. Adapted from Pallister and Watson, 2011.

### 1.2.5.1 The intrinsic pathway

The intrinsic pathway is the longer of the two pathways of secondary haemostasis. *In vitro* this pathway is initiated through platelet interaction with the exposed collagen within the damaged extracellular matrix of the vascular endothelium. This interaction initiates the activation of the serine kinase factor XII which becomes XII<sub>a</sub>, which in turn acts as a catalyst activating factor XI to factor XI<sub>a</sub>. This activated XI<sub>a</sub> then results in the activation of factor X to X<sub>a</sub>, giving rise to the subsequent stages of the coagulation cascade (Gailani and Renné, 2007).

### **1.2.5.2 The extrinsic pathway**

The extrinsic pathway is the shorter of the two haemostatic pathways and was named so because of its dependence on the exogenous stimulation by tissue factor (TF) (Davie, Fujikawa and Kisiel, 1991). Following damage to the vessel wall, endothelial cells release tissue factor forming the activated TF-VIIa complex (Nemerson, 1988). This TF-VIIa complex is the key initiator of the protease coagulation cascade, resulting in the activation of both factor IX to IXa and X to Xa (Mackman, 2009). The extrinsic pathway also results in the production of low amounts of thrombin, which further amplifies to coagulation cascade by activating the glycoprotein cofactors V and VIII (Edgington *et al.*, 1991).

### **1.2.5.3 The common pathway**

The common pathway begins with the activation of factor X to Xa, which unifies both the intrinsic and extrinsic pathways. Activated factor X, factor V, tissue phospholipids, platelet phospholipids as well as calcium ions form the thrombinase complex which cleaves prothrombin (factor II) to thrombin (factor IIa) (Coughlin, 2000). Thrombin then cleaves fibrinogen into insoluble fibrin and activates factor XIII, which covalently crosslinks the fibrin polymers, forming the dense fibrin mesh and a definitive secondary haemostatic plug (Palta, Saroa and Palta, 2014).

### **1.2.6 Platelet adhesion, aggregation and plug formation**

The complex series of events that result in normal haemostatic response not only require the enzymatic stages of the coagulation cascade but also rely on fundamental changes in platelet phenotype and cellular activity (Gailani and Renné, 2007). In platelets, primary adhesion or primary haemostasis refers to the attachment of platelets to the sub endothelium, while platelet to platelet 'adhesion' is termed aggregation to differentiate the two processes entirely (Clemetson and Polgár, 1997).

Upon the initial insult to the vessel wall, platelets are recruited to the injury site via interactions with the exposed subendothelial extracellular matrix (ECM), resulting in primary adhesion (Ruggeri, 2009). Following contact with the ECM, the platelet glycoprotein (GP) complex Ib-IX-V binds to von Willebrand factor associated with the exposed collagen fibres of the subendothelium. This initial tethering with GPIb-IX-V then leads platelets to undertake subsequent activation signalling and phenotypic cytoskeletal spreading/flattening (Ruggeri and Mendolicchio, 2007).

Once activated, platelets then initiate a further barrage of cellular events, resulting in secondary haemostasis and platelet plug stabilisation. Platelet aggregation is initiated through conformational changes within GPIIb/IIIa, which increases the receptors' binding affinity for fibrinogen, resulting in platelet-platelet aggregation (Clemetson and Polgár, 1997). The growing platelet aggregate is stabilised through a multitude of platelet to platelet interactions contained within the thrombus and remains adhered to the vessel wall through further interaction with the secondary collagen receptors GPIaIIa, GPIV and GPVI (Holinstat, 2017).

In addition to this, thrombin, as well as acting as a platelet agonist, converts fibrinogen to fibrin, forming a dense, insoluble, fibrin mesh that intertwines adhered platelets and

passing red blood cells, resulting in a definitive platelet plug (Tomaiuolo, Brass and Stalker, 2017). Once formed the haemostatic plugs become firmly adhered to the site of vascular injury, preventing further haemorrhage whilst also resisting the sheer force of circulatory blood flow (Minors, 2007).

### **1.2.7 The roles of platelet within innate and adaptive immunity**

As well as having a substantial involvement within the haemostasis, platelets also hold a primary role within the immune system, which at the very principle level rapidly accumulate to the epicentre of any vascular injury and provide an immediate barrier against infection (Gardiner and Andrews, 2013). Platelets have been shown to accumulate and attract other immune cells to sites of infection through active chemotaxis and the release of antimicrobial chemokines, such as platelet factor 4 and interleukin 8 (Lowenhaupt *et al.*, 1982; Juselius and MacDonald, 2004; Skoglund *et al.*, 2008; Ali, Wuescher and Worth, 2015). Further studies have demonstrated that platelets have both the ability to internalize pathogens (Yeaman, 1997, 2010a, 2010b) and to exhibit antimicrobial activity which is triggered by bacterial LPS stimulation (Zielinski *et al.*, 2001; Lopes-Pires *et al.*, 2012). Bacterial LPS has also been shown to upregulate the production of IL-6, cyclooxygenase-2 and prostaglandin E2 through stimulation of toll-like receptor 4, the MAP-kinase pathway and Nf-kB signalling (Scott and Owens, 2008). Periodontitis has also been implicated in bacterial-platelet interactions, with periodontal pathogens, specifically *Porphyromonas gingivalis* increasing the levels of P-selectin excretion, triggering platelet activation (Laky *et al.*, 2011; Ganji *et al.*, 2014), as well as causing an up regulation of CD40L expression through TLR-2 and 4 interactions (Assinger *et al.*, 2012).

## **1.3 Introduction Part III: Periodontitis and cardiovascular disease**

### **1.3.1 The systemic impact of periodontitis**

Periodontitis and the associated chronic periodontal inflammation have historically been linked to other systemic diseases (Kerr, 1951, 1962). Both periodontal diseases and systemic diseases share a number of the similar risk factors such as smoking, age and obesity and often have inflammation as an underlying principle basis (Beck *et al.*, 1998; Paquette, Brodala and Nichols, 2007). A highly studied example of the systemic impact of periodontitis is the development of endocarditis. Although the specific factors that lead to endocarditis are unknown, it is believed that the increased bacterial load of predominantly *Staphylococcus*, *Streptococcus* and *Enterococcus* species found within the bloodstream that leads to infected cardiac tissue could originate from the dysbiotic biofilm found within periodontitis (Carinci *et al.*, 2018). Further to this, recent research has shown that periodontal bacteria are found within post-mortem human brains (Poole *et al.*, 2013), have been implicated in nerve cell damage (Watts, Crimmins and Gatz, 2008) and shown to exacerbate pathogenesis (Miklossy, 2011) within Alzheimer's disease. In addition, there have been further links between periodontal pathogens and rheumatoid arthritis (RA) with genomic material derived from *P. gingivalis* been discovered within samples of patient synovial fluid (Martinez-Martinez *et al.*, 2009; Reichert *et al.*, 2013), encouraging suggestions that these bacteria may provide a novel mechanism for the progression of RA (Wegner *et al.*, 2010). Further relationships between periodontal pathogens and diabetes have also been suggested by groups such as Demmer *et al.*, 2008, with further groups

suggesting that periodontitis could produce adverse effects for patients with diabetes (Borgnakke *et al.*, 2013) but also that diabetes may increase the progression of periodontitis (Chávarry *et al.*, 2009). Furthermore, several mechanisms linking periodontitis to the atherosclerotic process and atherosclerotic disease such as stroke and myocardial infarction have been put forward (Joshi *et al.*, 2003; Reyes *et al.*, 2013; Scannapieco and Cantos, 2016).

Although clear evidence links oral infection and systemic disease, the bacterial interactions that take place are likely to be complex and involve more than a singular mechanism. Due to this fact several theorised mechanisms that have been proposed by which periodontal disease may impact further than the immediate oral environment and have a distal effect (Table 1.3).

---

#### Oral bacterial invasion of epithelial and endothelial cells;

- Protects bacteria from host defence to extend bacterial survival
- Stimulates innate immune response and exacerbates systemic inflammation

---

#### Oral bacteria penetrate and enter the vascular system;

- Able to migrate and establish infection within other organs and tissues (e.g. brain abscess)
- Exacerbate or stimulate inflammation in non-localised tissues
- Directly impact other organs or tissues (e.g. arteries, liver.).

---

#### Biologically active molecules from chronic oral inflammation enter the vascular system and impact both ongoing inflammation or organ/tissue systems (e.g. LPS, cytokines)

---


**Table 1.3 Theoretical mechanisms proposed to how explain periodontal disease may have a systemic impact.** Adapted from Reyes *et al* (2013).

### 1.3.2 Periodontal infection and atherosclerotic vascular disease

Cardiovascular disease (CVD) and atherosclerosis are globally a leading cause of death accounting for ~30% of all deaths worldwide (WHO, 2018). Various cross-sectional studies have suggested that periodontitis is directly associated with atherosclerotic cardiovascular disease independently of traditional risk factors such as smoking and obesity (Bahekar *et al.*, 2007; Friedewald *et al.*, 2009; Kebschull, Demmer and Papapanou, 2010).

When considered broadly, periodontal disease and atherosclerotic vascular disease (AVD) have a multitude of common etiological and epidemiological factors including sharing several risk factor groups (smoking, diabetes, diet) and producing correlative biological markers (C-reactive protein, interleukin 1, endothelial growth factor, interleukin 8 etc.) (Aarabi *et al.*, 2015). Periodontal infection has also been shown to cause an increase in AVD associated markers (Eberhard *et al.*, 2013). Studies have found bacterial DNA through PCR analysis of endarterectomy samples (Nakano *et al.*, 2006, 2007, 2008; Pucar *et al.*, 2007; Gaetti-Jardim *et al.*, 2009), with both genetic material and viable cells of both *P. gingivalis* and *T. forsythia* found in atherosclerotic lesions (Marcelino *et al.*, 2010). Further studies have shown that periodontal pathogens can directly influence endothelial cells *in vitro*, causing the up-regulation of inflammatory cytokines, such as IL-1 $\beta$ , IL-6 and IL-8, as well as causing up-regulation of adhesion molecules, monocyte chemoattractant protein (MCP-1), intracellular adhesion molecule (ICAM-1), vascular adhesion molecule (VCAM-1), and endothelial-leukocyte adhesion molecule (E-selectin) (Takahashi *et al.*, 2006; Ho *et al.*, 2009). Interestingly, *P. gingivalis* and its fimbriae are able to induce cell adhesion molecule cleavage and endothelial apoptosis (Sheets *et al.*, 2005, 2006). *In vitro* studies have demonstrated

that monocytes suffer very similar consequences to endothelial cells when exposed to periodontal pathogens (Hajishengallis *et al.*, 2006). Further reports also highlight an increased adhesion of monocytes to *P. gingivalis* infected endothelial cells (Roth, Moser, *et al.*, 2007), with both *P. gingivalis* and *T. forsythia* causing an increase in monocytic cytokine and adhesion molecule production (Pollreis *et al.*, 2010; Sahingur *et al.*, 2010). *P. gingivalis* has been described to increase the low density lipoprotein (LDL) uptake of monocytes, promoting the formation of foam cells (Giacona *et al.*, 2004). Although conclusive evidence is yet to be presented, three specific and distinct pathways have been proposed as to how periodontal pathogens may migrate into the vascular system; Firstly, bacteria conduct trans-cellular migration, moving through multiple epithelial cells until reaching vascular endothelial cells (Kebuschull, Demmer and Papapanou, 2010). Secondly, the pathogen either invade or exploit phagocytosis of host immune cells, evading the intracellular digestion processes and elicit a 'Trojan horse' method of transportation and thirdly, external influence, such as dental work, chewing or brushing of the teeth and gums, directly ruptures the vascular system , bridging the gap to the periodontal infection (Reyes *et al.*, 2013). It is therefore essential to understand the key stages of AVD progression and how periodontal pathogens may influence this process. The following three figures describe; (A) the potential role of periodontal pathogens in the initiation and development of endothelial dysfunction (Figure 1.10a), (B) how these pathogens may contribute to the formation of fatty streaks and atherosclerotic plaques (Figure 1.10b) and (C) the proposed pathways that model the maturation and rupture of atherosclerotic plaques (Figure 1.10c) (Kebuschull, Demmer and Papapanou, 2010).



**Figure 1.10 Schematic representation of the potential role of periodontal pathogens in atherosclerotic vascular disease progression. (A.)** Vascular endothelial cells are exposed to and invaded by periodontal pathogens e.g. *P. gingivalis*, which proceed to multiply intracellularly, triggering activation of toll-like receptor 2 (TLR2) and an up regulation of pro-inflammatory cytokines, cell adhesion molecules and apoptosis. **(B.)** Further potential progression of atherosclerotic plaque formation, through foam cell formation due to exposure to periodontal pathogens. Apoptosis of low-density laden (LDL) macrophages cause accumulation of lipids. Periodontal pathogens also influence the induction of smooth muscle cell proliferation, extracellular matrix (ECM) build-up and the attraction of T-cells within the plaque. **(C)** Exposure to periodontal pathogens causes the up regulation of endothelial apoptosis or anti-endothelial auto antibodies. Pathogen assisted breakdown of the ECM matrix also occurs by plaque macrophages, T-cells and plasma cells leading to mature plaque formation and subsequent vessel rupture. (Kebschull, Demmer and Papapanou, 2010)

Another mechanism that resides at the heart of atherosclerotic biology is the substantial role of platelets. Platelets can be activated either indirectly, through the vascular endothelium and exposed surface markers or through direct interaction with bacterium or their biological products such as LPS (Jennings, 2009). Oral pathogenic bacteria have been described to interact with platelets through toll-like receptors (TLR's), causing activation and the release of activation markers such as P-selectin and ADP (Shiraki *et al.*, 2004; Blair *et al.*, 2009; Zhang *et al.*, 2009). Both *T. forsythia* and *P. gingivalis* have been described to increase the activation of platelets, inducing the up regulation of P-selectin and platelet-monocyte complexes (Nicu *et al.*, 2009; Papapanagiotou *et al.*, 2009; Laky *et al.*, 2011), with *P. gingivalis* also inducing the pro-thrombotic pathway (Roth *et al.*, 2009). However, the mechanisms underlying these interactions and the resulting consequences remain to be elucidated.

## 1.4 Research rationale and Thesis aims

The periodontopathogens *Porphyromonas gingivalis* and *Tannerella forsythia* found within the chronic oral disease of periodontitis have been suggested to contribute to and exacerbate the progression of atherosclerotic vascular disease. It is hypothesised that through the destructive phenotypes of chronic periodontitis and the subsequent localised bleeding within the periodontium, opportunistic pathogens *P. gingivalis* and *T. forsythia* are able to gain access to the vasculature. During this process, these periodonto-pathogens are able to directly or indirectly interact with circulatory platelets, resulting in an activated platelet state and the formation of platelet aggregates. It is then this altered platelet state which exacerbates or contributes to the progression of atherosclerotic vascular disease.

In order to investigate the potentiated interactions between periodonto-pathogens and mammalian platelets:

- The use of the megakaryocytic-like cells, CHRF-288-11 was investigated as a putative *in vitro* platelet-like cell model.
- A multicolour flow cytometry panel was developed to study the effect of periodontal pathogen interactions on platelet marker expression.
- The direct interactions of pathogens with platelets were characterised
- The possible induction of platelet aggregation by a range of *P. gingivalis* and *T. forsythia* strains at varying multiplicities of infection was investigated.
- The mechanisms by which periodonto-pathogen might induce platelet activation were determined.

## **Chapter 2: Materials and methods**

## 2.1 Materials

All chemical reagents unless otherwise stated were purchased from Sigma-Aldrich or ThermoFisher Scientific. All manufacturers and suppliers are shown in Table 2.1.

<b>Supplier</b>	<b>Location</b>
ABBIOTEC	California, USA
Abcam	Cambridgeshire, UK
Biologend	London, UK
BMG Labtech	Buckinghamshire, UK
G E Healthcare	Buckinghamshire, UK
Gibco, ThermoFisher Scientific	Leicestershire, UK
Hawksley	Sussex, UK
Invivogen	Toulouse, Fr
Oxoid, ThermoFisher Scientific	Hampshire, UK
Pierce, ThermoFisher Scientific	Illinois, USA
Roche	Hertfordshire, UK
Sigma-Aldrich	Poole, UK
Sysmex	Buckinghamshire, UK
ThermoFisher Scientific	Leicestershire, UK
TOCRIS	Gloucestershire, UK

**Table 2.1 Manufacturers and suppliers.**

## 2.2 Antibodies

All antibodies against *P. gingivalis* and *T. forsythia* were kindly donated by Dr Graham Stafford, School of Clinical Dentistry, University of Sheffield, Sheffield, UK. Details of antibodies used in this study are provided in the Table 2.2 below:

Antibody Name	Host Animal	Raised Against
mAb 1B5	Mouse	<i>Porphyromonas gingivalis</i> LPS
TF S-Layer	Rabbit	<i>Tannerella forsythia</i> S-layer
TF Whole Cell 1		<i>Tannerella forsythia</i> ATCC 43037
PG Whole Cell 1		<i>Porphyromonas gingivalis</i> NCTC 11834
PG Whole Cell 2		<i>Porphyromonas gingivalis</i> , NCTC 11834
$\alpha$ nanH Sialidase	Rat	<i>Tannerella forsythia</i> ATCC 43037, sialidase mutant ( $\Delta$ nanH)
$\alpha$ nanS Sialate-esterase		<i>Porphyromonas gingivalis</i> ATCC 381, sialate-O-acetyl-esterase mutant ( $\Delta$ nanS)

**Table 2.2 Bacterial specific antibodies used within this study.**

Table 2.3 shows mammalian antibodies used throughout this body of work, with Table 2.4 detailing secondary antibodies used within this study.

Specificity	Alternate Name	Host Species	Supplier and Catalogue Number
Integrin $\beta$ 1	CD29	Mouse	Abcam #ab30394
Integrin $\beta$ 3	CD61	Mouse	Abcam #ab34409
mToR	N/A	Rabbit	Cell Signalling #7C10
Phalloidin-X Texas Red	N/A	N/A	ThermoFisher #T7471
Zombie Green	N/A	N/A	Biolegend #423111
CD42b-PE	GP1b	Mouse	Biolegend #303906
CD61-PE/Cy7	Integrin $\beta$ 3, GPIIIa	Mouse	Biolegend #336416
CD41-Pacific Blue	Integrin $\alpha$ IIb, GPIIb	Mouse	Biolegend #303714
CD62P-PE/Cy7	GMP-140, PADGEM	Mouse	Biolegend #304922
CD41/61-APC	Integrin $\alpha$ IIb $\beta$ 3, GPIIbIIIa	Mouse	Biolegend #359808
PE-IgG Control	N/A	Mouse	Biolegend #400112
Pacific Blue-IgG Control	N/A	Mouse	Biolegend #400151
PE/Cy7-IgG Control	N/A	Mouse	Biolegend #400126
APC-IgG Control	N/A	Mouse	Biolegend #4000222

**Table 2.3 Primary antibodies used throughout this study.** Antibodies were optimised and used at assay dependant concentrations detailed within each relevant section of Chapter 2.

Specificity	Host Species	Catalogue Number and Supplier
Anti-Rabbit Alexa Fluor 488	Goat	Invitrogen #A11008
Anti-Mouse Alexa Fluor 488	Goat	Abcam #ab150117

**Table 2.4 Secondary antibodies used throughout this study.**

## 2.3 Bacterial Strains and Mutants

All bacterial strains used were kindly donated by Dr G. Stafford and details of the strains are shown in Table 2.5.

Species	Genotype	Relevant characteristic(s)
<i>Tannerella forsythia</i>	43037	ATCC Strain
	43037 $\Delta$ NanH	<i>NanH</i> sialidase deficient mutant of ATCC 43037 (ery <sup>R</sup> ) (Honma, Mishima and Sharma, 2011)
	43037 $\Delta$ WecC	<i>WecC</i> isogenic mutant of ATCC 43037 (ery <sup>R</sup> ) (Honma <i>et al.</i> , 2007)
<i>Porphyromonas gingivalis</i>	NCTC 11834	NCTC Strain
	NCTC 11834 $\Delta$ OmpA1	<i>OmpA1</i> (PGN_0729) deletion mutant of ATCC 33277 (ery <sup>R</sup> ) (Naylor <i>et al.</i> , 2016)
	NCTC 11834 $\Delta$ OmpA2	<i>OmpA2</i> (PGN_0728) deletion mutant of ATCC 33277 (ery <sup>R</sup> ) (Naylor <i>et al.</i> , 2016)
	ATCC 381	ATCC Strain
	ATCC 381 $\Delta$ Sia0352	Sialidase 0352 deficient mutant of ATCC 381 (ery <sup>R</sup> )
	ATCC W50	ATCC Strain

**Table 2.5 Bacterial strains and mutants used within this study.** Ery<sup>R</sup> - erythromycin resistance.

## 2.4 Bacterial Growth

*P. gingivalis* strains were maintained on fastidious anaerobic agar (FA) supplemented with 5% horse blood (Oxoid, ThermoFisher) while *T. forsythia* strains were maintained on FA agar supplemented with 5% horse blood, 0.17 mM N-acetylmuramic acid (NAM) and 25 µg/mL gentamycin.

For growth in liquid cultures, *P. gingivalis* was grown in brain heart infusion (BHI) (Oxoid, ThermoFisher) broth supplemented with 0.4 % yeast extract, 1 mg/mL vitamin K1, 1 mg/mL hemin and 250 µg/mL cysteine.

*T. forsythia* was grown as liquid cultures in tryptic soy broth (TSB) supplemented with 0.5% yeast extract, 5 µg/mL hemin, 0.5 µg/mL vitamin K, 0.17 mM NAM and 0.1% cysteine.

Erythromycin (10 µg/mL) was included as a selective antibiotic in the media after autoclaving where appropriate (see table 2.5) and bacteria grown on solid surface or as liquid cultures were incubated at 37 °C under anaerobic conditions (10% H<sub>2</sub>, 80% N<sub>2</sub>, 10% CO<sub>2</sub>). Bacterial counts were determined using a bacterial counting chamber (Hawksley).

### 2.4.1 Long Term Bacterial Storage

For long term storage, bacterial cultures were kept at -80 °C. Routine bacterial cultures were maintained as in section 2.4 before being removed from supplemented FA plates, resuspended in ice-cold fresh growth medium containing 17% glycerol and immediately stored.

## **2.5 Megakaryocytic Cell Culture and Differentiation**

### **2.5.1 Megakaryocyte Cell Line CHRF-288-11**

The CHRF-288-11 cell line was kindly provided by Prof. Willem Ouwehand & Dr Cedric Ghevaert (Division of Transfusion Medicine, Department of Haematology, University of Cambridge, Cambridge, UK). The CHRF-288-11 cells were routinely cultured in RPMI-1640 medium containing L-glutamine (Gibco, ThermoFisher Scientific) supplemented with 1% non-essential amino acids and 10% foetal bovine serum (FBS) at 37 °C in a humidified incubator with 5% CO<sub>2</sub>.

### **2.5.2 Cell Passaging**

CHRF-288-11 cells were grown until confluent ( $\sim 1 \times 10^6$  cells/mL) before passaging. Cells suspensions were transferred to a fresh tube before centrifugation (200 *g*, 5 min, room temperature (RT)). The supernatant was discarded and the cell pellet was resuspended in phosphate-buffered saline (PBS). Following further centrifugation (200 *g*, 5 min, RT), cells were resuspended in fresh RPMI at a density of  $1 \times 10^5$  cells/mL.

### **2.5.3 Cryopreservation of Cells**

Cells were cryopreserved for long term storage. Cells at confluency ( $1 \times 10^6$  cells/mL) were pelleted at 200 *g* for 5 min at RT before being resuspended and washed in PBS. Cells were then further centrifuged for 5 min (200 *g*, RT) and re-suspended in freezing media (complete RPMI-1640 containing 10% dimethyl sulfoxide (DMSO)). Cells at a density of  $\sim 5 \times 10^5$  cells/mL were then transferred into cryopreservation tubes before being placed into a Mr Frosty™ for 24 hours at -80 °C, after which the vials were transferred to liquid nitrogen for long term storage. When needed, cells were revived by quickly thawing in a water bath at 37 °C. Cells were then immediately transferred

into fresh culture media and cultured for 6h. After this time period, the cell media was replaced to remove the DMSO and normal cell culture protocol was then followed.

#### **2.5.4 CHRF-288-11 Differentiation**

For differentiation, CHRF-288-11 cells were seeded in routine culture medium (RPMI-1640 with L-glutamine (Gibco, ThermoFisher Scientific), 1% non-essential amino acids, 10% FBS) containing 50 ng/mL of Phorbol 12-myristate 13-acetate (PMA). Cells were then cultured for five days without a media change at 37 °C in a humidified incubator with 5% CO<sub>2</sub>. For experiments requiring cells in suspension, differentiated CHRF-288-11 cells were washed twice with PBS and incubated in 1x trypsin-EDTA for two min at 37°C in a humidified incubator with 5% CO<sub>2</sub>. Cell detachment was confirmed using light microscopy and an equal volume of complete RPMI-1640 was added to neutralise trypsin activity. After detachment cells were then processed in an assay dependant manner.

#### **2.5.5 Cell Counting**

Cells were counted using the Countess II FL automated cell counter (Invitrogen). Cell suspensions were removed and mixed with an equal volume of trypan blue before being transferred into a countess chamber slide. Cell counts were then generated automatically, with none viable cells being discounted by trypan blue exclusion.

### **2.6 Platelet Isolation**

Blood was obtained from healthy volunteers within the Biomolecular Sciences Research Centre, Sheffield Hallam University, UK, with informed consent. The use of platelets in this study was approved by the Sheffield Hallam University Research Ethics Committee (Ethics application No. HWB-BIO-03), Sheffield Hallam University, Sheffield, UK.

### **2.6.1 Blood collection**

After a tourniquet had been applied, the first sample was drawn into an EDTA-containing Vacutainer. The tourniquet was then removed and any subsequent samples were drawn into sodium citrate Vacutainers, allowing blood to flow by gravity. All tubes were inverted to ensure full distribution of the anticoagulant and then processed accordingly. Full blood count (FBC) was determined using the EDTA blood sample by a haematology analyser (XP-300, Sysmex).

### **2.6.2 Platelet rich plasma preparation**

Each sample was centrifuged at 200 *g* for 20 min at room temperature with no brake applied. After centrifugation, the straw-coloured platelet rich plasma (PRP) layer was removed using a sterile Pasteur pipette and transferred to a fresh tube. The isolated PRP was analysed by the Sysmex XP-300 to determine platelet concentration and confirm that the sample is free of other blood contaminants.

### **2.6.3 Platelet poor plasma preparation**

Previously isolated PRP was further centrifuged at 800 *g* for 20 min at room temperature with no brake in order to pellet platelets. After centrifugation, the supernatant was carefully removed and transferred to a fresh tube before being utilised to set '0% aggregation' in an experiment dependant manner.

### **2.6.4 Modified Tyrode's Buffer**

Modified Tyrode's Buffer was made by adding; 134 mM NaCl, 12 mM NaHCO<sub>3</sub>, 2.9 mM KCl, 0.34 mM Na<sub>2</sub>HPO<sub>4</sub>, 1 mM MgCl<sub>2</sub>, 10 mM HEPES, to dH<sub>2</sub>O and adjusting the pH to 7.4. Prior to use, the buffer was supplemented with 5 mM glucose, 25 mM CaCl<sub>2</sub> and 3 mg/mL BSA.

## 2.7 Phenotypic Analysis Methods

### 2.7.1 Antibiotic Protection Assays

Antibiotic protection assays were carried out in a Class II safety cabinet that had previously been sterilised by UV light. CHR-288-11 cells were seeded at a density of  $1 \times 10^6$  cells/mL into 24 well plates in complete RPMI media and allowed to differentiate for five days (Section 2.5.4). Before starting the antibiotic protection assay, all buffers and cell culture media were pre-warmed to 37 °C. Three 'sacrificial' wells were washed three times with PBS, before 1x trypsin-EDTA was added to the plate and incubated for two min at 37 °C in a humidified incubator with 5% CO<sub>2</sub>. The trypsin-EDTA was then neutralised with an equal volume of complete media, the cell suspensions were removed, counted and averaged to determine the relevant bacterial count for an MOI of 1:100. The remaining wells were washed twice with PBS to remove any undifferentiated cells before incubating with complete RPMI supplemented with 2% BSA for one hour at 37 °C in a humidified incubator with 5% CO<sub>2</sub>. During this incubation, *P. gingivalis* strains (wild-type or mutants) were removed from 72 hour blood agar plates, resuspended in complete RPMI before being counted and adjusted to equal an MOI of 1:100. Following blocking of non-specific sites, wells were washed three times with PBS before the addition of the bacterial suspension. In parallel, the bacterial suspension was added to three wells not seeded with mammalian cells to assess bacterial viability throughout the assay. Well seeded with CHR-288-11 cells but not infected were also included as controls. Samples were incubated for 90 min at 37°C in a humidified incubator with 5% CO<sub>2</sub>. Following bacterial incubation, to determine percentage invasion, cells were washed three times with PBS, before being incubated for a further 60 min with complete RPMI media supplemented with 200 µM

of metronidazole in order to assess in the invaded population. All wells containing mammalian cells were then washed a further three times with PBS before the addition of sterile water and each well was scraped for one minute for ensure complete cell lysis. Cell lysates were then serially diluted and spotted onto blood agar plates using the Miles-Misra method. Well containing only bacterial cells were only serially diluted before being plated the same way. Blood agar plates with then incubated anaerobically at 37 °C for up to five days before colony forming units (CFU's) were counted and recorded.

## **2.7.2 Immunofluorescent Microscopy**

### **2.7.2.1 Phenotypic characterisation of CHR-288-11 differentiation**

Sterile 13mm coverslips were added to each well of a 24-well plate. The wells were then washed twice with PBS before being seeded at a density of  $1 \times 10^6$  cells and allowed to differentiate for up to seven days (Section 2.5.4). Cells were also seeded at a density of  $5 \times 10^5$  cells as an undifferentiated control. After the appropriate differentiation period, cell media was removed, each well was washed three times with PBS before cells were fixed for 10 min in 4% paraformaldehyde (PFA). After fixation, cells were washed three times in PBS, permeabilised with 0.5% Triton-X in PBS for 8 min and washed a further three times with PBS. Cells were then blocked with 3% BSA for one hour at room temperature, washed three times with PBS before being incubated with the high affinity F-actin probe Texas Red-X phalloidin at a concentration of 1:3500 in PBS with 3% BSA for a further hour at room temperature, protected from light. Each well was washed a further three times with PBS before the coverslips were removed and mounted with ProLong Gold anti-fade mountant with

DAPI (Invitrogen). Each slide was then left in the dark for 24 hours at room temperature before imaging with a fluorescent microscope (Olympus BX60).

### **2.7.2.2 Phenotypic evaluation of bacterial challenge on differentiated CHRF-288-11 cells**

Sterile 13 mm coverslips were added to each well of a 24-well plate. The wells were then washed twice with PBS before being seeded at a density of  $1 \times 10^6$  cells and allowed to differentiate for five days (Section 2.5.4) at 37°C in a humidified incubator with 5% CO<sub>2</sub>. Cells were also seeded at a density of  $5 \times 10^5$  cells as an undifferentiated control. *P. gingivalis* (wild-type or mutants) or *T. forsythia* strains were removed from 72 hour blood agar plates, resuspended in RPMI before being counted and adjusted to equal an MOI of 1:100. Cells were then challenged with bacterial suspensions for 90 min at 37°C in a humidified incubator with 5% CO<sub>2</sub> before fixation in 4% PFA for 10 min at room temperature. As above, cells were washed three times in PBS, permeabilised with 0.5% Triton-X in PBS for 8 min and washed a further three times with PBS. Cells were then blocked with 3% BSA for one hour at room temperature, washed three times with PBS before being incubated with primary antibodies (see Table 2.3) at a relevant concentration in 3% BSA. Cells were washed three times with PBS and before further incubation with the corresponding secondary antibodies (see Table 2.4) at the desired concentration in 3% BSA. Where applicable the high affinity F-actin probe Texas Red-X phalloidin (diluted 1:3500) was also included with the secondary antibodies. Each well was washed a further three times with PBS before the coverslips were removed and mounted with ProLong Gold anti-fade mountant with DAPI. Each slide was then left in the dark for 24 hours at room temperature to allow the mountant to cure before imaging with a fluorescent microscope (Olympus BX60).

### **2.7.2.3 Visualisation of platelets challenged with perio-pathogens**

Isolated platelets (PRP) in sodium citrate Vacutainers were counted using the Sysmex XP-300 and resuspended at  $1 \times 10^6$  platelets/mL of modified Tyrode's buffer. Where applicable, this modified Tyrode's suspension also included either 20 $\mu$ M ADP or *P. gingivalis* strains that had been removed from 72 hour blood agar plates, counted and resuspended at an MOI of 1:10. Each platelet suspension was incubated at room temperature for 20 min before fixation in 0.5% PFA for 30 min again at room temperature. Each sample was then cytospun onto separate slide at 800 *g* for 20 min at room temperature before being washed three times with PBS, permeabilised for 8 min with 0.5% Triton-X, washed a further three times with PBS and blocked with 3% BSA for an hour at room temperature. Each slide was then incubated with primary antibodies (anti-integrin  $\beta$ 1, anti-integrin  $\beta$ 3, anti-mTOR; see Table 2.3) for 1 hour at room temperature at a relevant concentration in 3% BSA, before being washed three times with PBS and further incubation with the corresponding secondary antibodies (see Table 2.4) at the desired concentration in 3% BSA for an hour at room temperature. Where applicable the high affinity F-actin probe Texas Red-X phalloidin was also included with the secondary antibodies at a concentration of 1:3500. Each slide was then washed three times with PBS before mounting with ProLong Gold antifade mountant containing DAPI. Each slide was left in the dark for 24 hours at room temperature before imaging with a fluorescent microscope (Olympus BX60).

## **2.7.3 Electron microscopy**

### **2.7.3.1 White's Saline**

White's saline A was made by adding; 2.4 M of sodium chloride (NaCl), 0.1 M of potassium chloride (KCL), 0.046 M of magnesium sulphate (MgSO<sub>4</sub>), 0.064 M of calcium nitrate tetrahydrate (Ca(NO<sub>3</sub>)<sub>2</sub> 4H<sub>2</sub>O) to 100 mL of distilled water.

White's saline B was made by adding; 0.131 M of sodium carbonate (NaHCO<sub>3</sub>), 0.008 M of sodium phosphate dibasic heptahydrate (Na<sub>2</sub>HPO<sub>4</sub> 7H<sub>2</sub>O), 0.004 M of potassium phosphate monobasic (KH<sub>2</sub>PO<sub>4</sub> anhydrous), 0.0003 M of phenol red to distilled water. The solution was adjusted to pH 7.4 before being further distilled water was added to a total volume of 100 mL.

### **2.7.3.2 Electron microscopy of platelet/perio-pathogen interactions**

Isolated platelets (PRP) were counted using the Sysmex XP-300 and transferred into fresh Eppendorph tubes ( 4x10<sup>8</sup> platelets/test). Platelets were then infected with *P. gingivalis* (at an MOI of 1:10 ) that had been removed from 72 hour blood agar plates, resuspended in modified Tyrode's buffer and counted. As a positive control platelets exposed to 20 µM of ADP were also included. Samples were incubated for 20 min at room temperature before the addition of glutaraldehyde in equal volumes of both White's saline A and B to give a final concentration of 0.1% glutaraldehyde. Samples were fixed for 30 min before centrifugation at 800 *g* for 20 min and resuspended in 3% glutaraldehyde in an equal volume of White's saline A and B for a further 60 min.

For SEM analysis, samples were post fixed using 2% aqueous osmium tetroxide for two hour at room temperature before being dehydrated in a graded series of ethanol solutions and partially dried in a 50/50 mixture of 100% ethanol and hexamethyldisilazane (HEX). Samples were fully dried in 100% HEX before being

mounted onto a pin-stub using Leit-C sticky tabs, gold coated using an Edwards S150B sputter coater and examined using a Tescan Vega3 LMU scanning electron microscope. Scanning electron microscope was operated at a voltage of 12 kV.

For TEM analysis, samples were post fixed in 2% aqueous osmium tetroxide, dehydrated using a graded series of ethanol solutions, cleared in epoxypropane (EPP) and infiltrated in 50/50 araldite resin:EPP mixture overnight on a rotor at room temperature. This mixture was replaced with two changes, over 8 hours with fresh araldite resin mixture before being embedded and cured at 60 °C for 72 hours. Ultrathin sections, approximately 85 nm thick, were cut on a Leica UC 6 ultramicrotome onto 200 mesh copper grids, stained for 30 min with saturated aqueous Uranyl Acetate followed by Reynold's Lead Citrate for 5 min. Sections were examined using a FEI Tecnai Transmission Electron Microscope at an accelerating voltage of 80 Kv. Electron micrographs were recorded using a Gatan Orius 1000 digital camera and Gatan Digital Micrograph software.

Sample processing and acquisition was conducted by Chris Hill at the department of Electron Microscopy Services, University of Sheffield.

## **2.7.4 Flow cytometry**

### **2.7.4.1 Relative expression of platelet markers by CHRF-288-11 cells**

Cell suspension of either differentiated or undifferentiated cells were counted using the Countess II cell counter and adjusted to  $1 \times 10^6$  cells/mL in complete RPMI. Where required cells were exposed to either ADP (20 $\mu$ M) or *P. gingivalis* (MOI 1:100, wild type or mutant strains) as previously described. Platelet/bacteria samples were then incubated for 90 min at 37 °C in a humidified incubator with 5% CO<sub>2</sub>. Cells were

pelleted by centrifugation at 200 *g* for 5 min at room temperature before resuspending in PBS. The cells were then centrifuged again for 5 min at 200 *g*, room temperature before the supernatants were discarded and the pellet gently resuspended in the residual volume. The expression of each cell marker was determined by incubating with the relevant antibodies or IgG controls (see Table 2.3) at room temperature for 20 min before each sample was washed with PBS, centrifuged at 200 *g* for 5 min at room temperature and supernatants then discarded. Each sample was re-suspended in PBS and analysed on a Beckman Coulter Gallios flow cytometer.

#### **2.7.4.2 Phenotypic analysis of platelet/periodontal-pathogen interactions**

Isolated platelets (PRP) were counted using the Sysmex XP-300 and resuspended in modified Tyrode's buffer at a density of  $1 \times 10^6 / 100 \mu\text{L}$ . *P. gingivalis* strains (wild-type or mutants) were removed from 72 hour blood agar plates and resuspended in modified Tyrode's buffer at an MOI of 1:10. Platelets were exposed to the bacteria or ADP (20 $\mu\text{M}$ ) for 20 min at room temperature before fixation with 0.5% PFA for 30 min. After fixation, each sample was resuspended in PBS before being centrifuged at 800 *g* for 20 min at room temperature. The supernatants were then discarded and the pellet gently resuspended in the residual volume. The expression of each cell marker was determined by incubating with the relevant antibodies or IgG controls (see Table 2.3) at room temperature for 20 min. Each sample was then diluted in PBS and analysed on a Beckman Coulter Gallios flow cytometer.

## 2.7.5 Enzyme linked immunosorbent assays (ELISAs)

### 2.7.5.1 Development of a cell-based ELISA

To investigate whether oral pathogens interacted with integrins  $\beta 1$  and  $\beta 3$ , an in-house ELISA was developed. Cells were seeded at a density of  $3 \times 10^4$  cells/well and allowed to differentiate for five days in a tissue culture grade 96-well plate (37 °C, 5% CO<sub>2</sub>). Following differentiation, media containing non-differentiated and non-viable cells were removed and discarded and cells were washed twice with PBS. Three of the wells were trypsinised to recover attached cells and the average number of differentiated cells per well was determined. The differentiated cells were subsequently challenged with bacteria (MOI 1:100 in complete media) and incubated for 90 min in a humidified incubator (37 °C, 5% CO<sub>2</sub>) after which supernatants were removed and discarded. The cells were washed twice with PBS containing 0.1% Tween20 (PBST) and blocked for one hour with PBS containing 3% BSA. Following blocking, cells were washed as described above and fixed using 4% paraformaldehyde. Wells were then incubated with anti-integrin  $\beta 1$  (2  $\mu\text{g}/\text{mL}$ ; Abcam), anti-integrin  $\beta 3$  (2  $\mu\text{g}/\text{mL}$ , Abcam), a polyclonal rabbit IgG anti-*P. gingivalis* (1:5000) or a polyclonal rabbit IgG anti-*T. forsythia* (1:5000) for a further hour, after which cells were washed before incubation with secondary antibodies; either the peroxidase anti mouse IgG (1:40,000) or peroxidase goat anti-rabbit IgG (1:20,000) for one hour. Wells were then washed three times with PBST and 3,3',5,5'-tetramethylbenzidine peroxidase substrate (Fisher Scientific) was added. The reaction was allowed to develop before stopping with 2 M H<sub>2</sub>SO<sub>4</sub>. Plates were read spectrophotometrically at 450 nm with a Clariostar microplate reader (BMG Labtech).

## **2.7.5.2 Recombinant protein-based ELISA**

### **2.7.5.2.1 Coating Buffer**

Sodium bicarbonate coating buffer was made by adding 0.019 M NaCO<sub>3</sub> and 0.035 M NaHCO<sub>3</sub> to 1 L of dH<sub>2</sub>O, pH 9.6. The pH of this buffer was not adjusted and if not correct was remade.

### **2.7.5.2.2 Detection of *P. gingivalis* binding to recombinant integrins**

Wells of 96-well Maxisorp™ microplates were coated with either recombinant integrin β1 or β3 at 5 µg/mL in coating buffer, overnight at 4 °C. After washing once with wash buffer (PBS with 0.05% Tween-20, 0.5 µM CaCl<sub>2</sub>), non-specific binding sites were blocked with blocking buffer (PBS with 3% BSA and 0.5 µM CaCl<sub>2</sub>) for one hour under agitation before washing a further two times. Bacterial cells were removed from FA agar, resuspended in blocking buffer before being added to the pre-coated plates and incubated at room temperature for one hour under agitation. Untreated wells were also included as a control. Wells were then washed three times with wash buffer before incubating with a polyclonal rabbit IgG anti-*P. gingivalis* (1:3500) or a polyclonal rabbit IgG anti-*T. forsythia* (1:3500) antibodies for one hour at room temperature under agitation. After washing three times with wash buffer, wells were incubated with peroxidase goat anti-rabbit IgG (1:20,000) for one hour under agitation, washed three times with PBST and 3,3',5,5'-tetramethylbenzidine peroxidase substrate (Fisher Scientific) was added. The reaction was allowed to develop before stopping with 2 M H<sub>2</sub>SO<sub>4</sub>. Plates were read spectrophotometrically at 450 nm with a Clariostar microplate reader (BMG Labtech).

## **2.8 Platelet Function Methodology**

### **2.8.1 Platelet Aggregation**

#### **2.8.1.1 Agonist preparation**

##### **2.8.1.1.1 Live perio-pathogens**

Initially bacterial strains (wild-type or mutants) of both *P. gingivalis* and *T. forsythia* were removed from 72 hour blood agar plates and resuspended in modified Tyrode's buffer. These suspensions were then counted and calculated to give a MOI of either 1:10 or 1:1

##### **2.8.1.1.2 Heat killed perio-pathogens**

Strains of *P. gingivalis* or *T. forsythia* were prepared as above (Section 2.9.1.1.1) before being boiled for 5 min at 100 °C. In order to confirm bacterial viability, each bacterial suspension was transferred to a fresh blood agar plate and cultured at 37 °C in an anaerobic environment for five days.

##### **2.8.1.1.3 2.9.1.1.3 Bacterial supernatants**

Wild-type strains of *P. gingivalis* were grown in liquid cultures until they reached an optical density (O.D.) of 0.8 at 600 nm. Each culture was centrifuged at 13,000 *g* for 5 min at room temperature before the supernatants were removed and passed through a 0.2 µm filter. 20 µL of this suspension was then added to platelet suspensions during aggregation determination.

##### **2.8.1.1.4 *P. gingivalis* lipopolysaccharide**

Commercial lipopolysaccharide (LPS; Invivogen) purified from *P. gingivalis* NCTC 11834 was used in aggregation investigations at concentrations of 10, 20 and 40 µg/mL.

### 2.8.1.2 Platelet inhibitors

Before measuring aggregation, 250  $\mu$ L of PRP was transferred into individual cuvettes and platelets were incubated with selective platelet inhibitors (shown in Table 2.6) for 15 min at room temperature. Each cuvette was then analysed routinely as described in 2.9.1.3.

Inhibitor	Supplier	Final Concentration
TRL-2	Invivogen	5 $\mu$ g/mL
TLR-4	Invivogen	5 $\mu$ g/mL
Integrin $\alpha_2\beta_1$	TOCRIS	20 $\mu$ M
Integrin $\beta_3$	ABBIOTEC	11.2 $\mu$ g/mL

**Table 2.6 Platelet inhibitors.**

### 2.8.1.3 Light transmission aggregometry

Prior to the measurement of aggregatory responses, each channel of the AggRAM light transmission aggregometer (Helena Biosciences), was blanked with PPP of the same donor. To measure aggregation, PRP was transferred into individual cuvettes containing a siliconised magnetic stirrer and incubated for one minute at 37 °C. Where applicable each agonist was then added to each cuvette and the aggregatory response was recorded for 10 min at 37 °C with continuous stirring at 650 nm. As a positive control measure and to determine 100% aggregation, PRP treated with 20  $\mu$ M ADP was also included. The raw data files were exported and further processed using Microsoft Excel to determine initiation of aggregation (AG0) and time taken to reach 50% aggregation (AG50).

## 2.8.2 Platelet Calcium Mobilisation

Isolated PRP was initially counted using the Sysmex XP-300 before incubating with 5µM FURA-2/AM for 45 min at room temperature. Platelets were then pelleted at 800 g for 20 min at room temperature before being resuspended in modified Tyrode's buffer at a concentration of 4x10<sup>8</sup> platelets/mL. Wild-type or mutant strains of *P. gingivalis* were removed from 72 hour blood agar plates, resuspended in modified Tyrode's buffer and counted to determine an MOI of 1:10. The preloaded platelet suspension was transferred to each well of a 96-well plate, before recording the excitation of fluorescent intensities at both 340 and 380 nm simultaneously using a Clariostar microplate reader (BMG Labtech). The fluorescent emission of each test was recorded at 510 nm for 210 seconds with the initial 20 seconds being used as a baseline before automatically injecting platelet agonists or a buffer control. Intracellular calcium levels are then determined using the following equation;

$$\text{Relative fluorescence of intracellular calcium} = \frac{\text{Emission at 340nm}}{\text{Emission at 380nm}}$$

### **2.8.3 Platelet Granule Release Quantitation by Enzyme-linked Immunosorbent Assay (ELISA)**

PRP was initially counted using the Sysmex XP-300 before platelets were pelleted at 800 *g* for 20 min at room temperature before resuspending at a density of  $2 \times 10^8$ /mL in modified Tyrode's buffer. Strains of *P. gingivalis* (wild-type or mutants) were removed from 72 hour blood agar plates, resuspended in modified Tyrode's buffer, counted and adjust to an MOI of 1:10.  $2 \times 10^8$  platelets were then incubated with bacteria or ADP (20  $\mu$ M) for 20 min at room temperature before fixing in 0.5% PFA for 30 min, again at room temperature. Samples were centrifuged at 13,000 *g* for 5 min at 4 °C before the supernatants were removed and processed following the manufacturer's instructions of one of the following ELISA kits; human platelet factor 4 (PF4) (Abcam), interleukin 1 $\beta$  (IL-1 $\beta$ ) (Bio-Techne LTD) or Serotonin (Abcam). ELISA plates were read using and the data recorded using a Clariostar microplate reader (BMG Labtech).

## **2.9 Statistical Analysis**

Statistical analysis was conducted using the StatsDirect3 software (StatsDirect Ltd, Cheshire, UK). Data normality was determined by a D'Agostino & Pearson normality test before subsequent statistical analysis.

Parametric data was analysed using paired t-test. Non-parametric paired data was analysed using the Friedman test whereas non-paired non-parametric data was evaluated using the Kruskal-Wallis Test (Conover-Iman). The threshold for statistical significance was set at  $p < 0.05$ ; \* =  $P \leq 0.05$ , \*\* =  $P \leq 0.01$  and \*\*\* =  $P \leq 0.001$ . All experiments consisted of at least three biological replicates.

**Chapter 3: Characterisation of an *in vitro* cellular model to study platelet-periodontal pathogen interactions**

### 3.1 Introduction

The development and application of megakaryocytic cell lines, derived from patients with leukaemia, allow a unique opportunity to study the maturation and differentiation of megakaryocytes and their associated platelet-like phenotypes (Saito, 1997). The overall aim of this thesis is to investigate the effect of periodontal pathogens on platelet aggregation, activation and function. However, as experimental work on platelets requires fresh blood which needs to be immediately used due to an inability to effectively store samples (Bausset *et al.*, 2012), the megakaryocytic cell line, CHRF-288-11 was recruited as a cellular model to study platelet-pathogen interactions.

The CHRF-288-11 cell line is a megakaryocytic cell line, which was initially isolated from a biopsy of a metastatic tumour in a 17 month old infant with acute megakaryoblastic leukaemia (Fugman *et al.*, 1990). Further characterisation of this cell line indicated that CHRF-288-11 cells can be used as an effective megakaryocyte/platelet model (Lev-Lehman *et al.*, 1997), which can be matured towards platelet production (Deutsch *et al.*, 2008) as the cells express platelet derived growth factors (Yang *et al.*, 1997) as well as expressing platelet markers including integrins which are involved in platelet adhesion, aggregation and activation (Fugman *et al.*, 1990; Conran and Hemming, 1998; Nurhayati, Ojima and Taya, 2015).

## 3.2 Aims

The overall aim of this chapter is to validate a differentiated megakaryocytic cell line for the study of platelet-periodonto-pathogen interactions. This will be achieved by:


- Investigating the use of the CHRF-288-11 cells as an *in vitro* platelet-like cell line by determining expression of platelet specific markers
- Investigating CHRF-288-11 cells as an *in vitro* platelet-like model to study platelet pathogen interactions

### **3.3 Results**


#### **3.3.1 Optimisation of CHRF-228-11 differentiation**

Differentiation and maturation of CHRF-288-11 (CHRF) cells following exposure to phorbol 12-myristate 13-acetate (PMA) was investigated by immunofluorescence microscopy. PMA at both concentrations (10 and 50 ng/ml) successfully induced CHRF differentiation over the period investigated.

Successful differentiation was determined through cellular adherence, DAPI staining for nucleic morphology and an F-actin probe for cytoskeletal phenotyping. Representative micrographs are shown for both 10 ng/ml (Figure 3.1) and 50 ng/ml (Figure 3.2) PMA treatments. Both 10 and 50 ng/ml of PMA treatment induced differentiation from the day one time point as characterised by development of large multi-lobed nuclei and the formation of pseudopodial structures that protrude from the main cellular body when compared to the control cells. No changes were observed with cells treated with DMSO vehicle control, with consistent low cell numbers observed across all investigated time points. The observed phenotypic cellular differentiation was maintained throughout the day three, five and seven time points within both PMA treatments, with both treatments resulting in highly heterogeneous cellular populations with varying pseudopodia and no distinctive cytoskeletal structure. Cellular viability was also confirmed by trypan blue exclusion and remained at ~98% throughout all PMA treatments (data not shown). It was determined that 50ng/ml for a period of five days yielded the most consistent differentiated cell densities and was therefore selected for future investigations utilising this cellular model.




**Figure 3.1** **CHRF-288-11 differentiation with 10 ng/ml of PMA.** CHRF-288-11 cells were differentiated onto glass coverslips before being stained with a high affinity F-actin probe and DAPI. DAPI staining revealed the formation of large multi-lobed nuclei within 24 hours of PMA treatment. F-actin positivity showed the development of large pseudopodia that protruded from the cell body and became more defined over a seven day time course. DMSO was included as a vehicle control and is shown at the 7 day time point. Images are representative of at least three independent observations. Scale bars= 50  $\mu$ m.



**Figure 3.2** CHRF-288-11 differentiation using 50 ng/ml of PMA. CHRF cells were differentiated onto glass coverslips before being treated with an F-actin probe and the nucleic stain DAPI. Staining revealed the formation of large multi-lobed nuclei and large pseudopodial structures over the seven days of treatment. DMSO is included as a vehicle control and is shown at the 7 day time point. Images are representative of at least three independent observations. Scale bars= 50  $\mu$ m.

To further characterise the differentiated CHRF cells, expression of megakaryocytic/platelet surface protein and activation markers was determined by flow cytometry. A general increase in expression of CD41 and CD41/61 was observed up to five days of culture after which a decrease was observed with both PMA treatments (10 and 50 ng/ml). Over the seven day time course CHRF-288-11 cells were found not to express CD42b, throughout both the 10 and 50 ng/ml treatments, whilst the expression of CD62P increased almost two-fold compared to the DMSO controls (Figure 3.3). No significant differences were observed between 10 and 50 ng/ml PMA treatments at any of the time points investigated. The decrease in overall expression at day seven was attributed to cell detachment.




**Figure 3.3 Analysis of megakaryocytic protein expression following CHRF-288-11 differentiation.** CHRF-288-11 cells were treated with either 10 or 50 ng/ml of PMA and differentiation was monitored over a period of seven days. Cells were analysed by flow cytometry to determine the relative expression of cell surface proteins and platelet activation markers: CD41 (A), CD41/61 (B), CD62P (C) and CD42b (D). Expression of CD41, CD41/61 and CD62P increased within both PMA treatments when compared to the DMSO vehicle control up to day five before decreasing. CHRF cells did not express CD42b across all treatments and time points. No changes were observed in the DMSO vehicle control across all time points, with the day seven time point being included as a representative control. Data is expressed as the mean fluorescent index (MFI)  $\pm$ SEM,  $n=3$ .


### **3.3.2 Periodontal pathogen invasion and adhesion of CHRF-288-11 cells**

Following optimisation of CHRF differentiation, the ability of periodontal pathogens to adhere to and invade the differentiated CHRF-288-11 cells were investigated. Initially, undifferentiated and differentiated cells were treated with either *P. gingivalis* NCTC 11834 or *T. forsythia* ATCC 43037 (MOI of 1:10 or 1:100) and probed with pathogen specific antibodies, a high affinity actin probe and DAPI as a nucleic stain.


It was observed that, *P. gingivalis* associated with and invaded the undifferentiated CHRF-288-11 cells (Figure 3.4), with association and invasion increasing following CHRF-288-11 differentiation independent of MOI (Figure 3.5). Similarly *T. forsythia* was shown to interact with undifferentiated CHRF-288-11 cells (Figure 3.6) with cellular association and invasion increasing following CHRF differentiation (Figure 3.7) at both MOIs investigated. Within both undifferentiated and differentiated cells, *P. gingivalis* and *T. forsythia* were shown to localise within the cell membrane and the perinucleic space.




**Figure 3.4 Invasion of CHRF-288-11 cells by *P. gingivalis* NCTC 11834.** Undifferentiated CHRF-288-11 cells were challenged with *P. gingivalis* NCTC 11834 (MOI of 1:10 and 1:100) for 90 minutes at 37 °C, before being fixed and mounted onto glass microscope slides. Cells were then permeabilised and probed with a pathogen specific antibody, PGWC1 (green), an F-Actin probe (red) and the nucleic stain DAPI (blue). *P. gingivalis* NCTC 11834 localised with and invade CHRF-288-11 cells (white arrows). Images are representative of at least three independent observations. Scale bars= 50  $\mu$ m.



**Figure 3.5 *P. gingivalis* invades differentiated CHRF-288-11 cells.** CHRF cells were differentiated for five days before being challenged with *P. gingivalis* NCTC 11834 (MOI 1:10 or 1:100) and fixed. Cells were then permeabilised and stained with a *P. gingivalis* specific antibody (PGWC1; green), an F-actin probe (red) and mounted with DAPI (blue). A high level of invasion was observed with differentiated CHRF cells, with *P. gingivalis* localising within the membrane and nucleic regions of the cells. Images are representative of at least three independent observations. Scale bars= 50  $\mu\text{m}$ .




**Figure 3.6 CHRF-288-11 cellular invasion by *T. forsythia* ATCC 43037.** Undifferentiated CHRF-288-11 cells were exposed at an MOI of 1:10 or 1:100 to *T. forsythia* ATCC 43037 before being fixed and permeabilised. Cells were then stained with a pathogen specific antibody, TFWC (green), an F-actin probe (red) and DAPI (blue). These images demonstrate that *T. forsythia* invades and adheres to undifferentiated CHRF-288-11 cells (white arrows). Images are representative of at least three independent observations. Scale bars= 50  $\mu\text{m}$ .



**Figure 3.7 Invasion of differentiated CHRF-288-11 cells by *T. forsythia*.** Cells were challenged with *T. forsythia* at an MOI of either 1:10 or 1:100 before fixation. Cells were then permeabilised and probed with a pathogen specific antibody, TFWC (green), a high affinity F-actin probe (red) and DAPI (blue). A high level of cellular invasion was observed with bacterial cells localising within the cellular membrane and around the nuclei (white arrows). Images are representative of at least three independent observations. Scale bars= 50  $\mu$ m.

To quantitate cellular invasion, an antibiotic protection assays were performed on differentiated CHRF-288-11 cells (Figure 3.8). Differentiated CHRF-288-11 cells were challenged with wild-type strains of *P. gingivalis* (NCTC 11834, ATCC W50) or *T. forsythia* (ATCC 43037). To determine the role of the *P. gingivalis* outer-membrane protein (OMPA), cells were also challenged with deficient mutants lacking the two major subunits of the OMPA protein (NCTC 11834  $\Delta ompA1$ , NCTC 11834  $\Delta ompA2$ ).

All of the wild-type strains and mutants tested successfully adhered to and invaded the megakaryocytic-like cells. Although some variation in both cellular adhesion and invasion were observed, no significant differences were calculated between any of the variables tested.




**Figure 3.8 Bacterial adhesion and invasion of CHRF-288-11 cell by periodontal pathogens.** Differentiated CHRF-288-11 cells were challenged with *P. gingivalis* (NCTC 11834, NCTC 11834  $\Delta ompA1$ , NCTC 11834  $\Delta ompA2$ , ATCC W50) or *T. forsythia* (ATCC 43037) for 90 minutes (37 °C, 5% CO<sub>2</sub>). Invasion was defined as the percentage of bacterial inoculum protected from metronidazole, whereas total associated is the total percentage of bacterial cells recovered. The adhered population is then determined by subtracting the 'invaded' from 'total associated'. All *P. gingivalis* and *T. forsythia* strains tested were shown to adhere to and invade differentiated CHRF-288-11 cells. Data is presented as a percentage recovery relative to the total inoculum.  $\pm$ SEM,  $n=3$ .

### **3.3.3 Analysis of CHRF-288-11 interactions with periodontal pathogens by immunofluorescent microscopy**


Following the initial immunofluorescent characterisation of periodontal-pathogen invasion of CHRF cells, further investigation focussed on exploring the impact of pathogen invasion on CHRF protein expression. The effects of *P. gingivalis* NCTC 11834 and *T. forsythia* ATCC 43037 were determined in relation to the expression of two proteins of interest; the Mammalian Target of Rapamycin (mTOR) and integrin  $\beta$ 3.

#### **3.3.3.1 Analysis of CHRF-288-11 mTOR expression following incubation with periodontal pathogens**


Undifferentiated CHRF-288-11 cells expressed mTOR and the rate of bacterial association increased with increasing MOI with both *P. gingivalis* NCTC 11834 (Figure 3.9) and *T. forsythia* 43037 (Figure 3.10). However, no variances in protein expression were observed in either bacterial treatment when compared to the untreated control. In contrast, while differentiated CHRF-288-11 cells also showed/demonstrated increased bacterial association with increasing MOI, the overall expression of mTOR decreased following exposure to both *P. gingivalis* NCTC 11834 (Figure 3.11) but not with *T. forsythia* 43037 (Figure 3.12).




**Figure 3.9** The effect of *P. gingivalis* invasion on mToR expression in CHR28-11 cells. CHR28-11 cells were challenged with *P. gingivalis* NCTC 11834 for 90 minutes before being fixed and permeabilised. Cells were then probed for mToR expression (red), a pathogen specific antibody (PGWC1, green) and DAPI. Images highlight the CHR28-11 cells express mToR but its relative expression is not effected through bacterial association at an increasing MOI. Images are representative of at least three independent observations. Scale bars= 50 $\mu$ m.



**Figure 3.10 Determination of mToR expression following exposure to *T. forsythia* in CHR-288-11 cells.** Cells were challenged with *T. forsythia* ATCC 43037 for 90 minutes before fixation. Cells were then permeabilised and stained for mToR (red), DAPI (blue) and *T. forsythia* (green). Despite bacterial association increasing with an increasing MOI, no changes in mToR expression were observed across any treatments. Images are representative of at least three independent observations. Scale bars= 50  $\mu$ m.




**Figure 3.11 *P. gingivalis* decreases mToR expression in differentiated CHR-288-11 cells.** CHR-288-11 cells were differentiated for five days before being challenged with *P. gingivalis* at an MOI of either 1:10 or 1:100. Cells were then fixed, permeabilised and probed for DAPI (blue), mToR (red) and *P. gingivalis* (PGWC1, green). Large lobed nuclei confirm cellular differentiation, with bacterial association also increasing with an increasing MOI. Bacterial treatment resulted in no change within expression of mToR at both an MOI of 1:10 and 1:100. Images are representative of at least three independent observations. Scale bars= 50  $\mu$ m.




**Figure 3.12** Effect of *T. forsythia* invasion on mToR expression in differentiated CHR2-288-11 cells. Cells were differentiated for five days before being exposed to *T. forsythia* ATCC 43037 for 90 minutes and fixed. Cells were then permeabilised before being stained for mToR expression (red), nucleic phenotyping (DAPI, blue) and bacterial cells (TFWC, green). Bacterial treatment with *T. forsythia* resulted in no change within mToR staining despite an increased bacterial association at both an MOI of 1:10 and 1:100. Images are representative of at least three independent observations. Scale bars= 50  $\mu$ m.

### **3.3.3.2 Analysis of CHRF-288-11 integrin $\beta$ 3 expression following incubation with periodontal pathogens**


Undifferentiated and differentiated CHRF-288-11 cells expressed integrin  $\beta$ 3, uniformly diffused across the cell membrane (Figure 3.13-3.16). Exposure to bacterial cells at an increasing MOI resulted in an increased bacterial association and invasion by both *P. gingivalis* NCTC 11834 and *T. forsythia* 43037. Within both undifferentiated (Figure 3.13 and 3.14) and differentiated (Figure 3.15 and 3.16) cells, exposure to either pathogen resulted in an increased expression of integrin  $\beta$ 3 although no localisation between either pathogen or integrin  $\beta$ 3 could be determined.




**Figure 3.13** The effect of *P. gingivalis* invasion on integrin  $\beta$ 3 expression in CHRF-288-11 cells. CHRF cells were challenged with *P. gingivalis* for 90 minutes before cells were fixed and permeabilised. Cells were then treated with anti- $\beta$ 3 (red) and pathogen specific (PGWC1, green) antibodies before being mounted with DAPI (blue). Incubation with *P. gingivalis* increases staining of integrin  $\beta$ 3 most notably at an MOI of 1:100. Images are representative of at least three independent observations. Scale bars= 50  $\mu$ m.



**Figure 3.14 Relative integrin  $\beta$ 3 expression following exposure to *T. forsythia* ATCC 43037.** CHRF cells were treated with *T. forsythia* ATCC 43037 for 90 minutes before associated bacterial cells were removed. Cells were then fixed, permeabilised and probed for integrin  $\beta$ 3 (red), *T. forsythia* ATCC 43037 (TFWC, green) and mounted with DAPI (blue). Bacterial challenge with *T. forsythia* ATCC 43037 increases integrin beta 3 expression at an MOI of 1:10 and 1:100. Images are representative of at least three independent observations. Scale bars= 50  $\mu$ m.



**Figure 3.15** The effect of *P. gingivalis* invasion on integrin  $\beta$ 3 expression by differentiated CHRF-288-11 cells. CHRF-288-11 cells were differentiated for five days before being challenged with *P. gingivalis* NCTC 11834 at an MOI of with 1:10 or 1:100 for 90 minutes at 37 °C. Cells were then fixed, permeabilised and probed for *P. gingivalis* NCTC 11834 (PGWC1, green), integrin  $\beta$ 3 expression (red) and DAPI (blue). Incubation with *P. gingivalis* NCTC 11834 increased  $\beta$ 3 expression at both an MOI of 1:10 and 1:100 when compared with the untreated controls. Images are representative of at least three independent observations. Scale bars= 50  $\mu$ m.




**Figure 3.16 *T. forsythia* increases  $\beta$ 3 expression in differentiated CHRF-288-11 cells.** CHRF-288-11 cells were differentiated before being exposed to *T. forsythia* ATCC 43037 at an MOI of either 1:10 or 1:100. Cells were then fixed and permeabilised before being stained for  $\beta$ 1 (red), *T. forsythia* ATCC 43037 (TFWC, green) and DAPI (blue). Following exposure to *T. forsythia* ATCC 43037, integrin  $\beta$ 1 staining increased at both an MOI of 1:10 and 1:100. Images are representative of at least three independent observations Scale bars= 50  $\mu$ m.

### **3.3.4 Flow cytometric analysis of megakaryocytic/platelet markers following *P. gingivalis* challenge**

Having demonstrated that *P. gingivalis* invade differentiated megakaryocytic-like cells, impacting on integrin  $\beta$ 1 and mTOR expression, further investigations were undertaken to determine the effect of periopathogens on surface megakaryocyte/platelet markers. Using flow cytometry, *P. gingivalis* association with differentiated CHRF cells and the relative expression of CD41, CD61, CD41/61 and CD62P were quantified (Figure 3.17).

Using this approach, sub-populations of cells associated with *P. gingivalis* (wild-type or OMPA deficient mutants) could not be identified as no significant increase in PGWC1 fluorescence was detected when bacterial treated samples were compared to untreated controls (Figure 3.17a). Similarly, no significant change in integrin expression was detected with either CD41 (Figure 3.17b), CD61 (Figure 3.17c), CD41/61 (Figure 3.17d) or CD62P (Figure 3.17e) following bacterial treatment with wildtype or mutant *P. gingivalis*.




**Figure 3.17 Quantitation of megakaryocytic surface marker expression following challenge with *P. gingivalis* using flow cytometry.** Differentiated CHRF-288-11 cells were challenged with either wild-type *P. gingivalis* (NCTC 11834, ATCC W50) or the OMPA deficient mutants NCTC 11834  $\Delta ompA1$  and NCTC 11834  $\Delta ompA2$  before being treated with antibodies to detect the expression of platelet surface antigens and pathogen presence (PGWC1). No significant changes in detection of bacterial association (A) or the expression of CD41 (B), CD61 (C), CD41/61 (D) and CD62P (E) following bacterial challenge. Data is expressed as  $\pm$ SEM,  $n=3$ .

### **3.3.5 Development of a cell-based ELISA for immunophenotyping of CHRF-288-11 cells following periodontal pathogen challenge**

To further quantify periodontal pathogen invasion of CHRF-288-11 cell and the effect of pathogen invasion on surface protein expression, a cell-based ELISA was developed. Cells were differentiated onto a solid surface and probed for bacterial binding using pathogen specific antibodies (PGWC1, TFWC) or the relative expression of CHRF integrins  $\beta$ 1 and  $\beta$ 3.


Following bacterial challenge at an MOI of 1:100, significant binding of *P. gingivalis* NCTC 11834 and ATCC W50 was observed ( $p < 0.001$ ; Figure 3.18a), as well as a significant increase in expression of integrin  $\beta$ 1 ( $p < 0.001$ , Figure 3.18b). *P. gingivalis* NCTC 11834 was also found to induce a significant increase of  $\beta$ 3 expression ( $p < 0.001$ ; Figure 3.18c). A slight increase in integrin  $\beta$ 3 expression was also observed following exposure to ATCC W50, although this was determined as not statistically significant (Figure 3.18c). *T. forsythia* ATCC 43037 did not associate with differentiated CHRF-288-11 cells (Figure 3.18a) or induce any change in either integrin  $\beta$ 1 (Figure 3.18b) or  $\beta$ 3 (Figure 3.18c) expression.



**Figure 3.18 Analysis of bacterial association and integrin expression by a cell-based ELISA.** CHR-288-11 were differentiated into well-plates before being challenged with periodontal pathogens (MOI 1:100), fixed and probed with pathogen specific antibodies (PGWC1 or TFWC) (A) or for expression of integrin  $\beta$ 1 (B) and integrin  $\beta$ 3 (C). Significant binding of *P. gingivalis* NCTC 11834 and ATCC W50 was detected at an MOI of 1:100 (A). A significant increase in expression of integrin  $\beta$ 1 was detected following treatment with *P. gingivalis* NCTC 11834 and ATCC W50 (B), with *P. gingivalis* NCTC 11834 also stimulating a significant increase in  $\beta$ 3 expression (C). Data is expressed as  $\pm$ SEM,  $p=*** <0.001$ ,  $n=3$ .


### **3.3.5.1 Is *P. gingivalis* association and interaction with CHRF-288-11 dependent on the multiplicity of infection?**

Investigations to determine whether the observed association to CHRF-288-11 cells by *P. gingivalis* was MOI dependant. Differentiated CHRF-288-11 cells were challenged with *P. gingivalis* at an increasing MOI before cells were fixed and probed with pathogen specific antibodies (PGWC1). *P. gingivalis* NCTC 11834 (Figure 3.19a) and ATCC W50 (Figure 3.19b) were both shown to increase in bacterial association relative to an increasing MOI.



**Figure 3.19 Specific periodontal pathogen interaction with differentiated CHRF-288-11 cells.** Differentiated CHRF-288-11 cells were challenged with bacterial cells at an increasing MOI before fixation and detection with pathogen specific antibodies. The data demonstrates specific, pathogen binding in a direct relationship with increasing MOI following treatment with *P. gingivalis* NCTC 11834 (A), *P. gingivalis* ATCC W50 (B). Data is expressed as  $\pm$ SEM,  $n=3$ .

After confirming that periodontal pathogen interaction was specific and MOI dependant, the relationship between integrin expression and bacterial invasion was investigated. As above, differentiated CHRF-288-11 cells were challenged with a titrated MOI of periodontal pathogens before fixation and the relative expression of integrin  $\beta$ 1 and  $\beta$ 3 was detected (Figure 3.20). These results show that *P. gingivalis* NCTC 11834 stimulates an increase in expression of integrin  $\beta$ 1 (Figure 3.20a) and integrin  $\beta$ 3 (Figure 3.20b) at all the MOI's tested with the observed increase in expression appearing to be independent of MOI and of direct consequence, solely to bacterial treatment. Similar findings were also observed when cells were treated with *P. gingivalis* ATCC W50 (Figure 3.20c-d).



**Figure 3.20** The effect of MOI on periodontal pathogen induced integrin expression in differentiated **CHRF-288-11** cells. Differentiated CHRF cells were challenged with periodontal pathogens at an increasing MOI, before being fixed and probed for expression of integrin  $\beta$ 1 and  $\beta$ 3. Both *P. gingivalis* NCTC 11834 and ATCC W50 induced an increase in expression of integrin  $\beta$ 1 (A and C) and  $\beta$ 3 (B and D). Data presented is a representative figure of three independent observations.

### 3.4 Discussion

The overall aim of this study is to determine whether an *in vitro* megakaryocytic cell line can be used to study platelet-pathogen interactions. Due to the ability of platelets to become readily activated and the lack of reliable storage options, platelet studies require fresh platelets and as such, also rely on regular blood donations (Bausset *et al.*, 2012). The availability of a platelet-like cell line will therefore help minimise the reliance on blood donations, an invasive procedure, whilst enabling studies to be conducted *in vitro*, prior to validation using fresh platelets isolated from donors.

Earlier studies have proposed the use of megakaryocytic-like cell lines such as DAMI (Greenberg *et al.*, 1988) and UT-7 (Komatsu *et al.*, 1991) within platelet research. However, as with many cell lines, megakaryocytic-like cells carry many caveats including misidentification, contamination as well as genomic and phenotypic instability (Geraghty *et al.*, 2014). As an example, UT-7 cells have since been shown to express markers of different cell lineages including those associated with erythroid and myeloid phenotypes (Saito, 1997). Further to this, although the DAMI cell line seemed promising as an *in vitro* platelet model, since its initial characterisation it is reported to either be contaminated with or share genetic markers with the HEL erythroleukemia cell line (MacLeod *et al.*, 1997). For these reasons, initial investigations focussed on characterising the CHRF-288-11 cell line and exploring its suitability as a platelet-like model.

Optimisations of the CHRF-288-11 cells confirmed that treatment with PMA (50 ng/ml) over a five day period yielded consistent CHRF differentiation. This was assessed by the characteristic changes in phenotype and illustrated by cell enlargement and the

formation of polyploid, multi-lobed nuclei in line with previous reports by Fugman and colleagues (1990).

Further analysis of differentiated CHRF cells via flow cytometry confirmed the expression of several markers attributed to the megakaryocytic cell lineage and platelet production. In agreement with findings by Conran and Hemming (1998), CHRF cells were found to express both CD41 ( $\alpha$ IIb, GPIIb) and CD61 ( $\beta$ 3, GPIIIa), which form the heterodimer complex of CD41/61 that is expressed by both megakaryocytes (Duperray *et al.*, 1987) and platelets (Wagner *et al.*, 1996b). The megakaryocytic-like cells were also shown to express the activated epitope of CD41/61, which acts as a fibrinogen receptor during platelet activation (Shattil *et al.*, 1985).

Additionally, an increase in CD62P expression, a protein normally contained within platelet alpha granules (Stenberg *et al.*, 1985), was observed following PMA treatment on the cell surface of the differentiated megakaryocytic cells. Surprisingly, it was also found that CHRF-288-11 cells did not express CD42b (GPIb $\alpha$ ) within either undifferentiated or differentiated cells. Although GPIb $\alpha$  is highly expressed on the surface of platelets (Li and Emsley, 2013), it is also expressed by megakaryocytes, with an increase in GPIb $\alpha$  expression being reported as a marker for both maturation and differentiation (Lepage *et al.*, 2000).

Following the initial characterisation of the CHRF-288-11 cells and their associated platelet-like phenotype, further investigations explored whether this cell type could interact with oral pathogens. Despite the role of platelets within the immune system being widely published (Klinger and Jelkmann, 2002; Yeaman, 2010b; Gardiner and Andrews, 2013; Ali, Wuescher and Worth, 2015; Koupenova and Freedman, 2015), research surrounding bacterial interactions with megakaryocytes is highly limited.

Megakaryocytes are derived through haematopoietic stem cell differentiation and as a cell type are extremely rare, accounting for approximately 0.1% of nucleated cells within the bone marrow, which would suggest that interactions with bacterial cells are highly improbable. However, as well as residing within the bone marrow, megakaryocytes are also routinely found within circulating blood (Kallinikos-Maniatis, 1969) and have been shown to migrate to, terminally differentiate and produce platelets within the lung tissue (Howell and Donahue, 1937; Lefrançois *et al.*, 2017) suggesting that although improbable, interactions with bacterial cells are not altogether impossible. It has also been previously reported that megakaryocytes express toll-like receptors, suggesting that they could hypothetically interact with bacterial cells (Beaulieu and Freedman, 2010), with a further study showing that isolated megakaryocytes can interact with heat-inactivated *Escherichia coli*, stimulating the translocation of complement protein C (Arbesu *et al.*, 2016).

In contrast, it is well-established that the periodontal pathogens *P. gingivalis* and *T. forsythia* ATCC 43037 interact and invade a range of cell types including epithelial cells (Nakajima *et al.*, 2006; Stathopoulou *et al.*, 2010; Suwannakul *et al.*, 2010; Mishima and Sharma, 2011; Stafford *et al.*, 2013), osteoblasts (Zhang *et al.*, 2010), trophoblasts (Inaba *et al.*, 2009) as well as cells of the hematopoietic stem cell lineage such as monocytes (Pollreis *et al.*, 2010; Bloch *et al.*, 2018). Periodontal pathogens have also been associated with increasing risk of cardiovascular disease (Kebuschull, Demmer and Papapanou, 2010) while *P. gingivalis* has been shown to induce platelet aggregation (Curtis *et al.*, 1993a). However, the mechanisms of these interactions are not fully understood.

Using the CHRF-288-11 cells as a platelet-like cell line, the interaction of both *P. gingivalis* and *T. forsythia* were investigated. Increased association of pathogens with differentiated CHRF cells were observed by immunofluorescence microscopy and further confirmed by ELISA. *P. gingivalis* and *T. forsythia* invaded the differentiated cells in an antibiotic-protection assay and were shown to localise within peri-nuclei regions. This observed cellular interaction with CHRF-288-11 cells agrees with previous findings that demonstrate that both *P. gingivalis* (Belton *et al.*, 1999) and *T. forsythia* (Inagaki *et al.*, 2006) are able to localise intracellularly with cellular invasion occurring in similar levels to that observed within host epithelium.

As well as characterising interactions with wild-type *P. gingivalis*, the role of the major outer membrane protein subunits OMPA1 and OMPA2 within CHRF-288-11 interactions were also explored. No significant differences were observed between either the  $\Delta ompA1$  or the  $\Delta ompA2$  deficient mutants when compared to the parent strain within CHRF-288-11 association as determined by antibiotic protection assays and flow cytometry. It has previously been shown that OMPA, specifically the OMPA2 subunit is fundamental for interactions between *P. gingivalis* and epithelial cells *in vitro* (Naylor *et al.*, 2016). However the data produced within this chapter of work suggests that *P. gingivalis* interactions with CHRF-288-11 cells occur independently of either OMPA subunit, suggesting that both of the OMPA subunits can facilitate bacterial association with CHRF-288-11 cells independently. Further investigations therefore targeted understanding how *P. gingivalis* interacts with megakaryocytic-like cells.

As pathogens such as *Escherichia coli* (Arbesu *et al.*, 2016) are known to activate platelets and alter the expression levels of surface platelet markers, the effect of *P.*

*gingivalis* NCTC 11834 and ATCC W50 on the expression of specific cellular markers expressed by both CHRF-288-11 cells and mammalian platelets was investigated.

The mammalian target of rapamycin (mTOR), a serine kinase that integrates with several key process including cell proliferation, protein synthesis and autophagy (Hay and Sonenberg, 2004) has been identified within previous research by Stafford and colleagues (2013) as a target for *P. gingivalis* host cell manipulation. Within this chapter of work, immunofluorescent analysis revealed that incubation with *P. gingivalis* resulted in a decreased expression of mTOR within differentiated CHRF-288-11 cells in an MOI dependant relationship, whereas incubation with *T. forsythia* did not. In agreement with these findings, within epithelial cells, gingipains derived from *P. gingivalis* have been shown to degrade mTOR and manipulate cell signalling pathways (Stafford *et al.*, 2013) and could suggest a similar mechanism in which *P. gingivalis* interacts with megakaryocytic-like cells.

Further to this, *P. gingivalis* is known to interact with host cells through multiple pathways including targeting and manipulating integrin expression, such as integrin  $\beta 1$  (Yilmaz, Watanabe and Lamont, 2002; Li *et al.*, 2013) and  $\beta 3$  (Li *et al.*, 2013; Boisvert, Lorand and Duncan, 2014). Within this chapter of work, it was investigated as to whether *P. gingivalis* could affect integrin  $\beta 1$  and  $\beta 3$  expression within the CHRF-288-11 cell line. Immunofluorescent images highlighted an overall increase in CHRF-288-11 expression of integrin  $\beta 3$  following bacterial challenge with both *P. gingivalis* and *T. forsythia*. It was also found that CHRF-288-11 integrin  $\beta 3$  expressions was uniformly diffused throughout the cell membranes and no distinct localisation between integrin expression and the presence of either *P. gingivalis* or *T. forsythia*. This initial data was also further confirmed through the application of a cell based ELISA, which

demonstrated an increase in expression in both integrin  $\beta 1$  and  $\beta 3$  following exposure to both *P. gingivalis* NCTC 11834 and ATCC W50 that was not dependent on MOI. Surprisingly however, further application of this developed ELISA revealed that *T. forsythia* did not bind to either recombinant  $\beta 1$  or  $\beta 3$ , suggesting that other external factors may be needed for *T. forsythia* to associate with CHRF-288-11 cells for example through binding of lectin-like receptors or interactions with host toll-like receptors through expressed leucine-rich repeat motifs (Sharma, 2010).

Although the development of this protocol is novel within the study of megakaryocytic-like cells, it has previously reported that several bacterial species including *Staphylococcus spp.*, *Streptococcus spp.* and *Escherichia coli* can induce and amplify platelet activation through interactions with the integrin complex  $\alpha IIb\beta_3$  (Arman *et al.*, 2014; Watson *et al.*, 2016), with *P. gingivalis* also being shown to bind to both integrin  $\alpha v\beta 3$  and  $\alpha 5\beta 1$  when overexpressed with a Chinese hamster ovary cell lines. However research surrounding the interactions between either *P. gingivalis* or *T. forsythia* and cells of megakaryocytic lineage is to date extremely limited. Within this study, a more in-depth analysis of integrin expression by flow cytometry following exposure to periodontal pathogens was attempted but was deemed unsuccessful and did not generate any observable differences within any of the markers tested. It was originally hypothesised that sub-populations of invaded CHRF-288-11 cells could be identified through the application of pathogen specific antibodies but due to experimental and equipment limitations this could not be achieved.

The application of the CHRF-288-11 cell line within this study has provided an unlimited and rapid screening methodology of bacterial interactions with several markers specific to mature mammalian platelets. However it must be noted that as

with many megakaryocytic cell lines, the CHRF-288-11 cells are of leukemic origin (Fugman *et al.*, 1990) and despite the CHRF-288-11 cells actively expressing multiple phenotypes associated with both megakaryocytes and platelets, it is important to confirm any finding within a highly purified platelet population. Further to this, recent developments within megakaryocyte culture techniques are detailing the routine culture of primary megakaryocytes and the production of large volumes of platelets *in vitro* (Moreau *et al.*, 2016; Strassel, Gachet and Lanza, 2018), meaning that the use of megakaryoblast cell lines as well as the need for regular blood acquisition could soon be abolished entirely within the field of platelet research.

### 3.5 Summary

In conclusion, this study has highlighted that the CHR-288-11 megakaryocytic-like cells can be utilised through a series of methodologies to study the pathogenic effects of periodontal pathogens on platelets and the megakaryocytic cells *in vitro*. This developed methodology could be applied to understand how these anaerobic bacteria can stimulate host cell responses and how platelets behave following infection.

Although multiple previous studies have shown that periodontal pathogens can infiltrate and interact with various cell types (Lamont *et al.*, 1995; Deshpande, Khan and Genco, 1998; Simin F Nakhjiri *et al.*, 2001; Yilmaz, Watanabe and Lamont, 2002; Yilmaz *et al.*, 2008; Kirschbaum *et al.*, 2010a; Suwannakul *et al.*, 2010; Honma, Mishima and Sharma, 2011; Stafford *et al.*, 2013; Naylor *et al.*, 2016), as well as alter host cellular functions (Darveau *et al.*, 1998; Tervahartiala *et al.*, 2000; Kiili *et al.*, 2002; Yilmaz *et al.*, 2003, 2008; Nakajima *et al.*, 2006; Posch *et al.*, 2011; Settem *et al.*, 2013; Stafford *et al.*, 2013; Ksiazek, Mizgalska, Enghild, *et al.*, 2015; Lee *et al.*, 2015; Naylor *et al.*, 2016) very little work has focussed on how these bacterial species may impact platelets or result in atherosclerotic phenotypes (Yun *et al.*, 2005; Nicu *et al.*, 2009; Papapanagiotou *et al.*, 2009; Arman *et al.*, 2014). More specifically, no current work has explored; how *T. forsythia* may affect any haematopoietic cell lineages, how periodontal pathogens could affect platelet function or how platelet/periopathogen interactions and the resulting consequences occur at the cellular level. Further work is needed to expand these initial studies to fully characterise the effects of *P. gingivalis* and *T. forsythia* on CHR-288-11 cells as well as moving on to validating these findings in platelets, in order to answer these questions.

## **Chapter 4: Can periodontal pathogens interact with and induce platelet aggregation?**

## 4.1 Introduction

The interactions between prokaryotes and mammalian platelets have been well documented with detailed studies showing that a broad spectrum of bacterial species can not only bind to platelets, but also induce platelet aggregation and activation (Clawson and White, 1971a, 1971b; Clawson, 1973; Clawson, Rao and White, 1975; Kerrigan, 2015). Examples of such interactions include the induction of aggregation and degranulation of platelets by *Staphylococcus aureus* (Hawiger *et al.*, 1979) and the indirect interaction between *Streptococcus pyogenes* and platelets that is mediated by the availability of fibrinogen and von Willebrand factor (vWf) (Kurpiewski *et al.*, 1983; Johnson and Bowie, 1992). Further to this several orally derived bacterial species, including *Streptococcus spp.*, *Staphylococcus spp.*, *Pseudomonas aeruginosa* and *Porphyromonas gingivalis*, have been implicated in cardiovascular disease (CVD) (McNicol and Israels, 2010; McNicol, 2015). It is thought that bacteria are able to gain access to the circulation, penetrate vascular walls causing secondary infections that ultimately lead to the formation of atherosclerotic plaques which then rupture and lead to platelet clotting and atherothrombosis (Kaplan and Jackson, 2011). Several studies have also suggested that bacterial-platelet interactions are crucial to the pathogenesis of some cardiovascular pathologies, as reviewed by McNicol and Israels (2010).

Blood platelets undoubtedly play a predominant role within haemostasis, but their emerging role within antimicrobial host defence and in modulation of inflammatory responses could hold a crucial link that underpins the mechanism behind thrombotic and inflammatory events (Von Hundelshausen and Weber, 2007). In the context of periodontal pathogens, oral pathogenic bacteria have been reported to interact with

platelets through toll-like receptors (TLR's), causing platelet activation and the release of activation markers such as P-selectin and ADP (Shiraki *et al.*, 2004; Blair *et al.*, 2009; Zhang *et al.*, 2009) as well as inducing the pro-thrombotic pathway (Roth *et al.*, 2009). However the exact mechanisms by which these interactions occur are not fully elucidated.

The sequence of events that follows platelet-bacterial association can be defined as; contact, shape change, early aggregation and irreversible aggregation (Clawson and White, 1971a). The use of light transmission aggregometry was initially developed in the 1960's (Born and Cross, 1963; Vigdahl, Marquis and Tavormina, 1969) and is still recognised as the gold-standard approach in platelet function testing in relation to cardiovascular diseases (Michelson, 2004). This chapter expands on the initial findings that *P. gingivalis* can induce platelet aggregation (Naito *et al.*, 2006; Naito, 2007; Li *et al.*, 2008) and investigates how viability and virulence factors of both *P. gingivalis* and *T. forsythia* could act as contributing factors to platelet/periopathogen interactions.

## 4.2 Aims

The studies described in this chapter aim to determine whether the periodontal pathogens *P. gingivalis* and *T. forsythia* induce platelet aggregation. This was investigated by determining:


- The possible induction of platelet aggregation by a range of *P. gingivalis* and *T. forsythia* strains at varying multiplicities of infection.
- The contribution of virulence associated bacterial proteins on the induction of platelet aggregation.
- Whether heat-killed bacteria can induce platelet aggregation.

## 4.3 Results

### 4.3.1 Platelet aggregation with wildtype *P. gingivalis* and *T. forsythia*

Light transmission aggregometry was initially used to screen wildtype (WT) *P. gingivalis* strains NCTC 11834, ATCC W50, ATCC 381 and *T. forsythia* ATCC 43037 to determine whether they induced platelet activation at varying multiplicity of infection (MOI). Isolated platelet rich plasma (PRP) was exposed to wildtype *P. gingivalis* at an MOI of 1:1 and 1:10. The rate of platelet aggregation was recorded over a period of 10 minutes at 37 °C and compared to untreated PRP or PRP treated with ADP (20 µM), as a negative and positive control respectively. A representative aggregation plot is shown in Figure 4.1a. As expected ADP induced platelet aggregation (red), while no aggregation was observed with untreated PRP (blue). *P. gingivalis* NCTC 11834 was also observed to induce platelet aggregation which reached a peak at 8 minutes when compared to ADP with maximum aggregation reached within 4 minutes.

Interestingly, aggregation was observed to be strain dependent with significant aggregation induced by *P. gingivalis* NCTC 11834 at an MOI of both 1:1 ( $p < 0.05$ ) and 1:10 ( $p < 0.001$ ), and by *P. gingivalis* ATCC 381 at an MOI of 1:10 ( $p < 0.001$ ; Figure 4.1b). With *P. gingivalis* ATCC W50, no aggregation was observed at either MOI within the 10 minute period (Figure 4.1b). In contrast to *P. gingivalis*, aggregation was not induced by wildtype *T. forsythia* at either MOI under the same experimental conditions (Figure 4.1c).




**Figure 4.1 Induction of platelet aggregation by wildtype (WT) periodontal pathogens.** (A) Example aggregation plot. An example trace of light transmission aggregometry recorded over 10 minutes at 37°C with *P. gingivalis* (green). Aggregation induced by ADP (20 µM, red) represents 100% aggregation and was included as a positive control. Untreated PRP (blue) was included as a negative control and demonstrates 0% aggregation. (B) Platelet aggregation by WT *P. gingivalis*. WT *P. gingivalis* NCTC 11834 and ATCC 381 triggered platelet aggregation at MOI of 1:1 and 1:10. Aggregation was not observed with ATCC W50 at either MOI investigated over the 10 minute period. (C) Platelet aggregation by WT *T. forsythia*. Platelet aggregation was not observed in the presence of WT *T. forsythia* at an MOI of either 1:1 or 1:10 ADP (20 µM) and untreated PRP are included as positive and negative control respectively. Data is expressed as  $\pm$ SEM,  $p = * \leq 0.05$ ,  $*** \leq 0.001$ .  $n = 4$ .

### **4.3.2 Investigation of the effect of bacterial virulence on platelet aggregation in induced by *P. gingivalis***

After the initial findings that wildtype *P. gingivalis* induces platelet aggregation in a strain dependant manner, further investigations were conducted to explore whether factors associated with bacterial virulence and/or interaction with cells could affect either the total percentage or the rate of aggregation. The ability of the *P. gingivalis* mutants *P. gingivalis* NCTC 11834  $\Delta ompA1$ , *P. gingivalis* NCTC 11834  $\Delta ompA2$  and *P. gingivalis* ATCC 381  $\Delta Sia0352$  (described in Section 3.4) on platelet aggregation was determined. All mutants investigated, induced aggregation ( $p < 0.001$ ) at MOI 1:10, which was comparable to the parental strain (Fig 4.2).


The rate of aggregation was determined by calculating the time taken to reach 50% aggregation (AG50). Interestingly, AG50 values were found to vary when wildtype and mutants were compared (Figure 4.2). Both PG mutants deficient in the outer-membrane proteins OMPA1 (*P. gingivalis* NCTC 11834  $\Delta ompA1$ ) and OMPA2, (*P. gingivalis* NCTC 11834  $\Delta ompA2$ ) significantly induce platelet aggregation when compared to the parent wildtype strain ( $p < 0.05$ , 0.01). The  $\Delta ompA2$  mutant also exhibited a faster rate of aggregation when compared to the  $\Delta ompA1$  mutant. This finding was also observed with *P. gingivalis* ATCC 381  $\Delta Sia0352$ , which induced a significantly faster rate of platelet aggregation when compared to the wildtype strain ( $p < 0.01$ ; Fig. 4.2).



**Figure 4.2 The effect of virulence associated proteins on platelet aggregation. (A)** Induction of aggregation by mutants of *P. gingivalis*. Following exposure to mutants or WT strains of *P. gingivalis*, significant levels of aggregation was observed when compared to untreated PRP samples. **(B)** Time taken for platelet aggregation to reach 50% (AG50) of platelet aggregation when stimulated by WT *P. gingivalis* and mutants. Both mutants deficient in the outer membrane proteins (OMP A1 and OMP A2) and the Sialidase deficient strain ( $\Delta$ Sia0352) significantly induced a faster rate of aggregation when compared to the relevant WT strains. The  $\Delta ompA2$  mutant was also observed to induce aggregation a faster rate when compared to the  $\Delta ompA1$  mutant. ADP (20  $\mu$ M) was included as a positive control for platelet aggregation. Data is expressed as  $\pm$ SEM,  $p = * \leq 0.05$ ,  $** \leq 0.01$ ,  $*** \leq 0.001$ .  $n = 4$ .

### 4.3.3 Investigation of aggregation induced by *T. forsythia* mutants

After previous experiments (Section 4.3.2) revealed that bacterial virulence associated factors could affect the rate of platelet aggregation it was hypothesised that the virulence factors associated with *T. forsythia* could be preventing an aggregatory response. In order to investigate this both the *T. forsythia* ATCC 43037  $\Delta nanH$  deficient mutant and the *T. forsythia* ATCC 43037  $\Delta wecC$  isogenic mutant (described in Section 3.4) were investigated in parallel with the wildtype strain. Contrary to the hypothesis, none of the bacterial stimulants caused platelet aggregation when compared to untreated PRP and PRP treated with ADP (20  $\mu$ M) as a negative and positive control respectively (Figure 4.3).




**Figure 4.3 Platelet aggregation by *T. forsythia* WT strain and mutants.** Platelets treated with *T. forsythia* ATCC 43037 or one of the two mutants (*T. forsythia* ATCC 43037  $\Delta nanH$  or *T. forsythia* ATCC 43037  $\Delta wecC$ ) did not induce platelet aggregation at an MOI of 1:10. ADP (20  $\mu$ M) was included as a positive control and all samples were directly compared to untreated PRP. Data is expressed as  $\pm$ SEM,  $p=***<0.001$ .  $n=4$ .

#### 4.3.4 Investigations into the effect of bacterial viability on platelet aggregation

After it had been demonstrated that platelet aggregation can be induced by viable periodontal pathogens, investigations were conducted to elucidate whether the pathogens need to be viable to elicit this effect. *P. gingivalis* NCTC 11834, ATCC W50 and *T. forsythia* ATCC 43037 were heat treated and the effect of the resulting heat-killed bacteria on platelet aggregation was determined. It was observed that both viable and heat killed *P. gingivalis* induced significant aggregation ( $p < 0.01$ , 0.001), however when compared to the wildtype, the heat killed bacteria showed a significant decrease in percentage aggregation ( $p < 0.001$ ; Figure 4.4a). In contrast to this, although some aggregatory response was observed with wild type *P. gingivalis* ATCC W50, no significant aggregation was recorded with *T. forsythia* ATCC 43037 or *P. gingivalis* ATCC W50 in either treatment (Figure 4.4a)

Earlier findings demonstrated that *P. gingivalis* lacking the outer membrane proteins OMPA1 and OMPA2 showed a significant increase in the rate of platelet aggregation. To further understand these findings, investigations were designed to explore whether bacterial viability could impact the aggregatory response as seen with wildtype *P. gingivalis* (Figure 4.4a). All bacterial treatments successfully resulted in stimulating platelet aggregation, however only the viable treatments resulted in significant readings (Figure 4.4b). Total percentage aggregation does not account for the time taken for aggregation to initiate or the rate of the recorded aggregatory response. To overcome this factor the data was further processed to analyse the time take for each sample to reach AG50. The analysis highlights that all bacterial treatments induce platelet aggregation (Figure 4.4b) but also that with heat killed, non-viable bacteria

there was a significant decrease in the rate of aggregation (Figure 4.4c) suggesting that interactions with viable bacteria are needed to induce a platelet aggregatory response.



**Figure 4.4 The effect of bacterial viability on platelet aggregation. (A)** Aggregation by periodontal pathogens. Both wild type (WT) and heat killed (HK) *P. gingivalis* NCTC 11834 induced a significant level of platelet aggregation. In contrast, both WT and HK *P. gingivalis* ATCC W50 and *T. forsythia* ATCC 43037 did not induce significant aggregation. Interestingly, the HK treated *P. gingivalis* NCTC 11834 bacterium produced a significant reduction in aggregatory response when compared to the WT. **(B)** Induction of aggregation by viable and heat killed *P. gingivalis* deficient in the outer membrane proteins. Significant levels of aggregation was observed by *P. gingivalis* NCTC 11834 and mutants (*P. gingivalis* NCTC 11834  $\Delta ompA1$  and *P. gingivalis* NCTC 11834  $\Delta ompA2$ ) when compared to untreated PRP. All HK treatments also induced some level of aggregation but none of these findings were statistically significant. **(C)** AG50 of aggregation triggered by both viable and HK *P. gingivalis*. Platelets were exposed to both viable and HK bacteria before aggregation times were recorded against A significant decrease in the time taken to reach 50% aggregation was observed in the WT *P. gingivalis* NCTC 11834 and both mutant strains (*PG* NCTC 11834  $\Delta ompA1$  and *PG* NCTC 11834  $\Delta ompA2$ ). Aggregation was measured following exposure to pathogens (WT and HK) at an MOI of 1:10 for 10 minutes at 37 °C. Data is expressed as  $\pm$ SEM,  $p \leq 0.01$ ,  $p \leq 0.001$ . n=4.

## 4.4 Discussion

Understanding the relationship by which periodontal pathogens and platelets interact is crucial to explicate the postulated impact of oral pathogens on cardiovascular disease. This chapter investigated the effect of periodontal pathogens on the induction of platelet aggregation. The data presented here corroborate previous findings suggesting that *P. gingivalis* NCTC 11834 interacts with platelets and induces aggregation at increasing MOI (Naito *et al.*, 2006; Naito, 2007; Li *et al.*, 2008).

This study demonstrates that *P. gingivalis* induced aggregation is strain specific as aggregation was observed with both *P. gingivalis* NCTC 11834 and *P. gingivalis* ATCC 381 strains but not with ATCC W50. This is in contrast to the findings of Klarström Engström and co-workers (2015) who reported that ATCC W50 caused approximately 50% aggregation when compared to NCTC 11834. The two studies however are not strictly comparable due to substantial differences in the methodology used. Klarström Engström *et al* (2015) conducted aggregation experiments in a modified Krebs Ringer glucose buffer, which replaces chelated cations that are lost within the platelet isolation process, over a longer time frame (15 minutes) and in the absence of relevant positive controls. In this work, all assays were conducted using isolated platelet rich plasma in citrate buffer and aggregation was monitored over 10 minutes. Throughout the optimisation of initial aggregation experiments with wildtype *P. gingivalis* strains within this body of work, it was noted that after three passages of bacterial culture all experimental conditions began to induce platelet aggregation. It is well documented that bacterial species are able adapt their behaviour and phenotype according to environmental conditions (Friedman *et al.*, 2015) and for this reason all experiments

reported within this thesis were done with bacteria that had undergone no more than three passages.

Strain-specific induction of platelet aggregation has been previously reported with other bacterial species including *Helicobacter pylori* which is associated with peptic stomach ulcers and *Streptococcus pneumoniae*, one of the underlying causes of bacterial pneumonia (Corcoran *et al.*, 2007; Keane *et al.*, 2010), thereby suggesting that strain-specific factors may affect the pathogenicity of different bacterial isolates. This is further illustrated by the fact that strain variances are known to impact on the invasive and virulent characteristics of *P. gingivalis* (Jandik *et al.*, 2008; Suwannakul *et al.*, 2010; Baek *et al.*, 2015). It was previously reported that both *P. gingivalis* NCTC 11834 and *P. gingivalis* ATCC 381 are highly invasive when compared to *P. gingivalis* ATCC W50 in human umbilical vein endothelial cells (HUVEC) and KB epithelial cell lines when characterised via antibiotic protection assays (Dorn *et al.*, 2000).

Other work has also begun to elucidate the underlying genetics which may explain the observed variances across bacterial isolates. Igboin and colleagues (2009) demonstrated that, when compared by heteroduplex and ribosomal intergenic spacer region (ISR) sequencing, *P. gingivalis* strains NCTC 11834 and 381 were genetically highly related but are both highly divergent when similarly compared with *P. gingivalis* ATCC W50. These findings by Igboin *et al.*, (2009) not only explain the observations of this study that NCTC 11834 and 381 but not ATCC W50 caused platelet aggregation, but may also provide an insight into the underlying genetic variances that contribute to *P. gingivalis* phenotypes and virulence.

As well as strain specific variations, it was also hypothesised that periodontal-pathogen mediated platelet aggregation could be dependent on specific bacterial membrane

proteins and their involvement in mammalian cellular interactions. Therefore the role of the outer-membrane proteins OMPA1 and OMPA2 was investigated.

Previous studies by Suwannakul and colleagues (2010) identified the OMPA protein as being important in host interactions. Further studies demonstrated that two major subunits of the outer membrane proteins namely OMPA1 and OMPA2 were important in biofilm formation as well as epithelial cell interactions (Naylor *et al.*, 2016). In this study, the deletion of either subunit OMPA1 and OMPA2 did not impact on the overall percentage of aggregation although the data suggest a possible role in triggering the onset of an aggregatory response. When compared to the parent strain, both OMPA1 and OMPA2 mutants were shown to significantly decrease the time taken to initiate platelet aggregation ( $p < 0.05$  and  $< 0.001$  for the OMPA1 and OMPA2 mutants, respectively). OMPA2 was also observed to induce aggregation at a faster rate than the OMPA1 mutant, but this difference was not statistically significant at the 0.05 level.

In addition to the OMPA proteins, the *P. gingivalis* sialidase enzyme 0352 has also been implicated in cellular interactions and bacterial pathogenesis. Work by Aruni *et al* (2011) identified that 0352 sialidase facilitates bacterial-host interactions within the periodontal pocket by allowing the exposure of potential binding receptors on glycoproteins and glycolipids. Further to this, sialidase activity has also been directly associated with the expression of virulence factors in *P. gingivalis* including LPS, capsule, gingipain activity, fimbriae as well as circumventing host response (Aruni *et al.*, 2011; Li *et al.*, 2017; Yang *et al.*, 2018). When the *P. gingivalis* ATCC 381 $\Delta$ Sia0352 was screened in platelet aggregation, no differences were observed, with both the mutant and parent strain inducing a significant level of percentage aggregation ( $p < 0.001$ ). However, similarly to the findings with the OMP deficient mutants, *P.*

*gingivalis* ATCC 381  $\Delta$ *Sia*0352 caused a significantly faster onset of platelet aggregation when compared to the wildtype *P. gingivalis* ATCC 381 ( $p < 0.001$ ).

The *P. gingivalis* mutants screened throughout these aggregation studies were selected on the basis of their involvement in cellular interactions. Despite the stark biological differences between the OMPA and the  $\Delta$ *Sia*0352 mutants, the data suggests that disrupting bacterial/cellular interactions, results in a faster rate of aggregation more akin to that of a naturally occurring stimulant such as ADP. The process of delaying the aggregatory response that was observed with wildtype strains of *P. gingivalis* (NCTC 11834 and ATCC 381) could reflect a bacterial counterstrategy against the antimicrobial properties of platelets. Similar findings by Svensson and colleagues (2014) suggested that *Streptococcus pyogenes* not only initiates platelet aggregation, but exploits the fact that the formed aggregate is not significantly bactericidal allowing the bacterium to evade further host response, before disaggregating the platelets and escaping. *P. gingivalis* is well documented to suppress and evade host response through a number of virulence factors including suppressing complement activation through the secretion of LPS and gingipains, which promote bacterial survival (Hajishengallis, 2011). Taken together these observations suggest a possible mechanism in which *P. gingivalis* is able to hijack platelet aggregation and might be able to contribute to systemic pathogenesis.

In contrast to *P. gingivalis*, the systemic impact of *T. forsythia* is less characterised. To date limited studies have investigated interactions between *T. forsythia* and platelets. Under the same experimental conditions as *P. gingivalis*, wild type *T. forsythia* did not induce platelet aggregation. In an attempt to determine whether *T. forsythia* does not induce platelet aggregation or whether it actively evades platelet response, two

virulence factors of interest were selected. Firstly, the NanH sialidase is a virulence associated enzyme present in the outer membrane of *T. forsythia* that cleaves sialic acids on host glycoproteins, destroying their integrity and promoting cellular adhesion and invasion (Honma, Mishima and Sharma, 2011). Secondly, further work by Honma *et al* (2007) identified that the *wecC* gene present in *T. forsythia* is responsible for regulating biofilm formation. Disruption of the *wecC* gene promotes exopolysaccharide synthesis, promotes biofilm formation and an overall increase in bacterial virulence (Honma *et al.*, 2007). These two virulence associated characteristics of *wecC* and *nanH* were then screened in further aggregation experiments using the *T. forsythia* ATCC 43037 $\Delta$ *nanH* deficient mutant and *T. forsythia* ATCC 43037  $\Delta$ *wecC* isogenic mutant. Neither the parental strain nor the mutants resulted in an aggregatory response, suggesting that under these conditions, *T. forsythia* ATCC 43037 does not induce platelet aggregation. However, the lack of an aggregatory response does not indicate that *T. forsythia* cannot interact with platelets. Previous work has also identified that other bacterial species such as *Staphylococcus aureus* (Loughman *et al.*, 2005) and *Streptococcus gordonii* (Kerrigan *et al.*, 2007) do not interact directly with platelets but interact with them indirectly via bridging molecules. This indirect interaction process results in an increased lag time of up to 18 minutes to induce platelet aggregation (Loughman *et al.*, 2005; Kerrigan *et al.*, 2007) and could explain why no aggregation was recorded following stimulation by wild-type *T. forsythia* within this thesis during the 10 minute time period. It is also well established that bacterial species induce an 'all or nothing' response in relation to platelet aggregation (Kerrigan, 2015) and thus further experiments are needed to fully characterise the potential interactions between platelets and *T. forsythia*.

In order to expand on initial aggregatory finding, the effects of bacterial viability were also explored within this chapter. The initial experiments screened both *P. gingivalis* (NCTC 11834 and ATCC W50) and *T. forsythia* (ATCC 43037) and found that both *P. gingivalis* ATCC W50 and *T. forsythia* ATCC 43037 did not induce significant levels of platelet aggregation with either the viable or heat-killed treatments. In contrast, *P. gingivalis* NCTC 11834 significantly induced platelet aggregation with both the viable and HK treatments ( $p < 0.001$ ), however comparatively the overall level of aggregation induced by the heat-killed *P. gingivalis* NCTC 11834 was significantly less in relation to the viable wildtype strain ( $p < 0.05$ ).

To probe this further, wild type *P. gingivalis* NCTC 11834 was comparatively screened by aggregation against the two OMPA deficient mutants OMPA1 and OMPA2. As previously mentioned, viable wild type NCTC11834 and both OMPA mutants were able to induce significant levels of aggregation ( $p < 0.001$ ). However in some cases, heat killed bacteria were observed to induce late-onset aggregation which is thought to reflect the variability in platelet response but this was not statistically significant. These finding were also compared to the rate at which aggregation occurred, with all the heat killed treatments (*P. gingivalis* NCTC 11834, OMPA1 and OMPA2) resulting in significantly longer times to reach AG50 when compared to the relevant viable treatments ( $p < 0.01, 0.001$ ). Taken together these findings suggest that while viability seems essential for a faster onset of platelet aggregation, it may be possible for non-viable bacterium to interact with platelets but at a slower rate. Similar findings were reported by Klarström Engström and colleagues (2015) who demonstrated that *P. gingivalis* NCTC 11834 induces platelet aggregation at an MOI of 1:1, whereas heat killing the bacterium completely eradicated any aggregatory response. The authors concluded that the heat killed treatment lacked gingipain proteolytic activity and the

ability to induce cytosolic calcium changes thereby preventing platelet activation and aggregation (Klarström Engström *et al.*, 2015). However, the observed reduction in platelet aggregation could also be explained by the experimental approach used, as although heat-killing bacterium is a standard laboratory procedure, the process does denature key proteins involved in bacterial virulence, such as gingipains (Belton *et al.*, 1999; Nakhjiri *et al.*, 2001; Ankersmit, *et al.*, 2007) and therefore it can be argued that these findings highlight the combined effect of denaturation and of bacteria cell viability.

#### **4.5 Summary**

In conclusion, this study demonstrates that viable *P. gingivalis* induces platelet aggregation in a strain dependant manner. Additionally, the data presented show that bacterial virulence associated with periopathogen/platelet interactions may reduce or dampen the aggregatory response. Within this study, neither wild-type *T. forsythia* nor any of the screened *T. forsythia* mutants were able to induce platelet aggregation. This suggests that *T. forsythia* cannot interact with platelets in the context that was observed with *P. gingivalis*.

## **Chapter 5: Development and characterisation of a multicolour flow cytometry panel**

## 5.1 Introduction

Platelets are small, anucleate discoid shaped blood cells, which play a fundamental role in both haemostasis and immune response (Sonmez and Sonmez, 2017). Normally, platelets circulate around the body in an unstimulated and resting form but, upon activation, they express a range of activation-specific markers (Jennings, 2009). This method was designed to identify and develop a panel for the simultaneous analysis of both platelet-surface and platelet-activation markers after treatment by an agonist or other stimulus following previously published guidelines on platelet analysis (Schmitz *et al.*, 1998). Despite flow cytometry being routinely applied to the clinical analysis of whole blood to monitor platelet function in diseased states and being a well-established tool within platelet research (Michelson *et al.*, 2000), very few comprehensive methodologies exist for quantitative analysis of platelet function that is relevant to their *in vivo* activity.

As platelets can be easily activated during sample processing (Wallén *et al.*, 1997) and storage (Rinder *et al.*, 1991; Vučetić *et al.*, 2018) in the absence of inhibitors, a standardised single-step analysis panel was developed and optimised using freshly acquired platelets from healthy donors. This would enable the capture of key platelet surface markers, as well as those altered during activation, thereby reducing experimental variability and the need for large sample volume.

This five-colour flow cytometry panel was optimised to allow the differential expression of platelet surface receptors to be quantified in both unstimulated and stimulated platelet populations, following treatment with adenosine diphosphate (ADP) or bacterial stimulation.

The panel was specifically designed to include commercially available antibodies in a single-step staining process to minimise the risk of spontaneous platelet activation during sample handling and preparation.

## 5.2 Aims

The aim of this chapter was to enable the quantification of a range of platelet surface markers following the addition of an agonist or bacterial stimulus. To minimise spontaneous activation of platelets and maximise the use of individual samples, a single-step protocol was developed to allow simultaneous measurement of key platelet markers. This chapter focusses on;

- The development of a multicolour flow cytometry panel to study marker expression in stimulated and unstimulated platelet populations following treatment with ADP
- The adaptation of an optimised multicolour flow cytometry panel to study the effect of periodontal pathogen interactions on platelet marker expression

The methodology developed within this chapter has been written up as an original paper and submitted to the journal *Cytometry Part A*.

### 5.3 Method development and gating strategy

This workflow has been optimised and validated for the analysis of freshly acquired platelets isolated from whole blood and from a range of healthy donors to ensure reproducibility.

#### 5.3.1 Panel selection

To identify the platelet population, CD41 ( $\alpha$ IIb, GPIIb) and CD61 ( $\beta$ 3, GPIIIa) were selected as markers. CD41 is expressed exclusively on select early haematopoietic progenitors, megakaryocytes and platelets (Wiles and Keller, 1991; Mitjavila-Garcia *et al.*, 2002), whilst CD61 is expressed on platelets, osteoclasts, fibroblasts, macrophages, and some tumour cells (Hynes, 1987; Savill *et al.*, 1990; Engleman *et al.*, 1997; Sloan *et al.*, 2006). To determine levels of platelet activation following treatment, three markers and corresponding antibodies were selected. The antibody, against an activated epitope of the heterodimer CD41/CD61 ( $\alpha$ IIb $\beta$ 3, GPIIbIIIa) was included in the panel (Gardiner *et al.*, 2007) as well as CD62P (P-selectin, GMP-140), a Type I transmembrane glycoprotein expressed on activated platelets (Ault *et al.*, 1989). Finally, CD42b (GPIb $\alpha$ ) was included within the panel because its shedding can be related to both platelet activation in treated samples and platelet viability in untreated samples (Bergmeier *et al.*, 2003, 2004; Gardiner *et al.*, 2007). The panel also includes IgG isotype controls although the specific focus of this work is on the comparison of unstimulated and stimulated platelets.

### **5.3.2 Flow cytometer instrument configuration**

The panel was optimised for use on the Gallios flow cytometer (Beckman Coulter; Table 5.1). The Gallios flow cytometer was selected due to its three laser, 10 colour configuration and its routine application in both research and diagnostics. The Gallios flow cytometer has previously been applied to the phenotypic study of various haematopoietic cells including dendritic cells (Ferreira *et al.*, 2013), monocytes (Morandi, Airoidi and Pistoia, 2014), B cells (Griffin and Rothstein, 2012), and platelets (Lacroix *et al.*, 2010; Maugeri *et al.*, 2012; Tynngård *et al.*, 2015).

Laser (nm)	Laser Power (mW)	Laser Type	Detector	Spectral Range for Detector (nm)	Dichroic Filter (nm)	Band Pass (nm)	Fluorochrome
488	22	Solid State Diode	FL-1	505-545	550	525/40	Alexa Fluor 488
			FL-2	560-590	595	575/30	PE
			FL-5	>755	N/A	755LP	PE/Cy7
638	25	Solid State Diode	FL-6	650-670	710	660/20	APC
405	40	Solid State Diode	FL-9	425-475	480	450/50	Pacific Blue

**Table 5.1 Flow cytometer instrument configuration.** This panel was optimised for a Gallios flow cytometer (Beckman Coulter), with a 10 colour, three laser configuration (Blue/Red/Violet). APC-allophycocyanin, Cy-cyanin, PE- R-phycoerythrin.

To assess suitability of conjugates in a multi-colour panel (Table 5.2) compensation matrix was generated using FlowJo to determine spill-over of signals (Table 5.3). FlowJo FACS data analysis software is a leading analysis platform that computes and applies compensation corrections and enables visualization of all flow cytometry data (Herzenberg *et al.*, 2006).

Fluorescent intensities from single stain treatments were compared to those obtained through full panel analysis to account for potential steric hindrance and overlapping epitopes of antibodies. This single-stain approach allows both sample processing and analysis within four hours of blood sampling, which is critical for limiting spontaneous platelet activation and retaining *in vivo* platelet characteristics.

Specificity	Fluorochrome	Clone	Antigen Reference	Stock Conc. (µg/ml)
CD61	PE/Cy7	VI-PL2	Zola <i>et al.</i> , (2007)	25
CD41	Pacific Blue	HIP8	Riberdy <i>et al.</i> , (1994); Denzin and Cresswell, (1995); Denzin, (1996)	80
CD41/61	APC	A2A9/6	Bennett <i>et al.</i> , (1983); Clemetson and Clemetson, (1994); Matsumura-Takeda <i>et al.</i> , (2007)	150
CD62P	Alexa Fluor 488	AK4	Varki, (1994); McEver, Moore and Cummings, (1995)	200
CD42b	PE	HIP1	Clemetson <i>et al.</i> , (1982); Fox, Aggerbeck and Berndt, (1988); Kuijpers <i>et al.</i> , (1992)	50

**Table 5.2 Commercial reagents used.** Samples were fixed with 0.5% paraformaldehyde and then incubated with listed antibodies for 20 minutes at room temperature in the dark prior to analysis.

	Alexa Fluor 488	PE	PE/Cy7	APC	Pacific Blue
Alexa Fluor 488	N/A	9.180%	2.430%	0.000%	5.880%
PE	2.460 %	N/A	1.360%	0.000%	0.021%
PE/Cy7	2.160%	0.463%	N/A	0.000%	0.027%
APC	0.000%	0.000%	0.000%	N/A	0.000%
Pacific Blue	5.400%	0.195%	0.047%	0.000%	N/A

**Table 5.3 Representative compensation matrix.** Data from one sample with compensation analysis completed in FlowJo (Ver 7.6) to assess spill-over.

The use of five fluorochromes allows additional application-specific markers to be introduced as needed. The selection of the antibody/fluorochrome combinations, based on expression levels of the antigen of interest and brightness of fluorophore; with the brighter fluorophores conjugated to lower density antigens, was guided by their commercial availability and possible application using a single-step staining approach. This also ensures that selected antibodies have a level of quality assurance and validation, whilst reducing the number of steps within the protocol.

Following initial isolation of platelet rich plasma (PRP) from whole blood, platelets were treated as described in Chapter 2. Following fixation, a platelet population was first defined on the basis of forward size scatter (FSC) and side scatter (SSC) followed by gating on two platelet surface proteins CD41 and CD61, which allow for platelet subsets to be identified, irrespective of stimulation (Saboor, Moinuddin and Ilyas, 2012).


To determine the activation status of platelets, three platelet activation markers/epitopes were selected; CD62P (Ault *et al.*, 1989), CD42b (glycoprotein Ib $\alpha$ ) (Bergmeier *et al.*, 2003, 2004; Gardiner *et al.*, 2007) and an antibody against an epitope expressed on activated but not resting platelets CD41/CD61 (Gardiner *et al.*, 2007).

The panel was designed with particular attention to antibody-fluorophore combinations to ensure that optimal staining was obtained whilst minimising spill-over of background fluorescence. The selection of antibodies was validated using non-permeabilised platelets as benefits of this approach include a simpler and shorter procedure with minimal sample handling and processing. The finalised constructed panel therefore consists of Pacific Blue-CD41, PE/Cy7-CD61, APC-CD41/61, Alexa Fluor 488-CD62P, PE-CD42b.

## **5.4 Results**

### **5.4.1 Antibody optimisation**

In order to optimise antibody concentrations, antibodies were serially titrated on platelets isolated from healthy volunteers ( $n=6$ ) before the scatter profiles were analysed to detect antibody saturation (Figure 5.1). Optimum antibody concentrations were determined at the plateau of signal intensity and are depicted with red boxes.




**Figure 5.1 Reagent titrations.** Antibodies were serially titrated (1:4) on platelets isolated from healthy volunteers. Individual files were concatenated to allow visualisation of all titrations in a single figure. Unstained controls samples are labelled as zero. Selected antibody titers used are highlighted with red boxes. IgG controls were used at the same concentration as the corresponding antibody. Antibody concentrations are arranged along the X-axis.


### **5.4.2 Gating strategy**

Following antibody optimisation, platelets were treated with ADP (20  $\mu$ M) before analysis was undertaken with the designed gating strategy and comparative histograms. A representative plot is shown in Figure 5.2. Platelet populations were successfully isolated on CD41, CD61 positivity, with subsequent comparative histograms demonstrating an increased expression of both CD41/61 and CD62P, as well as a decreased expression of CD42b following stimulation with ADP (20  $\mu$ M).

### Platelet Gating Strategy



### Platelet Activation Status




**Figure 5.2 Top Panel: Gating strategy.** Following platelet isolation and full blood count to confirm platelet purity and sample treatment, initial platelet population was first identified on basis of forward size scatter (FSC) and side scatter (SSC) (A). Corresponding isotype controls (B) and platelet markers CD41 and CD61 (C) were used to isolate CD41<sup>+</sup>CD61<sup>+</sup> platelet sub-population (>95% as shown).

**Bottom Panel: Comparative histograms.** Unstimulated (blue lines) and adenosine diphosphate treated platelets (ADP, 20  $\mu$ M; stimulated, red lines) illustrate changes in activation markers in relation to levels of CD41<sup>+</sup>/61<sup>+</sup> (D), CD62P<sup>+</sup> (E) and CD42b<sup>-</sup> (F) populations. Sample processing and analysis were completed within four hours of blood collection.


## 5.5 Adaptation of stimulated population

The optimised multicolour flow cytometry panel was then adapted to allow the simultaneous analysis of bacterial association and stimulation of platelets. Platelets were stimulated with periodontal pathogens (*P. gingivalis* or *T. forsythia*, MOI 1:10) before populations of interest were identified using forward scatter (FSC) and side scatter (SSC) profiles (Figure 5.3a). Platelet purity was selected on CD41 positivity (Figure 5.3b-c).




**Figure 5.3 Representative revised gating strategy of platelet isolation.** Platelet populations identified through forward-side scatter profiling (A) were selectively gated on CD41 positivity using IgG isotype controls (B) and antibody treated platelets (C).

Association of isolated platelets to bacterial cells was then determined by the relative fluorescent intensity of the bacterial specific antibodies, PGWC1 and TFWC. PGWC1 staining produced a 'smeared' scatter profile, which resulted in a lack of distinct populations (Figure 5.4). To overcome this issue, several methodologies were considered before quadrant gates were allocated on the third contour of both the negative (Figure 5.4a) and positive (Figure 5.4b) controls. This gating strategy allows the separation of bacterial associated platelets (Figure 5.4c, Q2), from platelets that remain unassociated (Figure 5.4c, Q3), with simultaneous analysis of platelet activation markers within both subpopulations (Figure 5.5). No distinct population separation could be achieved with platelets treated with *Tannerella forsythia* and subsequent staining with TFWC antibody.



**Figure 5.4 Isolation of pathogen associated platelets.** Example plots of CD41<sup>+</sup> platelets (left-hand panel), showing the applied gating strategy (right-hand panel) to untreated PRP (**A**), PRP treated with 20  $\mu$ M ADP (**B**) and *P. gingivalis* NCTC 11834 treated PRP (**C**). Due to the 'smeared' profile of bacterial antibody staining (PGWC1), upper gated quadrants were placed above the third contour of untreated PRP and PRP treated with ADP (20  $\mu$ M). Using these defined gates, platelets treated with *P. gingivalis* (**C**) could be separated to define un-associated platelets (**C,Q3**) and *P. gingivalis* associated platelets (**C,Q2**).



**Figure 5.5 Comparative histograms of platelet activation following exposure to *P. gingivalis*.** Comparative histograms of un-associated platelets (blue lines) and *P. gingivalis* associated platelets (red lines) illustrate platelet activation relative to the expression of CD62P (**A**), CD41/61 (**B**) and CD42b (**C**).

## 5.6 Discussion

This chapter of work focuses on the development and adaptation of a single-step multicolour flow cytometry panel for the evaluation of platelet activation following exposure to periodontal pathogens. The application of flow cytometry combines the advantages of both microscopy and biochemical analysis techniques allowing for rapid, simultaneous phenotypic analysis of a large volume of cellular events (Muirheadi, Horan and Poste, 1985).

The initial panel development and optimisation demonstrated that platelet sub-population could be identified following PRP isolation and selective gating on both CD41 and CD61 positivity. It was also shown that ADP (20  $\mu$ M) effectively stimulates platelet activation, which could be quantified through an increased expression of both CD62P and CD41/61 as well as a decreased expression of CD42b. As previously stated, one of the major difficulties surrounding platelet studies is spontaneous activation and a reduction in viability during sample processing (Wallén *et al.*, 1997) and storage (Rinder *et al.*, 1991). Within this study, utilising multiparameter flow cytometric analysis has allowed the detection of surface antigens in a sensitive and specific manner whilst in agreement with previously published guidelines limiting sample processing to a maximum of four hours (Schmitz *et al.*, 1998).

However, adaptation of the newly optimised panel to incorporate the application of bacterial specific antibodies produced a 'smeared' staining scatter profile, resulting in a lack of definition between expected populations. Although spontaneous platelet activation was kept to a minimum, some level of activation was expected in all experimental conditions and appears to result in positive staining throughout all samples incubated with bacterial specific antibodies.

In order to separate bacterial associated platelets treated with these antibodies, several gating methodologies were investigated in detail following previously published guidelines on flow cytometry data presentation (Alvarez *et al.*, 2010).

Initially it was hypothesised that the bacterial associated populations could be separated by comparative histograms but this was challenging due to the heterogeneous populations. Analysis by comparative histograms was also discarded due to reliance on the user to define which two samples were significantly different (Baggerly, 2001) with the resulting subjective selection of gating introducing over manipulation of data and inaccurate analysis (Overton, 1988). Similarly, although dot plots are widely used to view acquired data, this type of analysis also draws considerable limitations. The inherent characteristics of these plots can often mask the density and distribution of the data through overlapping dot placements and a lack of definition between highly populated and sparsely populated regions (Herzenberg *et al.*, 2006).

In agreement with Herzenberg and colleagues (2006), it was subsequently concluded that coloured density plots, (zebra plots, quantile contour plots) offer the most accurate representation of the acquired data, with the increased dynamic range and frequency definition allowing for accurate gating placement. Gates placed above the third contour of control samples resulted in *P. gingivalis* associated populations being successfully isolated and provides a reproducible analysis methodology for the quantitation of platelet activation markers. *P. gingivalis* association was determined to induce increased CD62P, CD41/61 and CD42b staining when compared to the unassociated populations. The developed methodology however was not effective in separating populations of platelets associated with *T. forsythia*. It was surmised that

this was due to a lack of association of the bacterium to platelets that resulted in a lack of population definition and was not attributed to limitations within the methodology.

Polychromatic flow cytometry, as with any analytical technique does carry a number of caveats that must be considered. The design and optimisation of multiparameter flow cytometry panels is an extremely labour intensive and costly process. It cannot be overlooked that without carefully constructed panels, extensive antibody titrations, antibody ranking and expression characterisation, as well as dismissal of incorrect antibody combinations and the correct compensation measures, this methodology would lack both accuracy and reproducibility (Mahnke and Roederer, 2007). As well as limitations surrounding instrument and panel set-up, another underlying issue surrounding multicolour flow cytometry is the magnitude of data produced during sample acquisition and the subsequent data analysis that follows.

One of the fundamental advantages to polychromatic flow cytometry is the ability to define and analyse subsets of cells within a population, however by introducing several antibody combinations as well as the possibility of exploring hundreds of different phenotypic characteristics, a pragmatic and sensible approach must be undertaken towards data analysis (Chattopadhyay and Roederer, 2012), which complies with the availability of suitable software (Roederer and Moody, 2008). Within this study, although five phenotypic parameters were applied within the panel, analysis was confined to the comparison of data within two-dimensional plots, meaning that only two phenotypes of interest can be compared at any one time.

Despite these limitations, the polychromatic, multiparameter flow cytometry panel designed within this study provides a robust analysis methodology that provides reliable data acquisition and analysis within this system.

## **5.7 Summary**

This study provides a practical tool to evaluate the status of freshly isolated platelets following treatment with a stimulus in a single-step staining process. The simple and relatively quick protocol described can be used in settings where spontaneous platelet activation needs to be minimised, minimal sample volumes are available and where platelets cannot be stored on-site for an extended period.

## **Chapter 6: The effect of periodontal pathogens on platelet function and protein expression**

## 6.1 Introduction

It has been postulated that oral pathogens can either penetrate the surrounding tissues and vascular network of the periodontal pocket or release a barrage of biologically active molecules including gingipains and hemagglutinins (Reyes *et al.*, 2013) that can then contribute to or exacerbate several systemic conditions including rheumatoid arthritis (Wegner *et al.*, 2010), diabetes (Borgnakke *et al.*, 2013) and cardiovascular disease (Kerr, 1951, 1962; Kechschull, Demmer and Papapanou, 2010).

Within the vascular system, the role of platelets within homeostasis is well established (Zucker and Nachmias, 1985). Recent studies have highlighted the antimicrobial role of platelets within both the adaptive and innate immunity and how these mechanisms may contribute to atherosclerosis (Ali, Wuescher and Worth, 2015; Hamzeh-Cognasse *et al.*, 2015; Koupnova and Freedman, 2015). Bacterial species are known to interact with platelets, including various streptococcal, staphylococcal and helicobacter strains (Kerrigan and Cox, 2010) with platelets being capable of immobilising and internalising pathogens (Yeaman, 1997, 2010a, 2010b) and exhibiting antimicrobial activity (Zielinski *et al.*, 2001; Lopes-Pires *et al.*, 2012). Several mechanisms have been reported to facilitate bacterial-platelet association including direct interactions via Toll-like receptors (Assinger *et al.*, 2012), glycoprotein (GP) IIb/IIIa, GPIb, the fcyRIIa receptor (Cox, Kerrigan and Watson, 2011), or indirect interactions such as lipopolysaccharides (LPS) (Shiraki *et al.*, 2004; Scott and Owens, 2008) or various plasma protein bridges such as fibrinogen or von Willebrand factor (vWF) (Cox, Kerrigan and Watson, 2011).

Periodontal pathogens in the form of biofilms have been reported to induce platelet aggregation (Tu *et al.*, 2016). More specifically, *P. gingivalis* been shown to induce both

platelet aggregation and activation (Curtis *et al.*, 1993b; Afrodite Lourbakos *et al.*, 2001; Li *et al.*, 2008; Assinger *et al.*, 2012; Klarström Engström *et al.*, 2015) which may suggest a possible role of periodontitis in CVD. Although the interaction of *P. gingivalis* and platelets has previously been reported within the literature the underlying mechanisms as well as the full extent and consequences of these interactions are yet to be elucidated.

## 6.2 Aims


Previous findings (Chapter 4) demonstrated that the periodontal pathogen *P. gingivalis* interacts with platelets in a strain-dependant manner and induces platelet aggregation. This chapter focuses on elucidating the mechanisms underlying these platelet/pathogen interactions by addressing the following questions:

- Do periodontal pathogens directly interact with platelets, resulting in the formation of aggregates?
- Does *P. gingivalis* or *T. forsythia* interaction result in platelet activation, changes in integrin expression and degranulation of mammalian platelets?
- What are the possible sites of interaction and association between platelets and periodontal pathogens?


## 6.3 Results

### 6.3.1 Analysis of platelet-*P. gingivalis* interactions by immunofluorescence microscopy.


Immunofluorescence (IF) microscopy was initially used to determine whether platelets are able to directly interact with the periodontal pathogens, *P. gingivalis* and *T. forsythia*. Platelets were exposed to *P. gingivalis* (MOI 1:10) and stained for F-actin to determine platelet morphology and with the pathogen specific antibody PGWC1 to identify *P. gingivalis* NCTC 11834 (Figure 6.1). The immunostaining demonstrates that *P. gingivalis* associates with, and appears to cause 'clumping' of the platelets when compared to control platelets not exposed to the pathogen. Platelets were also probed with integrin  $\beta 1$  (Figure 6.2) and  $\beta 3$  (Figure 6.3) specific antibodies, to investigate whether treatment with *P. gingivalis* NCTC 11834 could affect the overall expression of these integrins or whether any co-localisation of bacteria and integrins could be observed. DAPI staining was utilised for identification of *P. gingivalis*. Both integrin  $\beta 1$  and  $\beta 3$  are expressed across all samples but do not seem to be affected by *P. gingivalis* treatment. Integrin staining was diffused throughout the cytoplasmic space, detailing that with this methodology no specific localisation or changes in expression could be determined.



**Figure 6.1** *P. gingivalis* localises and associates with platelets. Isolated platelets were challenged with *P. gingivalis* NCTC 11834 (MOI: 10) for 20 minutes at RT before fixing. Platelets were permeabilised before incubation with pathogen specific antibody, PGWC1 (green) and an F-actin probe (red). Co-localisation and small aggregates of platelets with *P. gingivalis* were observed. Untreated and ADP treated platelets were included as negative and positive control respectively. Data is representative of at least three independent observations.




**Figure 6.2 The effect of *P. gingivalis* on platelet integrin  $\beta$ 1 expression.** Isolated PRP was exposed to *P. gingivalis* NCTC 11834 for 20 minutes at room temperature before fixation. Cells were permeabilised, incubated with an integrin  $\beta$ 1 specific antibody before analysis by immunofluorescence microscopy. DAPI staining was also included as a bacterial stain. Uniform diffused staining was observed throughout all treatments, with co-localisation between *P. gingivalis* and platelets (indicated by white arrows). Untreated and ADP treated platelets are included as negative and positive controls respectively. Data is representative of at least three independent observations.



**Figure 6.3** The effect of *P. gingivalis* on platelet integrin  $\beta$ 3 expression. Isolated PRP was incubated with *P. gingivalis* NCTC 11834 for 20 minutes at RT before fixation. Cells were then permeabilised, incubated with an integrin  $\beta$ 3 specific antibody before analysis by immunofluorescence microscopy. DAPI staining was also included as a bacterial stain. Platelets stained positive for integrin  $\beta$ 3, with diffused staining throughout all treatments. Co-localisation between *P. gingivalis* and platelets was also observed with platelets treated with NCTC 11834. Untreated and ADP treated platelets are included as negative and positive controls respectively. Data is representative of at least three independent observations.


Platelets were stained with an F-actin probe in combination with an anti-mTOR antibody to determine the cytoskeletal rearrangements undertaken during platelet aggregate formation (Figure 6.4). DAPI staining was included to identify bacterial cells. While both the untreated platelet control and the platelet stimulated control (ADP) display a similar phenotype to the other staining figures (Figure 6.1) in relation to F-actin staining, *P. gingivalis* NCTC 11834 treated platelets appear to have formed a large, fibrous matrix that is positively stained for mTOR (Figure 6.4). Additionally, distributed throughout this fibrous matrix are platelets that stained positive for F-actin and bacteria suggesting that *P. gingivalis* NCTC 11834 might become trapped within these large fibrous aggregates.



**Figure 6.4 Platelet aggregate phenotyping by immunofluorescence microscopy.** PRP was incubated with PG 11834(MOI: 10) for 20 minutes at RT before being fixed onto glass slides. The effect of *P. gingivalis* was determined by staining two cytoskeletal markers F-actin (red) and mToR (green), with DAPI also being included for bacterial visualisation. Platelets treated with PG 11834 form large fibrous aggregates that are highly positive for mToR staining that show F-actin positivity and bacterial cells distributed throughout. Untreated platelets and platelets treated with ADP (20 µM) were included as negative and positive controls. Data representative of at least three independent observations.


### **6.3.2 Investigation of platelet aggregates by electron microscopy**

The underlying characteristics of the platelet aggregates formed following *P. gingivalis* challenge were investigated by electron microscopy using PRP treated with *P. gingivalis* NCTC 11834 or ATCC W50. Untreated and ADP (20  $\mu$ M) treated PRP were included as negative and positive controls respectively. Scanning electron microscopy (SEM) revealed that untreated platelets remained in an inactivated spherical shape, whereas when stimulated with ADP as positive control, a combination of small platelet aggregates together with individual platelets were observed (Figure 6.5). In contrast, platelets exposed to either wildtype strains of *P. gingivalis* (NCTC 11834 or ATCC W50), showed drastic phenotypic changes in comparison to both the positive and negative controls (Figure 6.5), with the formation of large, fibrous aggregates in which individual platelets can no longer be defined. Bacteria were also identified within the samples treated with *P. gingivalis* ATCC W50 and found embedded within the centre of a platelet aggregate and are isolated to a small area of the overall aggregate. It is suspected that similar findings could be identified within *P. gingivalis* NCTC 11834 treated samples but due to the constraints of SEM and the expanse of the formed aggregates, bacteria could not be identified.



**Figure 6.5 Phenotypic analysis of platelet aggregates by scanning electron microscopy (SEM).** Platelets were treated with *P. gingivalis* (NCTC 11834 or ATCC W50) for 20 minutes at room temperature before fixation and mounting and analysis by SEM. Platelets treated with *P. gingivalis* form large fibrous aggregates that encase the bacteria. When compared to the negative (untreated PRP) and positive controls (ADP, 20  $\mu\text{M}$ ), individual platelets are no longer visible, with the aggregates forming large masses. White arrows indicate small aggregates formed with ADP treatment.

To further probe these findings, bacterially treated platelets were also analysed by transmission electron microscopy (TEM), to identify possible ultrastructural changes and determine whether platelets can internalise *P. gingivalis*. As with SEM, within untreated PRP samples, individual platelets are easily identifiable and are phenotypically comparable to that of a resting platelet state (Figure 6.6). Samples treated with ADP (20  $\mu$ M) were also easily identifiable and shown to have formed small aggregates with an increase in pseudopodial structures (white arrows; Figure 6.6). Platelets treated with *P. gingivalis* NCTC 11834 and ATCC W50, showed large amounts of cellular debris amongst distinctive bacterial cells (black arrows), with no definitive platelets visible (Figure 6.6). Within the cellular debris are small structures, that could be the remnants of activated platelets but without distinctive phenotype and visible organelles this cannot be confirmed.




**Figure 6.6 Visualisation of platelet aggregates by transmission electron microscopy (TEM).** Isolated PRP was incubated with *P. gingivalis* (NCTC 11834 or ATCC W50; MOI 1:10) for 20 minutes at room temperature before fixation and processing for imaging by TEM. Within the samples treated with *P. gingivalis*, bacteria surrounded by cellular debris (indicated with black arrows) are clearly visible. Platelets treated with ADP as a positive control show small aggregate formations indicated with white arrows. Untreated PRP was included as a negative control. Each image is shown at two magnifications (left panel 2  $\mu\text{m}$  and right panel 0.5  $\mu\text{m}$ ) for increased definition.

### **6.3.3 Analysis of platelet activation and bacterial association by flow cytometry**


Following the visualisation of platelet aggregates, flow cytometry was used to determine whether bacteria associated with platelets and induce platelet activation using the optimised multiparameter, polychromatic flow cytometry panel developed in Chapter 5.

Initial analysis was undertaken to determine wildtype bacterial association to platelets, in relation to bacterial specific antibody staining (PGWC1/TFWC; Figure 6.7). Significant association of both wildtype *P. gingivalis* NCTC 11834 and ATCC W50 was detected within populations of CD41<sup>+</sup> platelet ( $p < 0.001$ ), whereas no association of *T. forsythia* ATCC 43037 could be determined (Figure 6.7). A slight increase in staining was also observed within samples treated with ADP (20  $\mu$ M) but this was not statistically significant.



**Figure 6.7 Detection of wild-type periodontal pathogen-platelet association by flow cytometry.** Isolated platelets were exposed to periodontal pathogens (MOI 1:10) before fixation, staining and analysis by flow cytometry. Isolated CD41<sup>+</sup>platelet populations significantly associated with both *P. gingivalis* NCTC 11834 and ATCC W50. No bacterial association was observed with platelets treated with *T. forsythia* ATCC 43037. Untreated PRP and PRP treated with ADP (20  $\mu$ M) were included as a negative and positive control respectively. Data is presented as  $\pm$ SEM,  $p < 0.001$ . n=3.


*P. gingivalis*-associated platelets were further analysed to determine the relative expression of platelet activation markers. Platelets associated with *P. gingivalis* NCTC 11834 showed significantly higher expression levels of CD41/61 ( $p < 0.05$ ), CD62P ( $p < 0.05$ ) and CD42b ( $p < 0.01$ ) when compared with unassociated platelets within the same population (Figure 6.8). Similarly, platelets associated with *P. gingivalis* ATCC W50 were also shown to exhibit significantly higher expression of both CD41/61 ( $p < 0.05$ ) and CD42b ( $p < 0.05$ ), whilst also inducing an increase in CD62P expression although the latter was not statistically significant (Figure 6.8).




**Figure 6.8 Expression of platelet activation markers following association with *P. gingivalis*.** Platelet rich plasma was exposed to *P. gingivalis* NCTC 11834 and ATCC W50 (MOI 1:10) before fixation and staining for activation specific antigens. Samples were analysed via flow cytometry. Platelets associated with bacteria showed an increased expression of CD41/61 (A), CD62P (B) and CD42b (C) when compared to associated platelets within the sample population. Data is expressed at  $\pm$ SEM, n=3.  $p = * \leq 0.05$ ,  $** \leq 0.01$ .

After identifying a possible role for the *P. gingivalis* outer-membrane proteins OMPA1 and OMPA2 within platelet aggregation (Chapter 4), further investigations probed the role of these outer membrane proteins within *P. gingivalis*-platelet association and the induction of platelet activation.

OMPA1 and OMPA2 deficient mutants were shown to significantly associate with platelets ( $p < 0.001$ ) with no observable differences between the mutants and the parent strain NCTC 11834 (Figure 6.9). When compared to the unassociated platelet populations, bacterial association was also shown to induce significant increase in expression of CD41/61 ( $p < 0.05$ ), CD62P ( $p < 0.05$ ) and CD42b ( $p < 0.01$ ) within samples treated with the OMP A1 deficient mutant (Figure 6.10). Bacterial association with the OMP A2 deficient mutants also induced an increased expression of CD41/61 as well as significantly increasing the expression of CD62P ( $p < 0.05$ ) and CD42b ( $p < 0.01$ ) (Figure 6.10).




**Figure 6.9 The role of *P. gingivalis* outer membrane protein A (OMPA) in platelet association.** Isolated PRP was exposed to *P. gingivalis* (NCTC 11834, NCTC 11834  $\Delta ompA1$  or NCTC 11834  $\Delta ompA2$ ; MOI 1:10) and fixed. Bacterial association was determined through staining with a *P. gingivalis* specific antibody (PGWC1) and flow cytometry analysis. Significant levels of bacterial association were observed with wild type *P. gingivalis* and both OMPA subunit deficient mutants, OMPA1 and OMPA2. Untreated PRP and PRP treated with ADP (20  $\mu$ M) was included as a negative and positive control. Data is expressed as  $\pm$ SEM,  $p = *** < 0.001$ .  $n = 3$



**Figure 6.10 *P. gingivalis* outer membrane protein (OMP) deficient mutants induce platelet activation.** Isolated PRP was resuspended in modified Tyrode's buffer before being exposed to *P. gingivalis* (NCTC 11834, NCTC 11834  $\Delta ompA1$  or NCTC 11834  $\Delta ompA2$ ; MOI 1:10) and fixed. Platelets were stained with antibodies specific for platelet activation associated antigens and analysed on a Gallios flow cytometer. Platelets associated with *P. gingivalis* 11834 and the OMP A1 mutant induced significant expression of CD41/61 (A), CD62P (B) and CD42b (C) when compared with unassociated populations. Similarly, platelet populations associated with the OMP A2 deficient mutant showed an increased expression of CD41/61 (A), as well as significant increases in the expression of both CD62P (B) and CD42b (C). PRP treated with ADP (20  $\mu$ M) and untreated PRP were included as a positive and negative control respectively. Data is expressed as  $\pm$ SEM,  $p = * < 0.05$   $** < 0.01$ .  $n = 3$ .


#### 6.3.4 Induction of calcium mobilisation by periodontal pathogens

Having demonstrated that periodontal pathogens can associate with, and induce platelet activation, the effect on intracellular calcium mobilisation was investigated. Isolated platelets were pre-loaded with the intracellular calcium indicator FURA-2/AM and real-time calcium mobilisation was monitored following exposure to pathogens at an MOI of 1:10 (*P. gingivalis* NCTC 11834, ATCC W50; *T. forsythia* ATCC 43037). Untreated PRP and platelets treated with ADP (20  $\mu$ M) were included as a negative and positive control respectively. A representative plot of intracellular calcium flux is shown in Figure 6.11a. Both *P. gingivalis* NCTC 11834 and ATCC W50 induced significant platelet calcium mobilisation ( $p < 0.001$ ), whereas no response was recorded with *T. forsythia* ATCC 43037 (Figure 6.11b). *P. gingivalis* ATCC W50 induced a significantly higher level of calcium mobilisation when compared to *P. gingivalis* NCTC 11834 ( $p < 0.001$ ).



**Figure 6.11. Platelet calcium mobilisation is induced by wild type periodontal pathogens.** Platelets pre-loaded with FURA-2/AM were exposed to either wild type *P. gingivalis* (PG NCTC 11834 or PG ATCC W50) or wild type *T. forsythia* (*T. forsythia* ATCC 43037). Real time intracellular calcium mobilisation was monitored after injection of bacteria as a ratio of fluorescent emission excited at both 340 and 380 nm. **(A)** Representative calcium mobilisation plot. **(B)** Both wild type *P. gingivalis* strains significantly induce calcium mobilisation, with no response being recorded with *T. forsythia*. *P. gingivalis* ATCC W50 also induced a significantly higher level of calcium flux when compared to NCTC 11834. Untreated platelets and platelets treated with ADP (20  $\mu$ M) were included as a negative and positive control. Data is expressed as  $\pm$ SEM,  $p < 0.001$ .  $n=3$ .

Similarly to wild type *P. gingivalis* strains, the effect of the two outer-membrane proteins OMPA1 and OMPA2 on platelet calcium mobilisation was determined. As with the parental strain *P. gingivalis* NCTC 11834, both OMPA1 and OMPA2 deficient mutants significantly induced platelet intracellular calcium flux ( $p < 0.001$ ) (Figure 6.12) with the OMPA2 deficient mutant inducing a significantly higher levels of calcium mobilisation when compared to both the wildtype *P. gingivalis* NCTC 11834 and the OMPA1 mutant ( $p < 0.001$ ), whereas no difference was observed between the wildtype and OMPA1.




**Figure 6.12 Platelet calcium mobilisation is induced by OMPA deficient *P. gingivalis* mutants.** Platelets pre-loaded with FURA-2/AM were exposed to wild type *P. gingivalis* NCTC 11834 or either OMPA deficient mutants (PG NCTC 11834  $\Delta ompA1$  or PG NCTC 11834  $\Delta ompA2$ ) and intracellular calcium mobilisation was monitored as a ratio of fluorescent emission excited at both 340 and 380 nm. **(A)** An example calcium mobilisation plot. **(B)** Wildtype *P. gingivalis* and both OMPA mutants significantly induce calcium mobilisation. The OMPA2 mutant also induced significantly higher levels of calcium flux when compared to both the wildtype and OMPA1 mutant. Untreated platelets and platelets treated with ADP (20  $\mu$ M) were included as a negative and positive control. Data is expressed as  $\pm$ SEM,  $p < 0.001$ .  $n = 3$ .

### **6.3.5 Investigations into platelet degranulation by *P. gingivalis***

Having demonstrated that *P. gingivalis* can trigger intracellular calcium mobilisation, the effects on alpha and dense granule release were investigated.


Isolated PRP was exposed to either *P. gingivalis* NCTC 11834 or ATCC W50 before granular secretion of platelet factor 4 (PF4), serotonin and interleukin 1 $\beta$  (IL-1 $\beta$ ) was determined by enzyme-linked immunosorbent assays (ELISA). Untreated and ADP (20  $\mu$ M) treated PRP were included as a negative and positive control respectively. ELISA assays revealed that both *P. gingivalis* NCTC 11834 and ATCC W50 induced significant secretion of PF4 ( $p < 0.001$ ) and serotonin ( $p < 0.05$ ), whereas no significant levels of IL-1 $\beta$  were detected (Figure 6.13a-c).



**Figure 6.13 Induction of platelet degranulation by wild type *P. gingivalis*.** PRP, resuspended in modified Tyrode's buffer were exposed to *P. gingivalis* NCTC 11834 or *P. gingivalis* ATCC W50 after which the supernatants were removed and analysed by ELISAs specific for platelet factor 4 (PF4), serotonin and interleukin 1 $\beta$  (IL-1 $\beta$ ). Both *P. gingivalis* NCTC 11834 and ATCC W50 significantly induced PF4 (A) and serotonin (B) release from platelets whilst no changes in IL-1 $\beta$  release were observed (C). Untreated platelets and platelets treated with ADP (20  $\mu$ M) were included as a negative and positive control respectively. Data is presented as  $\pm$ SEM.  $p = * < 0.05$ ,  $** < 0.01$ ,  $*** < 0.001$ .  $n = 3$ .


### **6.3.6 Does the secretome of *P. gingivalis* induce platelet aggregation?**

To determine whether proteins secreted by *P. gingivalis* were sufficient to induce platelet aggregation, the bacterial culture supernatants of *P. gingivalis* NCTC 11834 and ATCC W50 was utilised as stimulants in aggregatory assays. An example aggregation plot is shown in Figure 6.14a. Both bacterial supernatants from *P. gingivalis* NCTC 11834 and ATCC W50 failed to induce an aggregatory response (Figure 6.14b). As expected, wildtype whole cell *P. gingivalis* NCTC 11834 is able to stimulate platelet aggregation whereas *P. gingivalis* NCTC 11834 does not. Untreated PRP, PRP treated ADP (20  $\mu$ M) and PRP treated with bacterial growth media were also included as both positive and negative experimental controls.



**Figure 6.14 Platelet aggregatory response following exposure to *P. gingivalis* culture supernatant.** Wildtype *P. gingivalis* NCTC 11834 and ATCC W50 were grown as liquid cultures in BHI media until an optical density of 0.8 at 600 nm before centrifugation at 13000 *g*. The supernatants were removed and used as stimulants in platelet aggregation assays. Sterile BHI media and the relevant WT strains were also included as experimental controls. **(A)** An example aggregation plot. **(B)** No aggregatory response was observed with supernatants from either *P. gingivalis* NCTC 11834 or ATCC W50. Untreated PRP and PRP treated with ADP (20 μM) was included as a negative and positive control. Data is expressed as ±SEM, n=3.

It was also hypothesised that lipopolysaccharide (LPS) from *P. gingivalis* could interact with and induce platelet aggregation at higher concentrations. This was determined using commercially available LPS derived from *P. gingivalis* NCTC 11834 at varying concentrations. An example aggregation figure is shown in Figure 6.15a. However as with bacterial supernatants, no aggregatory response was observed with LPS at concentrations of 10, 20 or 40 µg/ml (Figure 6.15b).




**Figure 6.15** *P. gingivalis* LPS as a platelet agonist. Isolated PRP was utilised in aggregation experiments where commercial LPS derived from *P. gingivalis* NCTC 11834 was used as a platelet stimulant. **(A)** An example aggregation plot. **(B)** No Platelet aggregation was recorded following stimulation with *P. gingivalis* NCTC 11834 LPS at all tested concentrations (10-40 µg). Untreated PRP and PRP treated with ADP (20 µg) was included a negative and positive control respectively. Data is expressed as  $\pm$ SEM, n=3.

### **6.3.7 Investigation of platelet receptor inhibitors on *P. gingivalis* induced platelet aggregation**


#### **6.3.7.1 The effect of Toll-like receptor inhibitors on *P. gingivalis* induced platelet aggregation**

Having demonstrated that *P. gingivalis* directly associates with platelets, possible mammalian site of interactions were investigated.

The role and contribution of Toll-like receptor 2 (TLR2), Toll-like receptor 4 (TLR4) in platelet aggregation were determined. Isolated platelets were pre-incubated with either a TLR2 or TLR4 inhibitor or a combination of both before being bacterially challenged with *P. gingivalis* NCTC 11834 and aggregation was measured (Figure 6.16a-c). A representative plot including the untreated and ADP treated platelets is shown in Figure 6.16a-b. No significant changes were observed in total percentage aggregation following pre-incubation with either TLR inhibitors or in combination when compared to PRP exposed to wildtype *P. gingivalis* NCTC 11834 (Figure 6.17a). In contrast however, all three of the TLR inhibitory treatments did cause a significantly quicker onset of aggregation (AGO) when compared to the wildtype control ( $p < 0.05$  or  $< 0.001$ ; Figure 6.17b)




**Figure 6.16** The effect of Toll-like receptor inhibitors on *P. gingivalis* induced platelet aggregation. Isolated PRP was pre-incubated with either TLR2, TLR4 or both inhibitors for 15 minutes at room temperature before aggregation assays in the presence or absence of *P. gingivalis* NCTC 11834 were undertaken. **(A)** An example aggregation plot of the effects of TLR2 and TLR4 inhibitors on untreated PRP aggregation. **(B)** An example aggregation plot of the effects of TLR2 and TLR4 inhibitors on platelets stimulated with ADP (20  $\mu$ M). **(C)** TLR2 and TLR4 inhibitors cause a faster onset of aggregation when compared to untreated PRP stimulated with *P. gingivalis* NCTC 11834. Unstimulated PRP and PRP stimulated with ADP (20  $\mu$ M) was included as a negative and positive control. n=3.




**Figure 6.17** The effects of Toll-like receptor inhibitors on *P. gingivalis*-platelet interactions. Isolated PRP was pre-incubated with TLR2 inhibitor, TLR4 inhibitor or both for 15 minutes at room temperature before aggregation experiments were undertaken. **(A)** No changes in total percentage aggregation were observed with TLR2, TLR4 or the combination of both TLR2+4 inhibitors. **(B)** Incubation with TLR2 and 4 inhibitors resulted in a significantly quicker onset of platelet aggregation (AGO) when compared with PRP stimulated with wild type *P. gingivalis* NCTC 11834 only. PRP treated with ADP (20  $\mu$ M) and untreated PRP were included as a positive and negative control respectively. Data is expressed as  $\pm$ SEM,  $p = * < 0.05$ ,  $*** < 0.001$ .  $n = 4$ .

### **6.3.7.2 The effects of integrin $\alpha_2\beta_1$ and $\beta_3$ inhibitors on *P. gingivalis*-induced platelet aggregation**

The role of the integrins  $\beta_3$  and  $\alpha_2\beta_1$  in *P. gingivalis*-induced platelet aggregation was determined using integrin-specific inhibitors. Following pre-incubation of isolated platelets with  $\beta_3$  and  $\alpha_2\beta_1$  inhibitors, aggregation assays were conducted. To ascertain whether these integrin inhibitors affected normal platelet function, effect on untreated PRP and PRP treated with ADP (20  $\mu$ M) were measured. Incubation with either inhibitor did not result in any changes in aggregatory response within unstimulated PRP or PRP stimulated with ADP (20  $\mu$ M). Representative aggregation plots for both integrin  $\beta_3$  inhibitor (Figure 6.18) and  $\alpha_2\beta_1$  (Figure 6.19) are shown below.




**Figure 6.18 Representative aggregation plots following incubation with integrin  $\beta_3$  inhibitor.** Isolated PRP was incubated with the  $\beta_3$  inhibitor for 15 minutes at room temperature before routine aggregation experiments were undertaken. The effects of the inhibitor were determined on untreated PRP as negative control (**A**) and PRP treated with ADP (20  $\mu\text{M}$ ) as a positive control (**B**). No changes in aggregatory response were recorded in any of the experimental conditions. Representative aggregation plots from three independent observations.




**Figure 6.19 Representative aggregation plots following incubation with integrin  $\alpha_2\beta_1$  inhibitor.** Isolated PRP was incubated with the  $\alpha_2\beta_1$  inhibitor for 15 minutes at room temperature before routine aggregation experiments were undertaken. The effects of the inhibitor were determined against untreated PRP as negative control (**A**) and PRP treated with ADP (20  $\mu\text{M}$ ) as a positive control (**B**). No changes in aggregatory response were recorded in any of the experimental conditions. Representative aggregation plots from three independent observations.

Following incubation with the  $\beta_3$  integrin inhibitor, no changes were observed in either the total percentage aggregation or the onset of aggregation (AGO) when platelets were exposed to *P. gingivalis* NCTC 11834 at an MOI of 1:10 (Figure 6.20). In contrast, following incubation with the  $\alpha_2\beta_1$  inhibitor at a concentration of 20  $\mu\text{M}$  resulted in a significant and complete inhibition of platelet aggregation following addition of *P. gingivalis* NCTC 11834 ( $p < 0.001$ ; Figure 6.21a-b). At a lower concentration of 10  $\mu\text{M}$ , no significant changes in total percentage aggregation were observed. The  $\alpha_2\beta_1$  inhibitor did not induce any alterations in the aggregatory response in either the negative (untreated PRP) or the positive (ADP treated) control at both 10 and 20  $\mu\text{M}$ . The  $\alpha_2\beta_1$  inhibitor also resulted in a significant increase in the onset of aggregation (AGO) at both 10 and 20  $\mu\text{M}$  ( $p < 0.001$ ), with a significant increase in lag time also being observed between platelets exposed 20  $\mu\text{M}$  compared with the lower concentration of 10  $\mu\text{M}$  ( $p < 0.001$ ; Figure 6.21c)



**Figure 6.20** Effects of integrin  $\beta_3$  inhibitor on *P. gingivalis* NCTC 11834 induced platelet aggregation. Isolated PRP was incubated with the  $\beta_3$  inhibitor for 15 minutes at room temperature before routine aggregation experiments were undertaken. Representative aggregation plot (A). No significant differences were observed with either total percentage aggregation (B) or the onset time of aggregation (C) following exposure to *P. gingivalis* NCTC 11834. Untreated PRP and PRP treated with ADP (20  $\mu\text{M}$ ) were included as a negative and positive control. Data is expressed as  $\pm$ SEM, n=3.




**Figure 6.21 Effects of integrin  $\alpha_2\beta_1$  inhibitor on *P. gingivalis* NCTC 11834 induced platelet aggregation.** Isolated PRP was pre-incubated with the  $\alpha_2\beta_1$  inhibitor for 15 minutes at room temperature before routine aggregation experiments were undertaken. **(A)** Representative aggregation plot. **(B)** Incubation with the  $\alpha_2\beta_1$  inhibitor at 20  $\mu\text{M}$  completely inhibited platelet aggregation following stimulation by *P. gingivalis* NCTC 11834, with no significant differences observed with the lower concentration (10  $\mu\text{M}$ ). **(C)** The integrin  $\alpha_2\beta_1$  inhibitor significantly increases the lag-time of platelet aggregation following stimulation with *P. gingivalis* NCTC 11834 at both 10 and 20  $\mu\text{M}$ . When incubated with 20  $\mu\text{M}$  of inhibitor *P. gingivalis* NCTC 11834 stimulated aggregation is abolished. Untreated PRP, PRP treated with ADP (20  $\mu\text{M}$ ) and PRP treated with *P. gingivalis* NCTC 11834 only were included as comparative experimental controls. Data is expressed as  $\pm\text{SEM}$ ,  $p = *** < 0.001$ .  $n = 3$ .

### **6.3.8 Development of a recombinant protein-based ELISA for the detection of *P. gingivalis*-platelet integrin interactions**

Having demonstrated that integrin  $\alpha 2\beta 1$  inhibition prevented *P. gingivalis* from stimulating platelet aggregation, a recombinant protein-based ELISA was developed to investigate whether *P. gingivalis* NCTC 11834 or ATCC W50 could directly bind to either integrin  $\alpha 2\beta 1$  or  $\alpha \text{IIb}\beta 3$  using immobilised recombinant integrins.

Successful immobilisation of recombinant integrins was confirmed with  $\beta 1$  and  $\beta 3$  specific monoclonal antibodies which showed integrin specific binding (Figure 6.22a-b). *P. gingivalis* NCTC 11834 showed significant levels of binding to the recombinant integrin  $\alpha 2\beta 1$  ( $p < 0.0001$ ), whereas no significant binding was observed with either *P. gingivalis* NCTC 11834 treated or untreated controls (Figure 6.22c). In contrast no significant binding was observed with integrin  $\alpha \text{IIb}\beta 3$  (Figure 6.22d).



**Figure 6.22 Detection of *P-gingivalis*-integrin binding by recombinant protein-based ELISA.** 96-well plates were coated with either recombinant  $\alpha 11\beta 3$  or  $\alpha 2\beta 1$  overnight at 4 °C. Plates were then either incubated with integrin specific antibodies (A-B) to determine successful protein coating or were challenged with *P. gingivalis* (NCTC 11834 or ATCC W50) and then incubated with PG specific antibodies to determine bacterial binding (C-D). Plates were successfully coated with  $\alpha 2\beta 1$  (A) and  $\alpha 11\beta 3$  (B). *P. gingivalis* NCTC 11834 significantly binds to integrin  $\alpha 2\beta 1$ , with no significant changes observed with either PG ATCC W50 treatment or untreated controls (C). No binding was observed in any of the experimental treatments with integrin  $\alpha 11\beta 3$  (D). Data is presented as  $\pm$ SEM,  $p=***<0.001$ .  $n=3$ .

## 6.4 Discussion

Periodontitis and its associated bacterial pathogens have been historically linked to several systemic diseases (Kerr, 1951, 1962). In this study, the interactions of periodontal pathogens and platelets were further characterised. A growing body of research has also documented the importance of platelets within the innate and adaptive immunity in the defence against bacterial infections (Kerrigan, 2015).

*P. gingivalis* induced platelet aggregates were analysed using both SEM and TEM. *P. gingivalis* (NCTC 1834 or ATCC W50) treated platelets resulted in aggregate formation as observed by SEM, whereby bacteria were found encapsulated within the aggregates and the platelets were phenotypically dissimilar to untreated or ADP stimulated controls. TEM analysis also revealed that incubation with *P. gingivalis* resulted in the complete loss of any defined platelet phenotypic structures. These observations are in agreement with those of Li and colleagues (2008) who demonstrated that NCTC 11834 induced the formation of small bacteria-associated aggregates (Li *et al.*, 2008). However as the later study used a lower MOI of .3 and was conducted under stirring conditions, it could explain why smaller aggregates were observed. Further confirmation of the pathogen encapsulated within the aggregates was obtained in TEM imaging. These findings are in agreement with those observed with both *Escherichia coli* and *Staphylococcus aureus* that show the formation of bacterial-platelet clusters (Kraemer *et al.*, 2011; Vieira-de-Abreu *et al.*, 2012).

Studies involving patients suffering from chronic periodontitis have shown the presence of an associated condition of heightened circulatory platelet activation and suggested that this is a direct consequence of the pathogenic bacteria present within the disease (Papapanagiotou *et al.*, 2009). Additionally, an increase in expression level of the platelet activation marker CD62P by *P. gingivalis* has been demonstrated in both

a murine model, (Yu *et al.*, 2011) and *in vitro* with isolated mammalian platelets exposed to the pathogen (Klarström Engström *et al.*, 2015). In this study, levels of a panel of platelet specific proteins were quantified. Using an optimised in-house flow cytometry, a significant increase in expression of both CD62P ( $p < 0.001$ ) and PAC-1 (CD41/61, GPIIb/IIIa,  $\alpha$ IIb $\beta$ 3;  $p < 0.05$ ) was observed in platelet population which was positive for *P. gingivalis* (NCTC 11834 or W50;  $p < 0.001$ ). CD62P is a type1 transmembrane glycoprotein, normally contained within the  $\alpha$ -granule but which becomes expressed on activated platelets (Ault *et al.*, 1989). CD41/61, also known as the glycoprotein heterodimer complex GPIIb/IIIa and as integrin  $\alpha$ IIb $\beta$ 3 is normally expressed on platelets as a heterodimer in a resting form (Bennett, 2005). However, during platelet activation, CD41/61 undergoes a change in conformation and expresses activation-induced epitopes to which the CD41/61 antibody also known as PCA-1 can bind to (Shattil *et al.*, 1985). The increase in PAC-1 suggest that the integrin CD41/61 has move from its resting state to an activated state (Shattil *et al.*, 1985) and confirms the activation status of platelets.

Surprisingly, an increase in CD42b expression ( $p < 0.01$ ) was observed following bacterial exposure. This is in contrast with previous studies which have documented a decrease in CD42b expression following platelet activation due to ectodomain shedding (Tao *et al.*, 2016) but supports the increase in CD42b expression induced on platelets by the Dengue virus (Núñez-Avellaneda *et al.*, 2018). CD42b also known as glycoprotein Ib $\alpha$  (GPIb $\alpha$ ) exists within a non-covalent complex of GPIb-IX-V on the platelet surface membrane (Modderman *et al.*, 1992) and plays a role on platelet adhesion to subendothelial matrix, endothelial cells and leukocytes (Berndt *et al.*, 2001). It has also been suggested that in addition to its role in haemostasis, GP1b $\alpha$

plays a fundamental role within platelet immune response and vascular inflammation (Pitchford, Pan and Welch, 2017) with the common structural motifs of leucine rich repeat regions within each subunit of the GPIb-IX-V complex mirroring those present in all 13 members of the TLR family and suggesting a common ancestry between platelet and leukocytes as well as an involvement with bacterial interaction (Corken *et al.*, 2014). Bacterial species including *Streptococcus gordonii* (Bensing, López and Sullam, 2004) and *Streptococcus sanguis* (Plummer *et al.*, 2005) have been shown to exploit the GP1b $\alpha$  ligand in order to bind to platelets and subsequently induce an aggregatory response. The consistent increase in GPIb $\alpha$  expression was observed following *P. gingivalis* exposure can also be partly attributed to the presentation of the receptor through alpha granule release however this would account for only ~10% of GPIb $\alpha$  expression (Berger, Massé and Cramer, 1996; Maynard *et al.*, 2007).

The increase in expression of both CD62P and CD41/61 and the observed platelet aggregation suggests platelet granule secretion, cytoskeletal rearrangements and further signal transduction (van Velzen *et al.*, 2012). To probe alterations occurring within platelets granular secretion and alteration in calcium mobilisation were investigated. A significant increase in intracellular calcium mobilisation ( $p < 0.001$ ), serotonin release ( $p < 0.05$ ) as well as PF4 secretion ( $p < 0.001$ ) was observed following *P. gingivalis* stimulation. Intracellular calcium mobilisation is an essential cofactor that drives platelet signalling at a molecular level, resulting in platelet activation, secretion and aggregation (Gerrard, White and Peterson, 1978; Heemskerk *et al.*, 1992, 2001). Our findings agree with earlier studies which demonstrated that *P. gingivalis* are able to induce calcium flux *in vitro* within both epithelial cells and washed platelet preparations (Lourbakos *et al.*, 2001; Klarström Engström *et al.*, 2015). The detection of both serotonin and platelet factor 4 release further confirms that *P. gingivalis*

stimulates the full signalling cascade of platelet aggregation, with granule release also being directly implicated within the role of platelets within the innate and adaptive immunity (Ali, Wuescher and Worth, 2015). Induction of platelet granular release have reported with several bacterial species with *Streptococcus sanguinis*, *Staphylococcus aureus*, *Streptococcus oralis* and *Streptococcus pneumoniae* stimulating both alpha and dense granule release as an adaptive immune response to bacterial stimulation (Erickson and Herzberg, 1993; Arman *et al.*, 2014). Interestingly, despite previous reports stating that platelets release IL-1 $\beta$  following stimulation with ADP (Sedlmayr *et al.*, 1995; Cha *et al.*, 2000; Brown *et al.*, 2013), both viable *P. gingivalis* and purified LPS failed to show secretion of IL-1 $\beta$ . The release of IL-1 $\beta$  by platelets is currently disputed as other studies (Pillitteri *et al.*, 2007) have suggested that the detectable levels of IL-1 $\beta$ , is a direct consequence of leukocyte contaminants within the platelet isolation process (Pillitteri *et al.*, 2007). Interestingly, *P. gingivalis* has also been shown to degrade several inflammatory chemokines and cytokines *in vitro*, for example; TNF, IL-6, CCL2, CCL5 (RANTES), CXCL1, CXCL8 (IL-8), CXCL10 and IL-2 excreted by fibroblasts (Palm, Khalaf and Bengtsson, 2013), IL-2 produced by Jurkat T-cells (Khalaf and Bengtsson, 2012) and isolated mammalian IL-1 $\beta$ , IL-6 and IL-1 receptor antagonist (Fletcher *et al.*, 1998). Thus, further work is required to determine whether IL-1 $\beta$  is being degraded by the well documented protease activity of *P. gingivalis* (Tokuda *et al.*, 1998; Holt, 1999; Loubakos *et al.*, 2001).

Studies investigating the interactions of *P. gingivalis* with oral epithelial cells identified the subunits of two major outer membrane proteins OMPA1 and OMPA2 of *P. gingivalis* NCTC 11834 as being essential for biofilm formation and a contributory factor to bacterial virulence (Suwannakul *et al.*, 2010; Aruni *et al.*, 2011; Naylor *et al.*, 2016) whilst the sialidase enzyme O352 as being crucial within *P. gingivalis* virulence

through bacterial adherence and biofilm formation (Li *et al.*, 2017; Yang *et al.*, 2018). The role and importance of these proteins in platelet aggregation was determined and aggregation studies revealed that not only do both OMPA deficient mutants induce a faster aggregatory response but they also induce significantly higher levels of platelet activation and intracellular calcium mobilisation when compared to the parental strain. A similar response was observed with the  $\Delta$ Sia0352 mutants suggesting that disrupting bacterial/cellular interactions, results in a heightened platelet response. As previously discussed (Chapter 4) it is hypothesised that these disruptions within key outer-membrane proteins such as OMPA and the sialidase enzyme possibly reduce the evasive characteristics of *P. gingivalis* resulting in a faster and more heightened combative platelet activation.

Bacteria are known to bind to oral epithelial cells and platelets via glycoprotein receptors such as integrins. Interactions between bacterial species such as *Escherichia coli* (Vieira-de-Abreu *et al.*, 2012) and *Staphylococcus aureus* (Kraemer *et al.*, 2011) with platelets have been previously visualised by both fluorescence and electron microscopy. Using fluorescence microscopy, uniform expression of integrins  $\beta$ 1 and  $\beta$ 3, as well as an F-actin probe was observed in the untreated samples showing a phenotypic discoid platelet shape. Additionally, an increase in clumping of platelets were seen when platelets were treated with *P. gingivalis*. Disruption in the expression of integrin  $\beta$ 1 (Yilmaz, Watanabe and Lamont, 2002; Li *et al.*, 2013), integrin  $\beta$ 3 (Li *et al.*, 2013; Boisvert, Lorand and Duncan, 2014) and in actin (Kinane *et al.*, 2012) following *P. gingivalis* treatment have been documented within epithelial cells. However, reduction in expression of the integrins was not observed with platelets and this could reflect the fact that platelets aggregate within minutes and protein degradation is not possible in

such a small time frame, protein degradation in epithelial cells, usually occurring after two to four hours following bacterial challenge.

The observed formation of platelet aggregates suggests that platelets must undergo cytoskeletal re-arrangements (Bearer, Prakash and Li, 2002). This was investigated by staining for the mammalian target of rapamycin (mTOR), a serine kinase that integrates with several key process including cell proliferation, protein synthesis and autophagy (Hay and Sonenberg, 2004) has been identified within previous research by Stafford and colleagues (2013) as a target for *P. gingivalis* host cell manipulation. Within platelets, mTOR has many reported functions including the regulation of mRNA translation and protein synthesis (Weyrich *et al.*, 1998). In this study, following exposure to *P. gingivalis* NCTC 11834, platelets were observed to form large aggregates consisting of interconnected, fibrous-like structures which stained positively for mTOR, within which were embedded a combination of pathogen and discoid platelet structures that are positively stained for F-actin. This is in contrast with reports of *P. gingivalis* degrading mTOR following cellular invasion of oral epithelial cells (Stafford *et al.*, 2013) and is likely to reflect the time taken for *P. gingivalis* to invade oral epithelial cells and degrade mTOR via its secreted gingipains (Stafford *et al.*, 2013) whilst the response of platelets to *P. gingivalis* happens at much faster rate within minutes such that protein degradation might not be feasible. The presence of mTOR within the aggregates might also contribute to aggregate formation as studies by Aslan and colleagues (2012) have implicated mTOR in lamellipodia formation and thrombus stability (Aslan and McCarty, 2012). Further to this mTOR is also known to be downstream of integrin/glycoprotein signalling (Watson *et al.*, 2005; Z. Li *et al.*, 2010), which as previously mentioned is a target for *P. gingivalis* cellular interactions

Proteases secreted by *P. gingivalis* known as gingipains (Curtis *et al.*, 1993b; A Lourbakos *et al.*, 2001; Naito *et al.*, 2006) and lipopolysaccharide (Zhang *et al.*, 2009) have been shown to induce platelet aggregation within washed platelet preparations. In this study, the effects of both gingipains and LPS on isolated but not washed platelets were investigated and it was observed that neither *P. gingivalis* culture supernatants containing gingipains nor isolated LPS initiated a platelet aggregatory response under the conditions used. This could reflect the different experimental conditions used i.e. isolated platelets contained within plasma as opposed to washed platelets. Despite both PRP and washed platelets being readily utilised within platelet research there are stark differences attached to each platelet preparation. Washed platelets are more resilient against spontaneous activation and allow analysis to be undertaken completely removed from any anticoagulant used within sample acquisition (Cazenave *et al.*, 2004). However one of the major caveats to washed platelet suspensions is the removal of key plasma proteins and the formation of highly selective platelet subpopulations through the centrifugation stages and the use of a physiological buffer (Cazenave *et al.*, 2004). The presence of plasma proteins has also been shown to have a direct impact on platelet function within immunity, with research by Damien and colleagues (2015) demonstrating that soluble CD14 present in plasma facilitates platelet TLR4 stimulation by bacterial LPS.

Previous work has also demonstrated that bacterial species including group B *Streptococcus* (Ma *et al.*, 2009) and *Streptococcus pneumoniae* (Keane *et al.*, 2010) can induce platelet activation through interactions with toll-like receptor 2 (TLR2), whereas bacterial LPS derived from *Escherichia coli* stimulates platelet activation through interaction with toll-like receptor 4 (TLR4) (Andonegui *et al.*, 2005; Ma *et al.*, 2009). *P. gingivalis* has also been shown to activate endothelial and dendritic cells through TLR4,

while epithelial cells were activated through TLR2 (Darveau *et al.*, 2004; Kocgozlu *et al.*, 2009). It was therefore hypothesised as platelets express TLR receptors, inhibiting platelet TLR2 and TLR4 independently as well as in a combined treatment should impede platelet-*P. gingivalis* interaction and consequently reduced or fully inhibit the observed aggregatory responses if *P. gingivalis* interacted with platelets through TLRs. Surprisingly, addition of TLR antagonists resulted in no alteration in the total percentage aggregation induced by the pathogen but caused a significantly quicker onset of aggregation when compared to the untreated *P. gingivalis* control ( $p =$  NCTC 11834  $<0.05$ , ATCC W50  $<0.001$ ). Although strain variation has previously been reported to impact platelet aggregation lag time (Moriarty *et al.*, 2016), the observed findings cannot be fully explained. One possible explanation could be that antagonising the TLR 2 and 4 receptors results in an upregulation or increased trafficking of further TLR receptors which has been previously reported in dendritic cells following LPS stimulation (Chamorro *et al.*, 2009), however further work would be needed to further explore this premise

Having demonstrated that *P. gingivalis* associated with and activated platelets inducing aggregation, which was not abrogated by TLR inhibitors, the interactions of *P. gingivalis* with platelet surface integrins were investigated. Studies using selective platelet inhibitors have led to the identification of potential binding sites for platelet-bacterial interaction: the selective inhibition of GPIIb/IIIa (integrin  $\alpha$ IIb $\beta$ 3) with Abciximab completely abolished *Streptococcus gordonii* binding to platelets (Petersen *et al.*, 2010) and both *Streptococcus sanguis* (Kerrigan *et al.*, 2002) and *Helicobacter pylori* (Byrne *et al.*, 2003) interact with platelets through GPIIb/IIIa. Using aggregation assays, the effect of selected integrin inhibitors on *P. gingivalis* induced aggregation was therefore determined. The addition of the selective  $\beta$ 3 inhibitor did not affect the

total percentage aggregation or the initiation of aggregatory response, suggesting that *P. gingivalis* induced aggregation is not dependent on integrin  $\beta 3$  interaction.

In contrast, the selective integrin  $\alpha_2\beta 1$  inhibitor, resulted in complete abolishment of any aggregatory response at 20  $\mu\text{M}$  ( $p < 0.001$ ) and a significant increase in lag time when compared to the untreated *P. gingivalis* control at 10  $\mu\text{M}$  ( $p < 0.001$ ). Previous research has shown that *P. gingivalis* can physically associate with  $\alpha 5\beta 1$  integrin expressed by endothelial cells via major fimbriae (FimA) proteins (Nakagawa *et al.*, 2002; Yilmaz *et al.*, 2003; Kato *et al.*, 2007; Al-Taweel, Douglas and Whawell, 2016) and could propose a common pathway by which *P. gingivalis* invades nucleated host cells (Olsen and Progulske-Fox, 2015) and interacts with platelets inducing platelet aggregation. This hypothesis is further supported by the ELISA based assays which revealed that findings that *P. gingivalis* NCTC 11834 but not ATCC W50 bound to recombinant integrin  $\beta 1$  ( $p < 0.001$ ) whilst both *P. gingivalis* strains did not bind to recombinant integrin  $\beta 3$ . Within epithelial cells it is suggested that integrin  $\beta 1$  provides a functional receptor for fimbriae mediated adherence and invasion for *P. gingivalis* NCTC 11834 (Amano, 2003).

Interestingly, *P. gingivalis* strains are known to express different types of the major fimbriae gene *fimA*, with NCTC 11834 expressing type I and ATCC W50 expressing type IV (Amano *et al.*, 1999). When compared phenotypically, this varying *fimA* expression results in *P. gingivalis* ATCC W50 displaying much shorter, sparsely populated fimbriae as opposed to the much longer and widely presented fimbriae of *P. gingivalis* NCTC 11834 (Sojar, Hamada and Genco, 1997). These inter-strain variances could therefore offer a possible explanation to the differential integrin  $\beta 1$  binding observed and account for the abrogation of the strain specific aggregation induced by *P. gingivalis* NCTC 11834 by integrin  $\beta 1$  inhibitors. Taken together, the data suggest that in the case

of by *P. gingivalis* ATCC W50 both platelet activation and calcium mobilisation occurs independently of integrin  $\beta$ 1 and additional adhesins or receptors are likely to contribute to *P. gingivalis* ATCC W50-platelet interactions.

Similar studies were conducted with *T. forsythia*, a well-documented periodontopathogen shown to be epidemiologically relevant to the progression of periodontitis (Darveau, 2010) and capable of invade epithelial cells (Sabet *et al.*, 2003; Inagaki *et al.*, 2006; Kirschbaum *et al.*, 2010a). Periodontitis patients who are positive for both *P. gingivalis* and *T. forsythia* also have a heightened level of platelet activity (Nicu *et al.*, 2009). However, *T. forsythia* does not associate with isolated platelets or initiate platelet activation via intracellular calcium mobilisation. Collectively, these findings suggest that *T. forsythia* does not interact with isolated mammalian platelets under the given conditions.

Other bacterial species including *Streptococcus sanguinis* and *Staphylococcus aureus* have shown that bacterial interactions with platelets can occur directly as well as indirectly through the dependent synthesis of plasma bridging proteins (Fitzgerald, Foster and Cox, 2006). This could highlight further mechanisms in which *T. forsythia* could interact with platelets but further work would be needed to fully test this hypothesis.

## 6.5 Summary

To conclude this chapter of work, this data demonstrate that *P. gingivalis* is able to directly associate with mammalian platelets, forming large fibrous aggregates, that stain highly for mTOR and encapsulate bacterial cells. The expression of mTOR may also be implemented in platelet cytoskeletal rearrangement and thrombus construction following *P. gingivalis* stimulation.

*P. gingivalis* is able to initiate platelet activation through intracellular calcium mobilisation that leads to the release of both alpha and dense granules, independent of bacterial outer membrane protein OMPA. *P. gingivalis* NCTC 11834 but not ATCC W50 actively associates and interacts with integrin  $\alpha_2\beta_1$  inducing strain dependant platelet aggregation and could suggest a role for bacterial fimbriae within platelet interactions.

Further work is required to determine the extent to which platelet-*P. gingivalis* interactions are dependent on inter-strain variations and could also provide novel pathways to fully characterise how these interactions take place and to identify pathways that could be developed as therapeutic targets.

## **Chapter 7: General discussion and future directions**

## 7.1 Introduction

The overall aim of this study was to increase current understanding of the mechanism by which periodontal pathogens interact with platelets. The main objectives were to (a) develop an *in vitro* platelet-like cell model and (b) to optimise and multicolour flow cytometry panel (c) to enable the interactions of two of the red complex oral pathogens *P. gingivalis* and *T. forsythia* with platelets to be further characterised. It is anticipated that these findings will contribute to current knowledge of how periopathogens-platelet interactions might contribute to cardio vascular disease, specifically atherosclerotic vascular disease. The findings of this study have been discussed in detail within each relevant chapter. Here a summary of the major findings are presented alongside implications and possible future directions for this work

## 7.2 The use of CHRF-288-11 cells as an *in vitro* platelet model

The CHRF-288-11 cell line originally characterised by Fugman and colleagues (1990) has been proposed as a lucrative model to study megakaryocyte/platelet behaviour (Lev-Lehman *et al.*, 1997). In this study, it was observed that through differentiation, CHRF-288-11 cells adopt a platelet like phenotype that be utilised to study periodonto-platelet pathogen interactions *in vitro*. PMA (50 ng/ml) over five days resulted in successful CHRF-288-11 differentiation as characterised by the formation of large multi-lobed nuclei and pseudopodia pro-platelet protrusions. Differentiated CHRF-288-11 cells were shown to express the platelet specific glycoprotein CD41, the complex CD41/61, the platelet activation marker CD62P (P-selectin) but not CD42b as quantified by flow cytometry.

CHRF-288-11 cells were shown to associate with and were invaded by *P. gingivalis* strains NCTC 11834, ATCC W50 and *T. forsythia* ATCC 43037. Association of *P.*

*gingivalis* resulted in an increase in binding of integrin  $\beta 1$  and  $\beta 3$  specific antibodies which suggest either a change in integrin conformation or potential upregulation of the receptor as well as a reduction in binding of mTOR antibodies, whereas association with *T. forsythia* did not.

These characteristics detail the novel application of the CHRF-288-11 cell line as a platelet-like *in vitro* cell model through the expression and utilisation of phenotypic platelet markers.

### **7.3 Development of a multiparameter flow cytometry panel**

Following previously published guidelines on flow cytometry panel development (Schmitz *et al.*, 1998), a single step staining and analysis protocol for platelets was designed to simultaneously record platelet-pathogen association and the resulting changes in the expression of platelet activation markers. Using an advanced multiparameter gating strategy, a subset population of platelets associated with *P. gingivalis* were isolated from CD41<sup>+</sup> platelet populations and the relative expression of CD41/61, CD62P and CD42b were determined. *P. gingivalis* association led to significant increases in CD41/61, CD62P and CD42b when compared to unassociated platelets. This optimised flow cytometry offers a new, practical analysis tool that can be used in settings where spontaneous platelets activation needs to be minimised, minimum sample volumes are available and where platelets cannot be stored on-site for extended period.

## 7.4 Periodontal pathogens and platelet interactions

Periodontal pathogen-platelet interaction studies revealed that viable *P. gingivalis* directly interacts with mammalian platelets whereas *T. forsythia* does not. Exposure to *P. gingivalis* induced platelet activation via calcium mobilisation and granule release, suggesting an immunological role against *P. gingivalis* infection.

Platelet activation, following platelet association with *P. gingivalis*, resulted in an increased expression of CD41/61, CD62P and CD42b as quantified by flow cytometry as well as the release of serotonin and platelet factor 4, quantified by ELISA. These investigations also revealed that platelet activation induced by *P. gingivalis* occurs independently of interactions with the major bacterial outer membrane subunits OMPA1 and OMPA2.

Surprisingly, although all strains of *P. gingivalis* induced platelet activation, platelet aggregation was only observed in a strain dependant manner by *P. gingivalis* NCTC 11834 and ATCC 381 but not by ATCC W50.

Investigations into the underlying mechanisms of *P. gingivalis* induced platelet aggregation demonstrated that within the applied methodology, both *P. gingivalis* secreted proteome and isolated *P. gingivalis* lipopolysaccharide (LPS) were unable to stimulate platelet aggregation, under the experimental conditions used in this study, possibly further emphasising a dependency on direct platelet to pathogen interactions.

Screening of *P. gingivalis* mutants deficient in either the major outer membrane protein subunits OMPA1/OMPA2 or the virulence associated sialidase 0352 resulted in no impact on the total percentage aggregation induced by *P. gingivalis* but did result in a faster onset of the aggregatory response. Similarly, screening of specific platelet

receptor inhibitors found that platelet aggregation occurred independently of interactions with toll-like receptor 2 and 4 as well as integrin  $\beta 3$  but all inhibitory experiments resulted in a faster onset of the aggregatory response.

Interestingly, platelet aggregation induced by *P. gingivalis* NCTC 11834 was completely abolished following incubation with a specific integrin  $\alpha 2\beta 1$  inhibitor, with *P. gingivalis* also being shown to directly associate with recombinant integrin  $\beta 1$  within an ELISA. Collectively, these findings suggest that platelet aggregation induced by *P. gingivalis* NCTC 11834 is dependent on interactions with integrin  $\alpha 2\beta 1$ , specifically the  $\beta 1$  subunit and could reveal independent virulence mechanisms such as fimbriae exhibited by *P. gingivalis*.

These findings provide novel data which demonstrate that *P. gingivalis* induces platelet aggregation and activation via granule release within platelet rich plasma, with the observed aggregatory response occurring in a strain dependant manner.

## **7.5 Future Directions**

Within this body of work, it was postulated that through the associated localised bleeding and increased bacterial load found within chronic periodontitis, pathogenic bacterial species, specifically *Porphyromonas gingivalis* and *Tannerella forsythia*, opportunistically penetrate the vascular system. During this invasive process, these pathogenic bacteria would interact with platelets, giving rise to an altered platelet state, the formation of bacterial-platelet aggregates and ultimately contribute to the progression of atherosclerotic vascular disease.

As detailed above, this study does not only demonstrate that periodontal pathogenic bacteria are able to interact with platelets and megakaryocytic-like cells but may also

provide novel pathways in which periodontitis is able to contribute to the progression of CVD's.

The CHRF-288-11 cell line provides a unique niche in which to study bacterial-platelet interactions and with further expansion could reduce the need for regular blood acquisition for platelet studies. Although within this study, CHRF-288-11 cells have been shown to express a number of platelet markers, further analysis of protein expression could reveal a plethora of platelet markers expressed by the CHRF cells adding further benefit to the reported applications of these megakaryocytic like cells. It is also possible that through varied differentiation protocols such as those detailed by Lepage and colleagues (2000) that utilise cytokines as opposed to PMA could reveal varying phenotypes within the cell line further adding to its applications within a platelet-like cell model. Novel developments within the field of *in vitro* megakaryocyte culture and *in vitro* platelet production could abrogate the need for blood donations entirely (Moreau *et al.*, 2016; Strassel, Gachet and Lanza, 2018), possibly replacing the CHRF-288-11 cells and allowing for platelet methodologies to become routine and high throughput.

Interestingly, it was found that although *T. forsythia* is able to interact with and invade the megakaryocytic cell line, it was not observed to interact with platelets within any investigations. However from the investigations undertaken within this body of work it cannot be concluded that *T. forsythia* is unable to interact with platelets and could suggest an alternative pathway in which periodontal-pathogens and platelets interact.

Further work could be used to highlight whether *T. forsythia* is able to interact with mammalian platelets, whether it actively evades platelet response or whether *T. forsythia*-platelet interactions are reliant on the synthesis of cofactors such as those observed with *Staphylococcus aureus* aggregation (Yeaman, 2010b).

Similarly, it is well established that pathogenic bacterial species within the oral biofilm are able to coaggregate (Kolenbrander, Andersen, Blehert, *et al.*, 2002), with suggestions that this may facilitate synergistic behaviour between the pathogens, increasing virulence activity (Kolenbrander, 2000; Kesavalu *et al.*, 2007; Kirschbaum *et al.*, 2010b). Exposing platelets to co-cultures of *P. gingivalis* and *T. forsythia* could expose mechanisms by which *T. forsythia* is able to interact with platelets and reveal further aspects of *P. gingivalis*-platelet interactions thereby providing a closer representation of the biofilm present with the periodontal pocket.


In addition, the inter-strain variances of *P. gingivalis* induced platelet aggregation and activation suggest that bacterial genetics as well as their associated virulence factors such as fimbriae contribute to the combative platelet response.

Interestingly, phylogenetic comparisons of the *P. gingivalis* strains utilised within this study reveal that NCTC 11834 and ATCC 381 are highly similar, whereas ATCC W50 is comparatively highly divergent (Griffen *et al.*, 1999). This is further emphasised through full genome comparisons as illustrated by a circular genome representation (Figure 7.1). In order to expand on the initial findings within this thesis, full screening of the ATCC 381 strain as well as the introduction of further *P. gingivalis* strains such as ATCC W83 which is closely related to ATCC W50 would further explore the strain specific nature of platelet aggregation in response to *P. gingivalis*. This study also found strain specific interactions with integrin  $\alpha 2\beta 1$ , with the full extent of *P.*

*gingivalis*-platelet interactions as well as the underlying mechanisms remaining inconclusive. It is hypothesised that through the application of pull-down assays, the specific mammalian protein targets for *P. gingivalis* could be identified and allow the proposal of a comprehensive mechanistic pathway.

These pull-down assays could then be coupled with an extensive proteomic study of both the mammalian platelets and the bacterial pathogens. With regards to platelets, it could be used to identify specific pathways in which platelets respond to varying pathogenic bacterial species and could implicate further roles for platelets within both the innate and adaptive immune system. Further work could also highlight the exact proteinous nature of the fibrin-like structures which form following platelet exposure to *P. gingivalis*. These investigations could utilise fluorescently labelled fibrinogen to determine whether the formed matrix is similar to that of a haemostatic fibrin mesh (Holinstat, 2017) as well as being coupled with further immunofluorescent microscopy and western blotting to confirm the presence of further proteins such as mTOR and actin which are known to stabilise thrombus formation (Aslan and McCarty, 2012).

As a separate approach, analysing the bacterial strains could also reveal specific bacterial genetic features and proteomic differences, which not only contribute to the observed variances in platelet activation and aggregation but could also highlight highly virulent pathogenic strains in relation specifically to CVD.



**Figure 7.1** Circular representation of the *P. gingivalis* NCTC 11834, ATCC 381 and ATCC W50 genomes. *P. gingivalis* NCTC 11834 (431947.7) and ATCC 381 (1403335.5) are genetically highly similar whereas comparatively ATCC W50 (1125722.3) is highly divergent. This representation was generated using the PATRIC online genome comparison tool.

In order to expand on the findings surrounding platelet-pathogen interactions, there are many potential investigative avenues that could be explored. Initially it would very interesting to investigate as to whether periodonto-pathogens influence platelet adhesion, which is a known contributor to atherosclerosis and atherothrombosis (Finn *et al.*, 2010; Badimon, Padró and Vilahur, 2012; Anlamlert, Lenbury and Bell, 2015). At the principle level, this could be undertaken using platelet adhesion assays which quantitate platelet adhesion to either glass coverslips or a collagen coated surface. This methodology could then be applied to a microfluidics system, which would investigate whether platelets can interact with periodonto-pathogens under shear flow and whether these interactions interfere with platelet adhesion properties under physiological conditions.

Further to this, platelet interactions with the vessel wall, specifically dysfunctional or activated endothelium are thought to be crucial in the role of platelets within the development of the atherosclerotic lesion as well as the terminal thrombotic events (Sachais, 2001). Recent developments within microfluidic chambers allow the study of the platelet endothelium interface and could be utilised to investigate whether periodontal pathogens promote the adherence to the endothelium, resulting in atherosclerotic disease-like phenotypes (Zilberman-Rudenko *et al.*, 2017).

These future studies could be coupled with patient blood samples and clinical isolates of periodonto-pathogens to ascertain whether the presence of specific strains of *P. gingivalis* is directly associated with the progression of CVD or whether patients with periodontitis behave differently to the healthy blood samples applied within this study, specifically addressing whether patients with an increasing severity of periodontitis

also present with an increase in platelet activation and aggregation, as well as an increased risk of CVD.

Used in combination, the findings within this thesis as well as further work could identify novel contributory factors to the development of CVD, aid in the identification of risk factors associated with periodontitis and help develop a personalised medical approach to the treatment of patients through the use of platelets as complex biomarkers. Here it is postulated that through the identification of specific 'at risk' patients as well as the application of preventative periodontal monitoring and treatments could hold substantial prognostic promise for the future treatment of CVD.

## Bibliography

Aarabi G, Eberhard J, Reissmann DR, Heydecke G and Seedorf U (2015) Interaction between periodontal disease and atherosclerotic vascular disease – Fact or fiction? *Atherosclerosis* 241(2): 555–560. Available at: <http://www.sciencedirect.com/science/article/pii/S0021915015010382> (accessed 24/11/15).

Al-Taweel FB, Douglas ICW and Whawell SA (2016) The periodontal pathogen *Porphyromonas gingivalis* preferentially interacts with oral epithelial cells in S phase of the cell cycle. *Infection and Immunity* 84(7): 1966–1974. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/27091929> (accessed 11/12/18).

Albandar JM and Rams TE (2002) Global epidemiology of periodontal diseases: an overview. *Periodontology* 2000. Munksgaard International Publishers 29(1): 7–10. Available at: <http://doi.wiley.com/10.1034/j.1600-0757.2002.290101.x> (accessed 04/10/16).

Ali RA, Wuescher LM and Worth RG (2015) Platelets: essential components of the immune system. *Current trends in immunology*. NIH Public Access 16: 65–78. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/27818580> (accessed 27/06/18).

Alvarez DF, Helm K, Degregori J, Roederer M and Majka S (2010) Publishing flow cytometry data. *American journal of physiology. Lung cellular and molecular physiology*. American Physiological Society 298(2): L127-30. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19915158> (accessed 07/12/18).

Amano A (2003) Molecular interaction of *Porphyromonas gingivalis* with host cells: Implication for the microbial pathogenesis of periodontal disease. *Journal of Periodontology* 74(1): 90–96. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/12593602> (accessed 30/09/16).

Amano A, Nakagawa I, Kataoka K, Morisaki I and Hamada S (1999) Distribution of *Porphyromonas gingivalis* strains with *fimA* genotypes in periodontitis patients. *Journal of Clinical Microbiology*. American Society for Microbiology (ASM) 37(5): 1426–1430. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/10203499> (accessed 09/11/18).

Amano A, Nakagawa I, Okahashi N and Hamada N (2004) Variations of *Porphyromonas gingivalis* fimbriae in relation to microbial pathogenesis. *Journal of periodontal research* 39(2): 136–42. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15009522> (accessed 27/11/18).

Andonegui G, Kerfoot SM, McNagny K, Ebbert KVJ, Patel KD and Kubes P (2005) Platelets express functional Toll-like receptor-4. *Blood*. American Society of Hematology 106(7): 2417–23. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/9326228> (accessed 16/09/18).

Andrews RK, Lopez JA and Berndt MC (1997) Molecular mechanisms of platelet adhesion and activation. *International Journal of Biochemistry and Cell Biology*, 91–105. Available at:

<https://www.sciencedirect.com/science/article/pii/S1357272596001227> (accessed 05/12/18).

Anlamlert W, Lenbury Y and Bell J (2015) Stability analysis of a mathematical model of atherosclerotic plaque development: Fibrous cap formation and degradation. *Kasetsart Journal - Natural Science*. Springer International Publishing 49(6): 971–982. Available at: <http://advancesindifferenceequations.springeropen.com/articles/10.1186/s13662-017-1252-9> (accessed 17/12/18).

Arbesu I, Bucsaiova M, Fischer MB and Mannhalter C (2016) Platelet-borne complement proteins and their role in platelet-bacteria interactions. *Journal of Thrombosis and Haemostasis*. Wiley/Blackwell (10.1111) 14(11): 2241–2252. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/27590476> (accessed 27/09/18).

Arman M, Krauel K, Tilley DO, Weber C, Cox D, Greinacher A, Kerrigan SW and Watson SP (2014) Amplification of bacteria-induced platelet activation is triggered by FcγRIIA, integrin αIIbβ3, and platelet factor 4. *Blood*. American Society of Hematology 123(20): 3166–74. Available at: <http://www.bloodjournal.org/content/123/20/3166.abstract> (accessed 02/10/15).

Aruni W, Vanterpool E, Osbourne D, Roy F, Muthiah A, Dou Y and Fletcher HM (2011) Sialidase and sialoglycoproteases can modulate virulence in *Porphyromonas gingivalis*. *Infection and Immunity*. American Society for Microbiology (ASM) 79(7): 2779–2791. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21502589> (accessed 06/07/18).

Aslan JE and McCarty OJT (2012) Regulation of the mTOR-Rac1 axis in platelet function. *Small GTPases*. Taylor & Francis 3(1): 67–70. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22714420> (accessed 06/03/18).

Assinger A, Laky M, Badrnya S, Esfandeyari A and Volf I (2012) Periodontopathogens induce expression of CD40L on human platelets via TLR2 and TLR4. *Thrombosis Research* 130(3): e73–e78.

Ault KA, Rinder HM, Mitchell JG, Rinder CS, Lambrew CT and Hillman RS (1989) Correlated measurement of platelet release and aggregation in whole blood. *Cytometry*. Wiley Subscription Services, Inc., A Wiley Company 10(4): 448–455. Available at: <http://doi.wiley.com/10.1002/cyto.990100413> (accessed 01/02/18).

Avila M, Ojcius DM and Yilmaz O (2009) The oral microbiota: living with a permanent guest. *DNA and cell biology* 28(8): 405–11. Available at: <http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2768665&tool=pmcentre&rendertype=abstract> (accessed 11/01/16).

Badimon L, Padró T and Vilahur G (2012) Atherosclerosis, platelets and thrombosis in acute ischaemic heart disease. *European Heart Journal: Acute Cardiovascular Care*. SAGE Publications 1(1): 60–74. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24062891> (accessed 17/12/18).

Baek KJ, Ji S, Kim YC and Choi Y (2015) Association of the invasion ability of *Porphyromonas gingivalis* with the severity of periodontitis. *Virulence*. Taylor & Francis 6(3): 274–281. Available at: <http://www.tandfonline.com/doi/full/10.1080/21505594.2014.1000764> (accessed 06/08/18).

Baggerly KA (2001) Probability binning and testing agreement between multivariate immunofluorescence histograms: Extending the chi-squared test. *Cytometry*. Wiley-Blackwell 45(2): 141–150. Available at: <http://doi.wiley.com/10.1002/1097-0320%2820011001%2945%3A2%3C141%3A%3AAID-CYTO1156%3E3.O.CO%3B2-M> (accessed 25/10/18).

Bahekar AA, Singh S, Saha S, Molnar J and Arora R (2007) The prevalence and incidence of coronary heart disease is significantly increased in periodontitis: A meta-analysis. *American Heart Journal*, 830–837. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17967586> (accessed 16/12/18).

Bakthavatchalu V, Meka a, Mans JJ, Sathishkumar S, Lopez MC, Bhattacharyya I, Boyce BF, Baker H V, Lamont RJ, Ebersole JL and Kesavalu L (2011) Polymicrobial periodontal pathogen transcriptomes in calvarial bone and soft tissue. *Molecular oral microbiology* 26(5): 303–320. Available at: <http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3170131&tool=pmcentrez&rendertype=abstract> (accessed 07/10/11).

Banbula A, Bugno M, Kuster A, Heinrich PC, Travis J and Potempa J (1999) Rapid and Efficient Inactivation of IL-6 Gingipains, Lysine- and Arginine-Specific Proteinases from *Porphyromonas Gingivalis*. *Biochemical and Biophysical Research Communications* 261(3): 598–602. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/10441472> (accessed 22/11/18).

Barczyk M, Carracedo S and Gullberg D (2010) Integrins. *Cell and tissue research*. Springer 339(1): 269–80. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19693543> (accessed 12/12/18).

Bausset O, Giraudo L, Veran J, Magalon J, Coudreuse J-M, Magalon G, Dubois C, Serratrice N, Dignat-George F and Sabatier F (2012) Formulation and storage of platelet-rich plasma homemade product. *BioResearch open access*. Mary Ann Liebert, Inc. 1(3): 115–23. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23516671> (accessed 05/10/16).

Bearer EL, Prakash JM and Li Z (2002) Actin dynamics in platelets. *International Review of Cytology*. NIH Public Access, 137–182. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/12019562> (accessed 09/09/16).

Beaulieu LM and Freedman JE (2010) The role of inflammation in regulating platelet production and function: Toll-like receptors in platelets and megakaryocytes. *Thrombosis Research*. Pergamon 125(3): 205–209. Available at: <https://www.sciencedirect-com.lcproxy.shu.ac.uk/science/article/pii/S0049384809005040#bib32> (accessed 25/05/18).

Beck JD, Offenbacher S, Williams R, Gibbs P and Garcia R (1998) Periodontitis: a risk factor for coronary heart disease? *Annals of periodontology / the American Academy of Periodontology* 3(1): 127–41. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/9722697> (accessed 04/10/16).

Belton CM, Izutsu KT, Goodwin PC, Park Y and Lamont RJ (1999) Fluorescence image analysis of the association between *Porphyromonas gingivalis* and gingival epithelial cells. *Cellular microbiology*. Blackwell Science Ltd 1(3): 215–223. Available at: <http://doi.wiley.com/10.1046/j.1462-5822.1999.00022.x> (accessed 02/09/16).

Bennett JS (2005) Structure and function of the platelet integrin  $\alpha$ IIb $\beta$ 3. *The Journal of clinical investigation*. American Society for Clinical Investigation, 3363–9. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16322781> (accessed 04/12/18).

Bennett JS, Hoxie JA, Leitman SF, Vilaire G and Cines DB (1983) Inhibition of fibrinogen binding to stimulated human platelets by a monoclonal antibody. *Proceedings of the National Academy of Sciences*. National Academy of Sciences 80(9): 2417–2421. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/6302680> (accessed 07/12/18).

Bensing BA, López JA and Sullam PM (2004) The *Streptococcus gordonii* surface proteins GspB and Hsa mediate binding to sialylated carbohydrate epitopes on the platelet membrane glycoprotein Ib $\alpha$ . *Infection and immunity*. American Society for Microbiology (ASM) 72(11): 6528–37. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15501784> (accessed 08/11/18).

Berger G, Massé JM and Cramer EM (1996) Alpha-granule membrane mirrors the platelet plasma membrane and contains the glycoproteins Ib, IX, and V. *Blood* 87(4): 1385–95. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/8608228> (accessed 08/11/18).

Bergmeier W, Burger PC, Piffath CL, Hoffmeister KM, Hartwig JH, Nieswandt B and Wagner DD (2003) Metalloproteinase inhibitors improve the recovery and hemostatic function of in vitro-aged or -injured mouse platelets. *Blood* 102(12): 4229–4235. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/12907434> (accessed 01/02/18).

Bergmeier W, Piffath CL, Cheng G, Dole VS, Zhang Y, von Andrian UH and Wagner DD (2004) Tumor Necrosis Factor- $\alpha$ -Converting Enzyme (ADAM17) Mediates GPIb Shedding From Platelets In Vitro and In Vivo. *Circulation Research* 95(7): 677–683. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15345652> (accessed 01/02/18).

Bernard J and Soulier JP (1948) Sur une nouvelle variété de dystrophie thrombocytaire hémorragique congénitale. *La semaine des hôpitaux : organe fondé par l'Association d'enseignement médical des hôpitaux de Paris* 24(Spec. No.): 3217–23. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18116504> (accessed 16/12/18).

Berndt MC, Shen Y, Doppeide SM, Gardiner EE and Andrews RK (2001) The vascular biology of the glycoprotein Ib-IX-V complex. *Thrombosis and Haemostasis*, 178–188. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11487006> (accessed 07/11/18).

Black C, Allan I, Ford SK, Wilson M and McNab R (2004) Biofilm-specific surface properties and protein expression in oral *Streptococcus sanguis*. *Archives of oral biology* 49(4): 295–304. Available at: <http://www.sciencedirect.com/science/article/pii/S0003996903003200> (accessed 22/01/16).

Blair P and Flaumenhaft R (2009) Platelet  $\alpha$ -granules: Basic biology and clinical correlates. *Blood Reviews*. NIH Public Access 23(4): 177–189. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19450911> (accessed 03/12/18).

Blair P, Rex S, Vitseva O, Beaulieu L, Tanriverdi K, Chakrabarti S, Hayashi C, Genco CA, lafrati M and Freedman JE (2009) Stimulation of Toll-Like Receptor 2 in Human Platelets Induces a Thromboinflammatory Response Through Activation of Phosphoinositide 3-Kinase. *Circulation Research*. NIH Public Access 104(3): 346–354. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19106411> (accessed 08/09/16).

Bledzka K, Pesho MM, Ma YQ and Plow EF (2013) Integrin  $\alpha$ IIb $\beta$ 3. Platelets. Academic Press, 233–248. Available at: <https://www-sciencedirect-com.hallam.idm.oclc.org/science/article/pii/B9780123878373000122#bib60> (accessed 05/12/18).

Bloch S, Zwicker S, Bostanci N, Sjöling Å, Boström EA, Belibasakis GN and Schäffer C (2018) Immune response profiling of primary monocytes and oral keratinocytes to different *Tannerella forsythia* strains and their cell surface mutants. *Molecular Oral Microbiology*. Wiley/Blackwell (10.1111) 33(2): 155–167. Available at: <http://doi.wiley.com/10.1111/omi.12208> (accessed 27/09/18).

Bodnar RJ, Gu M, Li Z, Englund GD and Du X (1999) The cytoplasmic domain of the platelet glycoprotein Ib $\alpha$  is phosphorylated at serine 609. *Journal of Biological Chemistry* 274(47): 33474–33479. Available at: <http://www.jbc.org/content/274/47/33474.short> (accessed 05/12/18).

Boisvert H, Lorand L and Duncan MJ (2014) Transglutaminase 2 is essential for adherence of *Porphyromonas gingivalis* to host cells. *Proceedings of the National Academy of Sciences of the United States of America*. National Academy of Sciences 111(14): 5355–60. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24706840> (accessed 09/10/18).

Borgnakke WS, Ylostalo P V, Taylor GW and Genco RJ (2013) Effect of periodontal disease on diabetes: systematic review of epidemiologic observational evidence. *Journal of Periodontology* 84(4 Suppl): S135-52. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23631574> (accessed 06/09/16).

Born GVR and Cross MJ (1963) The aggregation of blood platelets. *The Journal of Physiology*. Wiley-Blackwell 168(1): 178–195. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/14056485> (accessed 02/07/18).

Brown GT, Narayanan P, Li W, Silverstein RL and McIntyre TM (2013) Lipopolysaccharide Stimulates Platelets through an IL-1 Autocrine Loop. *The Journal of Immunology*. NIH Public Access 191(10): 5196–5203. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24081990> (accessed 16/09/18).

Byrne MF, Kerrigan SW, Corcoran PA, Atherton JC, Murray FE, Fitzgerald DJ and Cox DM (2003) *Helicobacter pylori* binds von Willebrand factor and interacts with GPIb to induce platelet aggregation. *Gastroenterology* 124(7): 1846–54. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/12806618> (accessed 17/09/18).

Calkins CC, Platt K, Potempa J and Travis J (1998) Inactivation of tumor necrosis factor- $\alpha$  by proteinases (gingipains) from the periodontal pathogen, *Porphyromonas gingivalis*. Implications of immune evasion. *The Journal of biological chemistry* 273(12): 6611–4. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/9506956> (accessed 22/11/18).

Carinci F, Martinelli M, Contaldo M, Santoro R, Pezzetti F, Lauritano D, Candotto V, Mucchi D, Palmieri A, Tagliabue A and Tettamanti L (2018) Focus on periodontal disease and development of endocarditis. *Journal of biological regulators and homeostatic agents* 32(2 Suppl. 1): 143–147. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/29460534> (accessed 17/12/18).

Caroff M and Karibian D (2003) Structure of bacterial lipopolysaccharides. *Carbohydrate Research*. Elsevier 338(23): 2431–2447. Available at: <https://www.sciencedirect.com/science/article/pii/S000862150300466X?via%3Dihub> (accessed 21/11/18).

Cazenave J-P, Ohlmann P, Cassel D, Eckly A, Hechler B and Gachet C (2004) Preparation of Washed Platelet Suspensions From Human and Rodent Blood. *Platelets and Megakaryocytes*. New Jersey: Humana Press, 013–028. Available at: <http://link.springer.com/10.1385/1-59259-782-3:013> (accessed 20/09/18).

Cerletti C, Evangelista V and de Gaetano G (1999) P-selectin-beta 2-integrin cross-talk: a molecular mechanism for polymorphonuclear leukocyte recruitment at the site of vascular damage. *Thrombosis and haemostasis* 82(2): 787–93. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/10605783> (accessed 05/12/18).

Cerletti C, de Gaetano G and Lorenzet R (2010) Platelet - leukocyte interactions: multiple links between inflammation, blood coagulation and vascular risk. *Mediterranean journal of hematology and infectious diseases*. Catholic University in Rome 2(3): e2010023. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21415976> (accessed 05/12/18).

Cha JK, Jeong MH, Bae HR, Han JY, Jeong SJ, Jin HJ, Lim YJ, Kim SH and Kim JW (2000) Activated platelets induce secretion of interleukin-1 $\beta$ , monocyte chemoattractant protein-1, and macrophage inflammatory protein-1 $\alpha$  and surface expression of intercellular adhesion molecule-1 on cultured endothelial cells. *Journal of Korean Medical Science* 15(3): 273. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/10895967> (accessed 16/09/18).

Chamorro S, Garcia-Vallejo JJ, Unger WWJ, Fernandes RJ, Bruijns SCM, Laban S, Roep BO, 't Hart BA and van Kooyk Y (2009) TLR Triggering on Tolerogenic Dendritic Cells Results in TLR2 Up-Regulation and a Reduced Proinflammatory Immune Program. *The Journal of Immunology* 183(5): 2984–2994. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19648269> (accessed 17/10/18).

Chattopadhyay PK and Roederer M (2012) Cytometry: Today's technology and tomorrow's horizons. *Methods*. Academic Press 57(3): 251–258. Available at: <https://www.sciencedirect.com/science/article/pii/S1046202312000333#b0165> (accessed 26/10/18).

Chaudhry R and Babiker HM (2018) Physiology, Coagulation Pathways. StatPearls. StatPearls Publishing. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/29489185> (accessed 30/11/18).

Chávarry NGM, Vettore MV, Sansone C and Sheiham A (2009) The relationship between diabetes mellitus and destructive periodontal disease: a meta-analysis. *Oral health & preventive dentistry* 7(2): 107–27. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19583037> (accessed 06/09/16).

Clawson CC (1973) Platelet interaction with bacteria. 3. Ultrastructure. *The American journal of pathology*. American Society for Investigative Pathology 70(3): 449–71. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/4632008> (accessed 02/07/18).

Clawson CC, Rao GH and White JG (1975) Platelet interaction with bacteria. IV. Stimulation of the release reaction. *The American journal of pathology*. American Society for Investigative Pathology 81(2): 411–20. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/811123> (accessed 02/07/18).

Clawson CC and White JG (1971a) Platelet interaction with bacteria. I. Reaction phases and effects of inhibitors. *The American journal of pathology*. American Society for Investigative Pathology 65(2): 367–380. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/4400052> (accessed 02/07/18).

Clawson CC and White JG (1971b) Platelet interaction with bacteria. II. Fate of the bacteria. *The American journal of pathology* 65(2): 381–97. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/5002629> (accessed 02/07/18).

Clemetson KJ and Clemetson JM (1994) Molecular abnormalities in Glanzmann's thrombasthenia, Bernard-Soulier syndrome, and platelet-type von Willebrand's disease. *Current opinion in hematology* 1(5): 388–93. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/9371310> (accessed 07/12/18).

Clemetson KJ and Clemetson JM (2007) Platelet receptors. *Platelets*. Academic Press, 117–143. Available at: <https://www-sciencedirect-com.hallam.idm.oclc.org/science/article/pii/B9780123878373000092> (accessed 05/12/18).

Clemetson KJ, McGregor JL, James E, Dechavanne M and Lüscher EF (1982) Characterization of the platelet membrane glycoprotein abnormalities in Bernard-Soulier syndrome and comparison with normal by surface-labeling techniques and high-resolution two-dimensional gel electrophoresis. *Journal of Clinical Investigation* 70(2): 304–311. Available at: <https://www.jci.org/articles/view/110618> (accessed 07/12/18).

Clemetson KJ and Polgár J (1997) Platelet Adhesion and Aggregation Receptors. *Platelets and Their Factors*. Springer, Berlin, Heidelberg, 155–179. Available at: [http://link.springer.com/10.1007/978-3-642-60639-7\\_8](http://link.springer.com/10.1007/978-3-642-60639-7_8) (accessed 01/12/18).

Colombo A V., da Silva CM, Haffajee A and Colombo AP V. (2007) Identification of intracellular oral species within human crevicular epithelial cells from subjects with chronic periodontitis by fluorescence in situ hybridization. *Journal of Periodontal Research*. Blackwell Publishing Ltd 42(3): 236–243. Available at: <http://doi.wiley.com/10.1111/j.1600-0765.2006.00938.x> (accessed 02/09/16).

Connolly E, Millhouse E, Doyle R, Culshaw S, Ramage G and Moran GP (2017) The *Porphyromonas gingivalis* hemagglutinins HagB and HagC are major mediators of adhesion and biofilm formation. *Molecular Oral Microbiology* 32(1): 35–47. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/28051836> (accessed 27/11/18).

Conran N and Hemming FW (1998) The effect of PMA-induced differentiation on the surface expression of integrins on CHRF 288-11 megakaryoblastic cells in culture. *Platelets* 9(2): 103–8. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16793684> (accessed 13/05/16).

Corcoran PA, Atherton JC, Kerrigan SW, Wadstrom T, Murray FE, Peek RM, Fitzgerald DJ, Cox DM and Byrne MF (2007) The effect of different strains of *Helicobacter pylori* on platelet aggregation. *Canadian journal of gastroenterology = Journal canadien de gastroenterologie*. Hindawi Limited 21(6): 367–370. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17571170> (accessed 02/07/18).

Corken A, Russell S, Dent J, Post SR and Ware J (2014) Platelet glycoprotein Ib-IX as a regulator of systemic inflammation. *Arteriosclerosis, thrombosis, and vascular biology*. NIH Public Access 34(5): 996–1001. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24504734> (accessed 07/11/18).

Costello EK, Stagaman K, Dethlefsen L, Bohannan BJM and Relman DA (2012) The Application of Ecological Theory Toward an Understanding of the Human Microbiome. *Science*. NIH Public Access 336(6086): 1255–1262. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22674335> (accessed 02/10/16).

Costerton JW, Geesey GG and Cheng KJ (1978) How bacteria stick. *Scientific American* 238(1): 86–95.

Coughlin SR (2000) Thrombin signalling and protease-activated receptors. *Nature*, 258–264. Available at: <http://www.nature.com/articles/35025229> (accessed 30/11/18).

Cox D, Kerrigan SW and Watson SP (2011) Platelets and the innate immune system: Mechanisms of bacterial-induced platelet activation. *Journal of Thrombosis and Haemostasis* 9(6): 1097–1107.

Cramer EM, Savidge GF, Vainchenker W, Berndt MC, Pizard D, Caen JP, Massé JM and Breton-Gorius J (1990) Alpha-granule pool of glycoprotein IIb-IIIa in normal and pathologic platelets and megakaryocytes. *Blood* 75(6): 1220–7. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/2310822> (accessed 01/12/18).

Curtis MA, Kuramitsu HK, Lantz M, Macrina FL, Nakayama K, Potempa J, Reynolds EC and Aduse-Opoku J (1999) Molecular genetics and nomenclature of proteases of *Porphyromonas gingivalis*. *Journal of periodontal research* 34(8): 464–72. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/10697803> (accessed 22/11/18).

Curtis MA, Macey M, Slaney JM and Howells GL (1993a) Platelet activation by protease I of *Porphyromonas gingivalis* W83. *FEMS Microbiology Letters*. Oxford University Press 110(2): 167–173. Available at: <https://academic.oup.com/femsle/article-lookup/doi/10.1111/j.1574-6968.1993.tb06315.x> (accessed 13/09/18).

Curtis MA, Macey M, Slaney JM and Howells GL (1993b) Platelet activation by protease I of *Porphyromonas gingivalis* W83. *FEMS Microbiology Letters*. Oxford University Press 110(2): 167–173. Available at: <https://academic.oup.com/femsle/article-lookup/doi/10.1111/j.1574-6968.1993.tb06315.x> (accessed 25/05/18).

Damien P, Cognasse F, Eyraud M-A, Arthaud C-A, Pozzetto B, Garraud O and Hamzeh-Cognasse H (2015) LPS stimulation of purified human platelets is partly dependent on plasma soluble CD14 to secrete their main secreted product, soluble-CD40-Ligand. *BMC immunology*. *BioMed Central* 16(1): 3. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25636826> (accessed 31/01/19).

Darveau RP (2010) Periodontitis: a polymicrobial disruption of host homeostasis. *Nature reviews. Microbiology*. Nature Publishing Group 8(7): 481–90. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20514045> (accessed 22/10/12).

Darveau RP, Belton CM, Reife RA and Lamont RJ (1998) Local Chemokine Paralysis, a Novel Pathogenic Mechanism for *Porphyromonas gingivalis*. *Infection and Immunity*. American Society for Microbiology (ASM) 66(4): 1660–1665. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/9529095> (accessed 02/09/16).

Darveau RP, Cunningham MD, Bailey T, Seachord C, Ratcliffe K, Bainbridge B, Dietsch M, Page RC and Aruffo A (1995) Ability of bacteria associated with chronic inflammatory disease to stimulate E-selectin expression and promote neutrophil adhesion. *Infection and immunity*. American Society for Microbiology (ASM) 63(4): 1311–7. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/7534275> (accessed 21/11/18).

Darveau RP, Pham T-TTT, Lemley K, Reife RA, Bainbridge BW, Coats SR, Howald WN, Way SS and Hajjar AM (2004) *Porphyromonas gingivalis* lipopolysaccharide contains multiple lipid A species that functionally interact with both toll-like receptors 2 and 4. *Infection and Immunity*. American Society for Microbiology Journals 72(9): 5041–5051. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15321997> (accessed 16/09/18).

Dauphinee SM and Karsan A (2006) Lipopolysaccharide signaling in endothelial cells. *Laboratory Investigation*. Nature Publishing Group, 9–22. Available at: <http://www.nature.com/doi/10.1038/labinvest.3700366> (accessed 14/12/18).

Davie EW, Fujikawa K and Kisiel W (1991) The coagulation cascade: initiation, maintenance, and regulation. *Biochemistry* 30(43): 10363–70. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/1931959> (accessed 30/11/18).

Dean WL (1984) Purification and reconstitution of a Ca<sup>2+</sup> pump from human platelets. *The Journal of biological chemistry* 259(11): 7343–8. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/6233283> (accessed 03/12/18).

Demmer RT, Jacobs DR and Desvarieux M (2008) Periodontal disease and incident type 2 diabetes: results from the First National Health and Nutrition Examination Survey

and its epidemiologic follow-up study. *Diabetes care*. American Diabetes Association 31(7): 1373–9. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18390797> (accessed 07/09/16).

Denzin LK (1996) HLA-DM Interactions with Intermediates in HLA-DR Maturation and a Role for HLA-DM in Stabilizing Empty HLA-DR Molecules. *Journal of Experimental Medicine*. Rockefeller University Press 184(6): 2153–2166. Available at: <http://jem.rupress.org/content/184/6/2153> (accessed 07/12/18).

Denzin LK and Cresswell P (1995) HLA-DM induces clip dissociation from MHC class II  $\alpha\beta$  dimers and facilitates peptide loading. *Cell*. Cell Press 82(1): 155–165. Available at: <https://www.sciencedirect.com/science/article/pii/0092867495900616> (accessed 07/12/18).

Deshpande RG, Khan MB and Genco CA (1998) Invasion of aortic and heart endothelial cells by *Porphyromonas gingivalis*. *Infection and immunity*. American Society for Microbiology 66(11): 5337–43. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/9784541> (accessed 02/09/16).

Deutsch V, Bitan M, Friedmann Y, Eldor A and Vlodavsky I (2008) Megakaryocyte maturation is associated with expression of the CXC chemokine connective tissue-activating peptide CTAP III. *British Journal of Haematology*. Blackwell Science Ltd 111(4): 1180–1189. Available at: <http://doi.wiley.com/10.1111/j.1365-2141.2000.02476.x> (accessed 05/10/16).

Deutsch VR and Tomer A (2006) Megakaryocyte development and platelet production. *British journal of haematology* 134(5): 453–66. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16856888> (accessed 13/05/16).

Díaz L, Hoare A, Soto C, Bugueño I, Silva N, Dutzan N, Venegas D, Salinas D, Pérez-Donoso JM, Gamonal J and Bravo D (2015) Changes in lipopolysaccharide profile of *Porphyromonas gingivalis* clinical isolates correlate with changes in colony morphology and polymyxin B resistance. *Anaerobe* 33: 25–32. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25638398> (accessed 22/11/18).

Donlan RM (2002) Biofilms: Microbial life on surfaces. *Emerging Infectious Diseases*. Centers for Disease Control and Prevention, 881–890. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/12194761> (accessed 06/10/16).

Dorn BR, Burks JN, Seifert KN and Progulske-Fox A (2000) Invasion of endothelial and epithelial cells by strains of *Porphyromonas gingivalis*. *FEMS Microbiology Letters* 187(2): 139–144.

Duperray A, Berthier R, Chagnon E, Ryckewaert JJ, Ginsberg M, Plow E and Marguerie G (1987) Biosynthesis and processing of platelet GPIIb-IIIa in human megakaryocytes. *The Journal of cell biology* 104(6): 1665–73. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/3108266> (accessed 15/11/18).

Eberhard J, Grote K, Luchtefeld M, Heuer W, Schuett H, Divchev D, Scherer R, Schmitz-Streit R, Langfeldt D, Stumpp N, Staufenbiel I, Schieffer B, Stiesch M, Kebschull M, Demmer R, Papapanou P, Pihlstrom B, Michalowicz B, Johnson N, Lockhart P, Bolger A, Papapanou P, Osinbowale O, Trevisan M, Elter J, Hinderliter A, Offenbacher S, Beck J, Caughey M, Tonetti M, D'Aiuto F, Nibali L, Donald A, Storry C, Demmer R, Papapanou P, Ericsson J, Abrahamsson K, Ostberg A, Hellstrom M, Jonsson K, Li Y, Lee S, Hujoel P, Su M, Zhang W, Hansson G, Libby P, Ridker P, Hansson G, Uno K, Nicholls S, Drakopoulou M, Toutouzas K, Stefanadi E, Tsiamis E, Tousoulis D, Wahaidi V, Kowolik M, Eckert G, Galli D, Koren O, Spor A, Felin J, Fak F, Stombaugh J, Loe H, Theilade E, Jensen S, Slawik S, Staufenbiel I, Schilke R, Nicksch S, Weinspach K, Silness J, Loe H, Loe H, Silness J, Haffajee A, Socransky S, Patel M, Song X, Socransky S, Haffajee A, Cugini M, Smith C, Jr RK, Honda T, Domon H, Okui T, Kajita K, Amanuma R, Wohlfeil M, Wehner J, Schacher B, Oremek G, Sauer-Eppel H, Andriankaja O, Barros S, Moss K, Panagakos F, DeVizio W, Zee K, Samaranayake L, Attstrom R, Haffajee A, Teles R, Patel M, Song X, Veiga N, Jr EG-J, Marcelino S, Feitosa A, Romito G, Avila-Campos M, Ridker P, Rifai N, Stampfer M, Hennekens C, Ridker P, Hennekens C, Buring J, Rifai N, Ylostalo P, Jarvelin M, Laitinen J, Knuuttila M, Eberhard J, Reimers N, Dommisch H, Hacker J, Freitag S, Eberhard J, Jepsen S, Albers H, Acil Y, Saglie F, Pertuiset J, Rezende M, Sabet M, Raoufi D, Forner L, Larsen T, Kilian M, Holmstrup P, Elkaim R, Dahan M, Kocgozlu L, Werner S, Kanter D, Chiu B, Libby P, Egan D, Skarlatos S, Lu Q, Jin L, Groot L de, Posthumus M, Kallenberg C, Bijl M, Boucelma M, Haddoum F, Chaudet H, Kaplanski G, Mazouni-Brahimi N, Baumgartner J, Watkins B, Bae K, Xia T, Conrads G, Gharbia S, Gulabivala K, Lampert F, Shah H, Hoshino T, Kawaguchi M, Shimizu N, Hoshino N, Ooshima T, Conrads G, Mutters R, Fischer J, Brauner A, Lütticken R, Ashimoto A, Chen C, Bakker I, Slots J, Igarashi E, Kamaguchi A, Fujita M, Miyakawa H, Nakazawa F, Kim S, Kim S, Kim M, Kim H and Kook J (2013) Experimental Gingivitis Induces Systemic Inflammatory Markers in Young Healthy Individuals: A Single-Subject Interventional Study. PLoS ONE. Public Library of Science 8(2): e55265. Available at: <http://dx.plos.org/10.1371/journal.pone.0055265> (accessed 07/09/16).

Edgington TS, Mackman N, Brand K and Ruf W (1991) The structural biology of expression and function of tissue factor. *Thrombosis and Haemostasis*, 67–79. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/1833852> (accessed 30/11/18).

Eichinger A, Beisel HG, Jacob U, Huber R, Medrano FJ, Banbula A, Potempa J, Travis J and Bode W (1999) Crystal structure of gingipain R: an Arg-specific bacterial cysteine proteinase with a caspase-like fold. *The EMBO Journal* 18(20): 5453–5462. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/10523290> (accessed 22/11/18).

Enersen M, Nakano K and Amano A (2013) *Porphyromonas gingivalis* fimbriae. *Journal of Oral Microbiology*. Taylor & Francis 5(2013): 20265. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23667717> (accessed 27/11/18).

Engleman VW, Nickols GA, Ross FP, Horton MA, Griggs DW, Settle SL, Ruminski PG and Teitelbaum SL (1997) A peptidomimetic antagonist of the  $\alpha\beta 3$  integrin inhibits bone resorption in vitro and prevents osteoporosis in vivo. *Journal of Clinical Investigation*. American Society for Clinical Investigation 99(9): 2284–2292. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/9151803> (accessed 01/02/18).

Erickson PR and Herzberg MC (1993) The Streptococcus sanguis platelet aggregation-associated protein. Identification and characterization of the minimal platelet-interactive domain. *The Journal of biological chemistry* 268(3): 1646–9. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/8420939> (accessed 16/09/18).

Escolar G, Leistikow E and White JG (1989) The fate of the open canalicular system in surface and suspension-activated platelets. *Blood* 74(6): 1983–8. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/2804343> (accessed 01/12/18).

Escolar G, Lopez-Vilchez I, Diaz-Ricart M, White JG and Galan AM (2008) Internalization of tissue factor by platelets. *Thrombosis Research*, S37–S41. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18691498> (accessed 01/12/18).

Ferreira GB, Overbergh L, Verstuyf A and Mathieu C (2013) 1 $\alpha$ ,25-Dihydroxyvitamin D<sub>3</sub> and its analogs as modulators of human dendritic cells: A comparison dose-titration study. *Journal of Steroid Biochemistry and Molecular Biology*. Pergamon, 160–165. Available at: <https://www.sciencedirect.com/science/article/pii/> (accessed 07/12/18).

Finn A V., Nakano M, Narula J, Kolodgie FD and Virmani R (2010) Concept of vulnerable/unstable plaque. *Arteriosclerosis, Thrombosis, and Vascular Biology*, 1282–1292. Available at: <https://www.ahajournals.org/doi/10.1161/ATVBAHA.108.179739> (accessed 17/12/18).

Fitzgerald JR, Foster TJ and Cox D (2006) The interaction of bacterial pathogens with platelets. *Nature reviews. Microbiology*. Nature Publishing Group 4(6): 445–57. Available at: <http://www.nature.com.lcproxy.shu.ac.uk/nrmicro/journal/v4/n6/full/nrmicro1425.html> (accessed 06/01/16).

Flaumenhaft R (2013) Platelet Secretion. *Platelets*. Academic Press 343–366. Available at: <https://www.sciencedirect.com/science/article/pii/B9780123878373000183> (accessed 03/12/18).

Fletcher J, Nair S, Poole S, Henderson B and Wilson M (1998) Cytokine degradation by biofilms of *Porphyromonas gingivalis*. *Current Microbiology*. Springer-Verlag 36(4): 216–219. Available at: <http://link.springer.com/10.1007/s002849900297> (accessed 16/09/18).

Fogelson AL and Wang NT (1996) Platelet dense-granule centralization and the persistence of ADP secretion. *American Journal of Physiology-Heart and Circulatory Physiology* 270(3): H1131–H1140. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/8780211> (accessed 01/12/18).

Fornig RY, Champagne C, Simpson W and Genco CA (2000) Environmental cues and gene expression in *Porphyromonas gingivalis* and *Actinobacillus actinomycetemcomitans*. *Oral Dis*. John Wiley & Sons, Ltd 6(6): 351–65. Available at: <http://doi.wiley.com/10.1111/j.1601-0825.2000.tb00127.x> (accessed 21/11/18).

Fox JEB, Aggerbeck LP and Berndt MC (1988) Structure of the glycoprotein Ib-IX complex from platelet membranes. *Journal of Biological Chemistry* 263(10): 4882–4890. Available at: <http://www.jbc.org/content/263/10/4882.short> (accessed 07/12/18).

Friedewald VE, Kornman KS, Beck JD, Genco R, Goldfine A, Libby P, Offenbacher S, Ridker PM, Van Dyke TE and Roberts WC (2009) The American Journal of Cardiology and Journal of Periodontology Editors' Consensus: Periodontitis and Atherosclerotic Cardiovascular Disease. *American Journal of Cardiology* 104(1): 59–68. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19576322> (accessed 16/12/18).

Friedman G, Gurevich P, McCarthy S and Rachinskii D (2015) Switching behaviour of two-phenotype bacteria in varying environment. *Journal of Physics: Conference Series*. IOP Publishing 585(1): 012012. Available at: <http://stacks.iop.org/1742-6596/585/i=1/a=012012?key=crossref.89e467b808908f64a61d827377cf67df> (accessed 24/08/18).

Fugman DA, Witte DP, Jones CL, Aronow BJ and Lieberman MA (1990) In vitro establishment and characterization of a human megakaryoblastic cell line. *Blood*. American Society of Hematology 75(6): 1252–61. Available at: <http://www.bloodjournal.org/content/75/6/1252.abstract> (accessed 13/05/16).

Gaetti-Jardim E, Marcelino SL, Feitosa ACR, Romito GA and Avila-Campos MJ (2009) Quantitative detection of periodontopathic bacteria in atherosclerotic plaques from coronary arteries. *Journal of Medical Microbiology*. Microbiology Society 58(12): 1568–1575. Available at: <http://jmm.microbiologyresearch.org/content/journal/jmm/10.1099/jmm.0.013383-0> (accessed 08/09/16).

Gailani D and Renné T (2007) Intrinsic pathway of coagulation and arterial thrombosis. *Arteriosclerosis, Thrombosis, and Vascular Biology*, 2507–2513. Available at: <https://www.ahajournals.org/doi/10.1161/ATVBAHA.107.155952> (accessed 16/12/18).

Ganji K, Pendor S, Perumal R, Rajendran M and Krishnamurthy M (2014) Modulation of P-selection and platelet aggregation in chronic periodontitis: A clinical study. *Journal of Indian Society of Periodontology*. Medknow Publications and Media Pvt. Ltd. 18(3): 293. Available at: <http://www.jisponline.com/text.asp?2014/18/3/293/134563> (accessed 09/09/16).

Gardiner EE and Andrews RK (2013) Platelets: Envoys at the infection frontline. *Journal of Infectious Diseases*. Oxford University Press, 871–873. Available at: <http://jid.oxfordjournals.org/lookup/doi/10.1093/infdis/jit305> (accessed 09/09/16).

Gardiner EE, Karunakaran D, Shen Y, Arthur JF, Andrews RK and Berndt MC (2007) Controlled shedding of platelet glycoprotein (GP)VI and GPIb-IX-V by ADAM family metalloproteinases. *Journal of Thrombosis and Haemostasis*. Blackwell Publishing Ltd 5(7): 1530–1537. Available at: <http://doi.wiley.com/10.1111/j.1538-7836.2007.02590.x> (accessed 01/02/18).

Garred S, Eick AM, Blom Bielecka M, Ksiazek K, Riesbeck PM, Jusko J, Potempa D, Mizgalska E, Jusko M, Potempa J, Mizgalska D, Bielecka E, Ksiazek M, Riesbeck K, Garred P, Eick S and Blom AM (2016) Complement System Inhibits All Pathways of the forsythia Tannerella A Metalloproteinase Mirolysin of A Metalloproteinase Mirolysin of Tannerella forsythia Inhibits All Pathways of the Complement System. *J Immunol* Available at: <http://www.jimmunol.org/content/195/5/2231> (accessed 05/09/16).

George JN (2000) Platelets. *The Lancet* 355(April): 1531–1539. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/10801186> (accessed 09/09/16).

Geraghty RJ, Capes-Davis A, Davis JM, Downward J, Freshney RI, Knezevic I, Lovell-Badge R, Masters JRW, Meredith J, Stacey GN, Thraves P and Vias M (2014) Guidelines for the use of cell lines in biomedical research. *British Journal of Cancer*. Nature Publishing Group 111(6): 1021–1046. Available at: <http://www.nature.com/articles/bjc2014166> (accessed 15/11/18).

Gerrard J, White J and Peterson D (1978) The Platelet Dense Tubular System: its Relationship to Prostaglandin Synthesis and Calcium Flux. *Thrombosis and Haemostasis*. Schattauer GmbH 39(01): 224–231. Available at: <http://www.thieme-connect.de/DOI/DOI?10.1055/s-0038-1648656> (accessed 13/09/18).

Giacona MB, Papapanou PN, Lamster IB, Rong LL, D'Agati VD, Schmidt AM, Lalla E, Beck JD, Offenbacher S, Desvarieux M, Demmer RT, Rundek T, Boden-Albala B, Jacobs DR, Papapanou PN, Sacco RL, Lulis AJ, Grayston JT, Kuo CC, Campbell LA, Wang SP, Jackson LA, Elkind MS, Lin IF, Grayston JT, Sacco RL, Haraszthy VI, Zambon JJ, Trevisan M, Zeid M, Genco RJ, Sandros J, Papapanou P, Dahlen G, Lamont RJ, Chan A, Belton CM, Izutsu KT, Vassel D, Weinberg A, Deshpande RG, Khan MB, Genco CA, Lalla E, Lamster IB, Hofmann MA, Bucciarelli L, Jerud AP, Tucker S, Lu Y, Papapanou PN, Schmidt AM, Malek R, Fisher JG, Caleca A, Stinson M, Oss CJ van, Lee JY, Cho MI, Genco RJ, Evans RT, Dyer DW, Redgrave TG, Roberts DC, West CE, Schaffner T, Taylor K, Bartucci EJ, Fischer-Dzoga K, Beeson JH, Glagov S, Wissler RW, Dorn BR, Dunn WA, Progulsk-Fox A, Jotwani R, Cutler CW, Weinberg A, Belton CM, Park Y, Lamont RJ, Hanazawa S, Murakami Y, Hirose K, Amano S, Ohmori Y, Higuchi H, Kitano S, Takeshita A, Murakami Y, Yamashita Y, Ishida M, Fujisawa S, Kitano S, Hanazawa S, Hajishengallis G, Martin M, Sojar HT, Sharma A, Schifferle RE, DeNardin E, Russell MW, Genco RJ, Hiramane H, Watanabe K, Hamada N, Umemoto T, Baqui AA, Meiller TF, Chon JJ, Turng BF, Falkler WA, Kalayoglu MV, Byrne GI, Qi M, Miyakawa H, Kuramitsu HK, Chen T, Nakayama K, Belliveau L, Duncan MJ, Kontani M, Kimura S, Nakagawa I, Hamada S, Madianos PN, Papapanou PN, Nannmark U, Dahlén G, Sandros J, Dorn BR, Dunn WA, Progulsk-Fox A, Kuramitsu HK, Qi M, Kang IC and Chen W (2004) *Porphyromonas gingivalis* induces its uptake by human macrophages and promotes foam cell formation in vitro. *FEMS microbiology letters*. The Oxford University Press 241(1): 95–101. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15556715> (accessed 08/09/16).

Gibbons RJ and Nygaard M (1970) Interbacterial aggregation of plaque bacteria. *Archives of oral biology* 15(12): 1397–400. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/5280139> (accessed 22/01/16).

Godoy VG, Dallas MM, Russo TA and Malamy MH (1993) A role for *Bacteroides fragilis* neuraminidase in bacterial growth in two model systems. *Infection and Immunity* 61(10): 4415–4426.

Greenberg S, Rosenthal D, Greeley T, Tantravahi R and Handin R (1988) Characterization of a new megakaryocytic cell line: the Dami cell. *Blood* 72(6). Available at: <http://www.bloodjournal.org/content/72/6/1968.long?sso-checked=true> (accessed 15/11/18).

Grenier D and Mayrand D (1987) Functional characterization of extracellular vesicles produced by *Bacteroides gingivalis*. *Infection and immunity* 55(1): 111–7. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/3539799> (accessed 21/11/18).

Griffen AL, Lyons SR, Becker MR, Moeschberger ML and Leys EJ (1999) *Porphyromonas gingivalis* strain variability and periodontitis. *Journal of clinical microbiology*. American Society for Microbiology (ASM) 37(12): 4028–33. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/10565925> (accessed 03/10/18).

Griffin DO and Rothstein TL (2012) Human B1 cell frequency: Isolation and analysis of human B1 cells. *Frontiers in Immunology*. Frontiers, 122. Available at: <http://journal.frontiersin.org/article/10.3389/fimmu.2012.00122/abstract> (accessed 07/12/18).

Gu M, Xi X, Englund GD, Berndt MC and Du X (1999) Analysis of the Roles of 14-3-3 in the Platelet Glycoprotein Ib-IX-mediated Activation of Integrin  $\alpha$ . *Cell* 147(5): 1085–1096. Available at: <http://jcb.rupress.org/content/147/5/1085.abstract> (accessed 05/12/18).

Hadjkacem B, Gargouri J and Gargouri A (2011) Bernard Soulier Syndrome: A Genetic Bleeding Disorder. *Advances in the Study of Genetic Disorders*. InTech. Available at: <http://www.intechopen.com/books/advances-in-the-study-of-genetic-disorders/bernard-soulier-syndrome-a-genetic-bleeding-disorder> (accessed 12/12/18).

Haffajee AD, Cugini MA, Tanner A, Pollack RP, Smith C, Kent RL and Socransky SS (1998) Subgingival microbiota in healthy, well-maintained elder and periodontitis subjects. *Journal of Clinical Periodontology* 25(5): 346–353. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/9650869> (accessed 21/11/18).

Hajishengallis G (2011) Immune evasion strategies of *Porphyromonas gingivalis*. *Journal of oral biosciences*. NIH Public Access 53(3): 233–240. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22162663> (accessed 27/08/18).

Hajishengallis G, Darveau RP and Curtis MA (2012) The keystone-pathogen hypothesis. *Nature Reviews Microbiology*. NIH Public Access, 717–725. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22941505> (accessed 21/11/18).

Hajishengallis G, Wang M, Harokopakis E, Triantafilou M and Triantafilou K (2006) *Porphyromonas gingivalis* fimbriae proactively modulate beta2 integrin adhesive activity and promote binding to and internalization by macrophages. *Infection and immunity* 74(10): 5658–66. Available at: <http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1594907&tool=pmcentrez&rendertype=abstract> (accessed 07/11/12).

Hall-Stoodley L, Costerton J and Stoodley P (2004) Bacterial biofilms: from the natural environment to infectious diseases. *Nature Reviews Microbiology*. Nature Publishing Group 2(February): 95–108. Available at: <http://www.nature.com/doi/10.1038/nrmicro821> (accessed 02/10/16).

Hamada N, Watanabe K, Sasakawa C, Yoshikawa M, Yoshimura F and Umemoto T (1994) Construction and characterization of a fimA mutant of Porphyromonas gingivalis. Infection and immunity 62(5): 1696–704. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/7909537> (accessed 27/11/18).

Hamzeh-Cognasse H, Damien P, Chabert A, Pozzetto B, Cognasse F and Garraud O (2015) Platelets and infections - complex interactions with bacteria. Frontiers in Immunology. Frontiers Media SA 6(FEB): 82. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25767472> (accessed 25/11/15).

Han N, Whitlock J and Progulske-Fox A (1996) The hemagglutinin gene A (hagA) of Porphyromonas gingivalis 381 contains four large, contiguous, direct repeats. Infection and immunity 64(10): 4000–7. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/8926061> (accessed 27/11/18).

Harrison P, Wilbourn B, Debili N, Vainchenker W, Breton-Gorius J, Lawrie AS, Masse JM, Savidge GF and Cramer EM (1989) Uptake of plasma fibrinogen into the alpha granules of human megakaryocytes and platelets. Journal of Clinical Investigation 84(4): 1320–1324. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/2677051> (accessed 01/12/18).

Hawiger J, Steckley S, Hammond D, Cheng C, Timmons S, Glick AD and Des Prez RM (1979) Staphylococci-induced Human Platelet Injury Mediated by Protein A and Immunoglobulin G Fc Fragment Receptor. Journal of Clinical Investigation 64(4): 931–937. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/479376> (accessed 22/08/18).

Hay N and Sonenberg N (2004) Upstream and downstream of mTOR. Genes and Development, 1926–1945. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15314020> (accessed 16/11/18).

Heemskerk JW, Hoyland J, Mason WT and Sage SO (1992) Spiking in cytosolic calcium concentration in single fibrinogen-bound fura-2-loaded human platelets. The Biochemical journal. Portland Press Limited 283 ( Pt 2)(2): 379–83. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/1575681> (accessed 13/09/18).

Heemskerk JWM, Willems GM, Rook MB and Sage SO (2001) Ragged spiking of free calcium in ADP-stimulated human platelets: Regulation of puff-like calcium signals in vitro and ex vivo. Journal of Physiology. Wiley/Blackwell (10.1111) 535(3): 625–635. Available at: <http://doi.wiley.com/10.1111/j.1469-7793.2001.00625.x> (accessed 13/09/18).

Heijnen H and van der Sluijs P (2015) Platelet secretory behaviour: As diverse as the granules... or not? Journal of Thrombosis and Haemostasis. Wiley/Blackwell (10.1111), 2141–2151. Available at: <http://doi.wiley.com/10.1111/jth.13147> (accessed 03/12/18).

Heijnen HFG and Korporaal SJA (2017) Platelet Morphology and Ultrastructure. Platelets in Thrombotic and Non-Thrombotic Disorders. Cham: Springer International Publishing, 21–37. Available at: [http://link.springer.com/10.1007/978-3-319-47462-5\\_3](http://link.springer.com/10.1007/978-3-319-47462-5_3) (accessed 01/12/18).

Herzenberg LALA, Tung J, Moore WA, Herzenberg LALA and Parks DR (2006) Interpreting flow cytometry data: A guide for the perplexed. *Nature Immunology*, 681–685. Available at: <http://www.nature.com/articles/ni0706-681> (accessed 25/10/18).

Ho YS, Lai MT, Liu SJ, Lin CT, Naruishi K, Takashiba S and Chou HH (2009) *Porphyromonas gingivalis* fimbriae-dependent interleukin-6 autocrine regulation by increase of gp130 in endothelial cells. *Journal of Periodontal Research*. Blackwell Publishing Ltd 44(4): 550–556. Available at: <http://doi.wiley.com/10.1111/j.1600-0765.2008.01150.x> (accessed 08/09/16).

Holinstat M (2017) Normal platelet function. *Cancer and Metastasis Reviews*. NIH Public Access, 195–198. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/28667366> (accessed 29/11/18).

Holt C (1999) Virulence factors of *Porphyromonas gingivalis*. *Periodontology 2000* 20: 168–238.

Holt SC and Ebersole JL (2005) *Porphyromonas gingivalis*, *Treponema denticola*, and *Tannerella forsythia*: the ‘red complex’, a prototype polybacterial pathogenic consortium in periodontitis. *Periodontology 2000* 38(0906–6713 (Print) LA–eng PT–Journal Article PT–Research Support, N.I.H., Extramural PT–Research Support, U.S. Gov’t, P.H.S PT–Review RN–0 (Virulence Factors) SB–D): 72–122. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15853938>.

Holt SC, Kesavalu L, Walker S and Genco CA (1999) Virulence factors of *Porphyromonas gingivalis*. *Periodontology 2000* 20(1): 168–238. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/10522227> (accessed 16/02/16).

Honma K, Inagaki S, Okuda K, Kuramitsu HK and Sharma A (2007) Role of a *Tannerella forsythia* exopolysaccharide synthesis operon in biofilm development. *Microbial Pathogenesis* 42(4): 156–166.

Honma K, Mishima E and Sharma A (2011) Role of *tannerella forsythia* nanH sialidase in epithelial cell attachment. *Infection and Immunity*. American Society for Microbiology (ASM) 79(1): 393–401. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21078857> (accessed 05/09/16).

Howell WH and Donahue DD (1937) THE PRODUCTION OF BLOOD PLATELETS IN THE LUNGS. *The Journal of experimental medicine* 65(2): 177–203. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19870594> (accessed 16/11/18).

Von Hundelshausen P and Weber C (2007) Platelets as immune cells: Bridging inflammation and cardiovascular disease. *Circulation Research*. American Heart Association, Inc., 27–40. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17204662> (accessed 23/04/18).

Hynes RO (1987) Integrins: a family of cell surface receptors. *Cell* 48(4): 549–54. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/3028640> (accessed 01/02/18).

Hynes RO (2002) Integrins: Bidirectional, allosteric signaling machines. *Cell*, 673–687. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/12297042> (accessed 04/12/18).

Igboin CO, Griffen AL and Leys EJ (2009) *Porphyromonas gingivalis* strain diversity. *Journal of Clinical Microbiology*. American Society for Microbiology (ASM) 47(10): 3073–3081. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19675220> (accessed 06/08/18).

Imamura T, Tanase S, Hamamoto T, Potempa J and Travis J (2001) Activation of blood coagulation factor IX by gingipains R, arginine-specific cysteine proteinases from *Porphyromonas gingivalis*. *The Biochemical journal*. Portland Press Ltd 353(Pt 2): 325–31. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11139397> (accessed 22/11/18).

Inaba H, Kuboniwa M, Bainbridge B, Yilmaz O, Katz J, Shiverick KT, Amano A and Lamont RJ (2009) *Porphyromonas gingivalis* invades human trophoblasts and inhibits proliferation by inducing G1 arrest and apoptosis. *Cellular microbiology* 11(10): 1517–32. Available at: <http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2766574&tool=pmcentrez&rendertype=abstract> (accessed 23/04/12).

Inagaki S, Onishi S, Kuramitsu HK and Sharma A (2006) *Porphyromonas gingivalis* vesicles enhance attachment, and the leucine-rich repeat BspA protein is required for invasion of epithelial cells by ‘*Tannerella forsythia*’. *Infection and Immunity*. American Society for Microbiology 74(9): 5023–5028. Available at: <http://iai.asm.org/cgi/doi/10.1128/IAI.00062-06> (accessed 02/09/16).

Italiano JE and Hartwig JH (2007) Megakaryocyte Development and Platelet Formation. *Platelets*. Academic Press, 23–44. Available at: <https://www.sciencedirect.com/science/article/pii/B978012387837300002X> (accessed 15/12/18).

Italiano JE, Lecine P, Shivdasani RA and Hartwig JH (1999) Blood Platelets Are Assembled Principally at the Ends of Proplatelet Processes Produced by Differentiated Megakaryocytes. *The Journal of Cell Biology*. Rockefeller University Press 147(6): 1299–1312. Available at: <http://www.jcb.org/lookup/doi/10.1083/jcb.147.6.1299> (accessed 08/09/16).

Ito R, Ishihara K, Shoji M, Nakayama K and Okuda K (2010) Hemagglutinin/Adhesin domains of *Porphyromonas gingivalis* play key roles in coaggregation with *Treponema denticola*. *FEMS Immunology and Medical Microbiology* 60(3): 251–260. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21039921> (accessed 27/11/18).

Iwami J, Murakami Y, Nagano K, Nakamura H and Yoshimura F (2007) Further evidence that major outer membrane proteins homologous to OmpA in *Porphyromonas gingivalis* stabilize bacterial cells. *Oral Microbiology and Immunology* 22(5): 356–360. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17803635> (accessed 17/10/18).

Izutsu KT, Belton CM, Chan A, Fatherazi S, Kanter JP, Park Y and Lamont RJ (1996) Involvement of calcium in interactions between gingival epithelial cells and *Porphyromonas gingivalis*. *FEMS Microbiology Letters* 144: 145–150.

Jandik KA, Bélanger M, Low SL, Dorn BR, Yang MCK and Progulske-Fox A (2008) Invasive differences among *Porphyromonas gingivalis* strains from healthy and diseased periodontal sites. *Journal of periodontal research*. NIH Public Access 43(5): 524–30. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18544120> (accessed 06/08/18).

Jenkinson HF and Lamont RJ (2005) Oral microbial communities in sickness and in health. *Trends in microbiology* 13(12): 589–95. Available at: <http://www.sciencedirect.com/science/article/pii/S0966842X0500257X> (accessed 21/01/16).

Jennings LK (2009) Mechanisms of platelet activation: Need for new strategies to protect against platelet-mediated atherothrombosis. *Thrombosis and Haemostasis* 102(2): 248–257. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19652875> (accessed 21/02/18).

Johnson B, Fletcher SJ and Morgan N V. (2016) Inherited thrombocytopenia: novel insights into megakaryocyte maturation, proplatelet formation and platelet lifespan. *Platelets*. Taylor & Francis 27(6): 519–525. Available at: <https://www.tandfonline.com/doi/full/10.3109/09537104.2016.1148806> (accessed 08/09/16).

Johnson CM and Bowie EJ (1992) Pigs with von Willebrand disease may be resistant to experimental infective endocarditis. *The Journal of laboratory and clinical medicine* 120(4): 553–8. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/1402331> (accessed 22/08/18).

Jonson A-B, Normark S and Rhen M (2004) Fimbriae, Pili, Flagella and Bacterial Virulence. *Concepts in Bacterial Virulence*. Basel: KARGER, 67–89. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15496777> (accessed 27/11/18).

Joshiyura KJ, Hung H-C, Rimm EB, Willett WC and Ascherio A (2003) Periodontal Disease, Tooth Loss, and Incidence of Ischemic Stroke. *Stroke*. Lippincott Williams & Wilkins 34(1): 47–52. Available at: <http://stroke.ahajournals.org/cgi/doi/10.1161/01.STR.0000052974.79428.0C> (accessed 06/09/16).

Jung SM and Moroi M (1998) Platelets interact with soluble and insoluble collagens through characteristically different reactions. *Journal of Biological Chemistry* 273(24): 14827–14837. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/9614084> (accessed 05/12/18).

Jung SM and Moroi M (2000) Signal-transducing mechanisms involved in activation of the platelet collagen receptor integrin  $\alpha(2)\beta(1)$ . *The Journal of biological chemistry* 275(11): 8016–26. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/10713121> (accessed 05/12/18).

Juselius K and MacDonald R (2004) International parity relationships between the USA and Japan. *Japan and the World Economy* 16(1): 17–34. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/677324> (accessed 09/09/16).

Jusko M, Potempa J, Karim AY, Ksiazek M, Riesbeck K, Garred P, Eick S and Blom AM (2012) A metalloproteinase karilysin present in the majority of *Tannerella forsythia* isolates inhibits all pathways of the complement system. *Journal of immunology* (Baltimore, Md.: 1950). NIH Public Access 188(5): 2338–49. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22287711> (accessed 06/09/16).

Kallinikos-Maniatis A (1969) Megakaryocytes and platelets in central venous and arterial blood. *Acta haematologica*. Karger Publishers 42(6): 330–5. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/4986100> (accessed 16/11/18).

Kaplan ZS and Jackson SP (2011) The role of platelets in atherothrombosis. *Hematology / the Education Program of the American Society of Hematology*. American Society of Hematology. Education Program 2011(1): 51–61.

Kato T, Kawai S, Nakano K, Inaba H, Kuboniwa M, Nakagawa I, Tsuda K, Omori H, Ooshima T, Yoshimori T and Amano A (2007) Virulence of *Porphyromonas gingivalis* is altered by substitution of fimbria gene with different genotype. *Cellular Microbiology* 9(3): 753–765. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17081195> (accessed 11/12/18).

Keane C, Tilley D, Cunningham A, Smolenski A, Kadioglu A, Cox D, Jenkinson HF and Kerrigan SW (2010) Invasive *Streptococcus pneumoniae* trigger platelet activation via Toll-like receptor 2. *Journal of Thrombosis and Haemostasis*. Blackwell Publishing Ltd 8(12): 2757–2765. Available at: <http://doi.wiley.com/10.1111/j.1538-7836.2010.04093.x> (accessed 24/01/17).

Kebschull M, Demmer RT and Papapanou PN (2010) ‘Gum bug, leave my heart alone!’--epidemiologic and mechanistic evidence linking periodontal infections and atherosclerosis. *Journal of dental research*. SAGE Publications 89(9): 879–902. Available at: <http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3318075&tool=pmcentrez&rendertype=abstract> (accessed 31/10/12).

Kerr DA (1951) Summary of Systemic Relations in Periodontal Disease. *Journal of Periodontology* 22(1): 27–29. Available at: <http://www.joponline.org/doi/10.1902/jop.1951.22.1.27a> (accessed 04/10/16).

Kerr DA (1962) III . THE MECHANISM OF PERIODONTAL BREAKDOWN Relations. *Journal of dental research* 41(1): 302–304.

Kerrigan SW (2015) The expanding field of platelet–bacterial interconnections. *Platelets*. Informa Healthcare 26(4): 293–301. Available at: <http://www.tandfonline.com/doi/full/10.3109/09537104.2014.997690> (accessed 01/11/16).

Kerrigan SW and Cox D (2010) Platelet–bacterial interactions. *Cellular and Molecular Life Sciences*. SP Birkhäuser Verlag Basel 67(4): 513–523. Available at: <http://link.springer.com/10.1007/s00018-009-0207-z> (accessed 03/03/18).

Kerrigan SW, Douglas I, Wray A, Heath J, Byrne MF, Fitzgerald D and Cox D (2002) A role for glycoprotein Ib in Streptococcus sanguis-induced platelet aggregation. *Blood*. Department of Clinical Pharmacology, Royal College of Surgeons in Ireland, Dublin, Ireland 100(0006–4971 (Print)): 509–516. Available at: pm:12091342.

Kerrigan SW, Jakubovics NS, Keane C, Maguire P, Wynne K, Jenkinson HF and Cox D (2007) Role of Streptococcus gordonii Surface Proteins SspA/SspB and Hsa in Platelet Function. *Infection and Immunity* 75(12): 5740–5747. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17893126> (accessed 28/08/18).

Kesavalu L, Sathishkumar S, Bakthavatchalu V, Matthews C, Dawson D, Steffen M and Ebersole JL (2007) Rat model of polymicrobial infection, immunity, and alveolar bone resorption in periodontal disease. *Infection and Immunity* 75(4): 1704–1712. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17210663> (accessed 17/12/18).

Khalaf H and Bengtsson T (2012) Altered T-Cell Responses by the Periodontal Pathogen Porphyromonas gingivalis. *PLoS ONE* 7(9): e45192. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22984628> (accessed 16/09/18).

Kiili M, Cox SW, Chen HW, Wahlgren J, Maisi P, Eley BM, Salo T and Sorsa T (2002) Collagenase-2 (MMP-8) and collagenase-3 (MMP-13) in adult periodontitis: molecular forms and levels in gingival crevicular fluid and immunolocalisation in gingival tissue. *Journal of Clinical Periodontology*. Munksgaard International Publishers 29(3): 224–232. Available at: <http://doi.wiley.com/10.1034/j.1600-051x.2002.290308.x> (accessed 06/09/16).

Kinane JA, Benakanakere MR, Zhao J, Hosur KB and Kinane DF (2012) Porphyromonas gingivalis influences actin degradation within epithelial cells during invasion and apoptosis. *Cellular microbiology*. Wiley/Blackwell (10.1111) 14(7): 1085–1096. Available at: <http://doi.wiley.com/10.1111/j.1462-5822.2012.01780.x> (accessed 06/03/12).

Kirschbaum M, Schultze-Mosgau S, Pfister W and Eick S (2010a) Mixture of periodontopathogenic bacteria influences interaction with KB cells. *Anaerobe* 16(4): 461–468.

Kirschbaum M, Schultze-Mosgau S, Pfister W and Eick S (2010b) Mixture of periodontopathogenic bacteria influences interaction with KB cells. *Anaerobe* 16(4): 461–468. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20380884> (accessed 17/12/18).

Kitamura Y, Matono S, Aida Y, Hirofuji T and Maeda K (2002) Gingipains in the culture supernatant of Porphyromonas gingivalis cleave CD4 and CD8 on human T cells. *Journal of periodontal research* 37(6): 464–8. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/12472841> (accessed 22/11/18).

Klarström Engström K, Khalaf H, Kälvegren H and Bengtsson T (2015) The role of Porphyromonas gingivalis gingipains in platelet activation and innate immune modulation. *Molecular Oral Microbiology*. Wiley/Blackwell (10.1111) 30(1): 62–73. Available at: <http://doi.wiley.com/10.1111/omi.12067> (accessed 28/06/18).

Klinger MHF and Jelkmann W (2002) Role of Blood Platelets in Infection and Inflammation. *JOURNAL OF INTERFERON & CYTOKINE RESEARCH* 22: 913–922.

Kocgozlu L, Elkaim R, Tenenbaum H and Werner S (2009) Variable cell responses to *P. gingivalis* lipopolysaccharide. *Journal of Dental Research* 88(8): 741–745. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19734462> (accessed 14/09/11).

Kolenbrander P, Ganeshkumar N, Cassels F and Hughes C (1993) Coaggregation: specific adherence among human oral plaque bacteria. *FASEB J* 7(5): 406–413. Available at: <http://www.fasebj.org/content/7/5/406> (accessed 22/01/16).

Kolenbrander PE (2000) Oral Microbial Communities: Biofilms, Interactions, and Genetic Systems. *Annual Review of Microbiology* 54(1): 413–437. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11018133> (accessed 17/12/18).

Kolenbrander PE, Andersen RN, Blehert DS, Eglund PG, Foster JS and Palmer RJ (2002) Communication among Oral Bacteria. *Microbiology and Molecular Biology Reviews* 66(3): 486–505. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/12209001> (accessed 17/12/18).

Kolenbrander PE, Andersen RN, David S, Eglund PG, Foster JS, Robert J, Jr P, Blehert DS and Jr RJP (2002) Communication among Oral Bacteria Communication among Oral Bacteria. *Microbiology and Molecular Microbiology Reviews* 66(3): 486–505.

Kolenbrander PE, Palmer RJ, Periasamy S and Jakobovics NS (2010) Oral multispecies biofilm development and the key role of cell–cell distance. *Nature Reviews Microbiology*. Nature Publishing Group 8(7): 471–480. Available at: <http://www.nature.com/doi/10.1038/nrmicro2381>.

Kolenbrander PE, Palmer RJ, Rickard AH, Jakobovics NS, Chalmers NI and Diaz PI (2006) Bacterial interactions and successions during plaque development. *Periodontology* 2000 42(1): 47–79. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16930306> (accessed 25/01/16).

Komatsu N, Nakauchi H, Miwa A, Ishihara T, Eguchi M, Moroi M, Okada M, Sato Y, Wada H and Yawata Y (1991) Establishment and characterization of a human leukemic cell line with megakaryocytic features: dependency on granulocyte-macrophage colony-stimulating factor, interleukin 3, or erythropoietin for growth and survival. *Cancer research* 51(1): 341–8. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/1824823> (accessed 15/11/18).

Koupenova M and Freedman JE (2015) Platelets: the unsung hero of the immune response. *Journal of thrombosis and haemostasis : JTH. NIH Public Access* 13(2): 268–70. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25471925> (accessed 27/06/18).

Kraemer BF, Campbell RA, Schwertz H, Cody MJ, Franks Z, Tolley ND, Kahr WHA, Lindemann S, Seizer P, Yost CC, Zimmerman GA and Weyrich AS (2011) Novel anti-bacterial activities of  $\beta$ -defensin 1 in human platelets: Suppression of pathogen growth and signaling of neutrophil extracellular trap formation. *PLoS Pathogens* 7(11): e1002355. Available at: <http://dx.plos.org/10.1371/journal.ppat.1002355> (accessed 12/09/18).

Kroll MH and Schafer AI (1989) Biochemical mechanisms of platelet activation. *Blood* 74(4): 1181–95. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/2669994> (accessed 03/12/18).

Ksiazek M, Mizgalska D, Eick S, Thøgersen IB, Enghild JJ and Potempa J (2015) KLIKK proteases of *Tannerella forsythia*: Putative virulence factors with a unique domain structure. *Frontiers in Microbiology*. *Frontiers Media SA* 6(MAR): 312. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25954253> (accessed 05/09/16).

Ksiazek M, Mizgalska D, Enghild JJ, Scavenius C, Thogersen IB and Potempa J (2015) Miropin, a novel bacterial serpin from the periodontopathogen *Tannerella forsythia*, inhibits a broad range of proteases by using different peptide bonds within the reactive center loop. *Journal of Biological Chemistry* 290(1): 658–670.

Kuijpers RW, Ouwehand WH, Bleeker PM, Christie D and von dem Borne AE (1992) Localization of the platelet-specific HPA-2 (Ko) alloantigens on the N-terminal globular fragment of platelet glycoprotein Ib. *Blood* 79(0006–4971 (Print)): 283–288. Available at: <http://www.bloodjournal.org/content/79/1/283.short> (accessed 07/12/18).

Kurpiewski GE, Forrester LJ, Campbell BJ and Barrett JT (1983) Platelet aggregation by *Streptococcus pyogenes*. *Infection and immunity*. *American Society for Microbiology (ASM)* 39(2): 704–8. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/6403459> (accessed 22/08/18).

Lacroix R, Robert S, Poncelet P, Kasthuri RS, Key NS and Dignat-George F (2010) Standardization of platelet-derived microparticle enumeration by flow cytometry with calibrated beads: results of the International Society on Thrombosis and Haemostasis SSC Collaborative workshop. *Journal of Thrombosis and Haemostasis*. *Wiley/Blackwell* (10.1111) 8(11): 2571–2574. Available at: <http://doi.wiley.com/10.1111/j.1538-7836.2010.04047.x> (accessed 07/12/18).

Laky M, Assinger A, Esfandeyari A, Bertl K, Haririan H and Volf I (2011) Decreased phosphorylation of platelet vasodilator-stimulated phosphoprotein in periodontitis - A role of periodontal pathogens. *Thrombosis Research* 128(2): 155–160.

Lamont RJ, Chan A, Belton CM, Izutsu KT, Vasel D and Weinberg A (1995) *Porphyromonas gingivalis* invasion of gingival epithelial cells. *Infection and immunity*. *American Society for Microbiology (ASM)* 63(10): 3878–85. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/7558295> (accessed 02/09/16).

Lamont RJ, El-Sabaeny A, Park Y, Cook GS, Costerton JW and Demuth DR (2002) Role of the *streptococcus gordonii* SspB protein in the development of *Porphyromonas gingivalis* biofilms on streptococcal substrates. *Microbiology* 148(6): 1627–1636. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/12055284> (accessed 27/11/18).

Lee J-Y, Jung Y-J, Jun H-K and Choi B-K (2015) Pathogenic potential of *Tannerella forsythia* enolase. *Molecular Oral Microbiology* 31: n/a-n/a. Available at: <http://doi.wiley.com/10.1111/omi.12115>.

- Lee SW, Hillman JD and Progulske-Fox A (1996) The hemagglutinin genes hagB and hagC of *Porphyromonas gingivalis* are transcribed in vivo as shown by use of a new expression vector. *Infection and immunity* 64(11): 4802–10. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/8890242> (accessed 27/11/18).
- Lefrançois E, Ortiz-Muñoz G, Caudrillier A, Mallavia B, Liu F, Sayah DM, Thornton EE, Headley MB, David T, Coughlin SR, Krummel MF, Leavitt AD, Passegué E and Looney MR (2017) The lung is a site of platelet biogenesis and a reservoir for haematopoietic progenitors. *Nature*. NIH Public Access 544(7648): 105–109. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/28329764> (accessed 16/11/18).
- Lepage A, Leboeuf M, Cazenave JP, de la Salle C, Lanza F and Uzan G (2000) The alpha(IIb)beta(3) integrin and GPIb-V-IX complex identify distinct stages in the maturation of CD34(+) cord blood cells to megakaryocytes. *Blood* 96(13): 4169–77. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11110688> (accessed 16/11/18).
- Lev-Lehman E, Deutsch V, Eldor A and Soreq H (1997) Immature Human Megakaryocytes Produce Nuclear-Associated Acetylcholinesterase. *Blood* 89(10).
- Levine RF, Eldor A, Shoff PK, Kirwin S, Tenza D and Cramer EM (1993) Circulating megakaryocytes: delivery of large numbers of intact, mature megakaryocytes to the lungs. *European journal of haematology* 51(4): 233–46. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/8243613> (accessed 29/11/18).
- Lewis JP, Plata K, Yu F, Rosato A and Anaya C (2006) Transcriptional organization, regulation and role of the *Porphyromonas gingivalis* W83 hmu haemin-uptake locus. *Microbiology* 152(11): 3367–3382. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17074906> (accessed 27/11/18).
- Li C, Yang X, Pan Y, Yu N, Xu X, Tong T, Tang X, Zhang D, Liu J and Lin L (2017) A Sialidase-Deficient *Porphyromonas gingivalis* Mutant Strain Induces Less Interleukin-1 $\beta$  and Tumor Necrosis Factor- $\alpha$  in Epi4 Cells Than W83 Strain Through Regulation of c-Jun N-Terminal Kinase Pathway. *Journal of Periodontology* 88(8): e129–e139. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/28362225> (accessed 24/08/18).
- Li J, Helmerhorst EJ, Corley RB, Luus LE, Troxler RF and Oppenheim FG (2003) Characterization of the immunologic responses to human in vivo acquired enamel pellicle as a novel means to investigate its composition. *Oral microbiology and immunology*. Munksgaard International Publishers 18(3): 183–91. Available at: <http://doi.wiley.com/10.1034/j.1399-302X.2003.00065.x> (accessed 03/10/16).
- Li J, Helmerhorst EJ, Leone CW, Troxler RF, Yaskell T, Haffajee AD, Socransky SS and Oppenheim FG (2004) Identification of early microbial colonizers in human dental biofilm. *Journal of applied microbiology* 97(6): 1311–8. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15546422> (accessed 22/01/16).
- Li N and Collyer CA (2011) Gingipains from *Porphyromonas gingivalis* - Complex domain structures confer diverse functions. *European journal of microbiology & immunology*. Akadémiai Kiadó 1(1): 41–58. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24466435> (accessed 22/11/18).

- Li N, Yun P, Nadkarni MA, Ghadikolaee NB, Nguyen K-A, Lee M, Hunter N and Collyer CA (2010) Structure determination and analysis of a haemolytic gingipain adhesin domain from *Porphyromonas gingivalis*. *Molecular Microbiology* 76(4): 861–873. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20233299> (accessed 22/11/18).
- Li R and Emsley J (2013) The organizing principle of the platelet glycoprotein Ib-IX-V complex. *Journal of thrombosis and haemostasis : JTH. NIH Public Access* 11(4): 605–14. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23336709> (accessed 16/11/18).
- Li S, Dong G, Moschidis A, Ortiz J, Benakanakere MR, Kinane DF and Graves DT (2013) *P. gingivalis* modulates keratinocytes through FOXO transcription factors. *PloS one. Public Library of Science* 8(11): e78541. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24265696> (accessed 09/10/18).
- Li X, Iwai T, Nakamura H, Inoue Y, Chen Y, Umeda M and Suzuki H (2008) An ultrastructural study of *Porphyromonas gingivalis*-induced platelet aggregation. *Thrombosis Research. Pergamon* 122(6): 810–819. Available at: <https://www.sciencedirect.com/science/article/pii/S0049384808000856?via%3Dihub#fig2> (accessed 05/10/16).
- Li Z, Delaney MK, O'Brien KA and Du X (2010) Signaling during platelet adhesion and activation. *Arteriosclerosis, Thrombosis, and Vascular Biology* 30(12): 2341–2349. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21071698> (accessed 11/12/18).
- Lin X, Wu J and Xie H (2006) *Porphyromonas gingivalis* minor fimbriae are required for cell-cell interactions. *Infection and immunity. American Society for Microbiology (ASM)* 74(10): 6011–5. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16988281> (accessed 27/11/18).
- Lopes-Pires ME, Casarin AL, Pereira-Cunha FG, Lorand-Metze I, Antunes E and Marcondes S (2012) Lipopolysaccharide treatment reduces rat platelet aggregation independent of intracellular reactive-oxygen species generation. *Platelets* 23(3): 195–201. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21806496> (accessed 09/09/16).
- López JA (1994) The platelet glycoprotein Ib-IX complex. *Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis* 5(1): 97–119. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/8180344> (accessed 07/11/18).
- López JA, Andrews RK, Afshar-Kharghan V and Berndt MC (1998) Bernard-Soulier syndrome. *Blood* 91(12): 4397–4418. Available at: <http://www.bloodjournal.org/content/91/12/4397.short> (accessed 05/12/18).
- Loughman A, Fitzgerald JR, Brennan MP, Higgins J, Downer R, Cox D and Foster TJ (2005) Roles for fibrinogen, immunoglobulin and complement in platelet activation promoted by *Staphylococcus aureus* clumping factor A. *Molecular Microbiology* 57(3): 804–818. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16045623> (accessed 28/08/18).

Lourbakos A, Potempa J, Travis J, D'Andrea MR, Santulli R, Mackie EJ and Pike RN (2001) Arginine-specific protease from *Porphyromonas gingivalis* activates protease-activated receptors on human oral epithelial cells and induces interleukin-6 secretion. *Infection and Immunity. American Society for Microbiology Journals* 69(8): 5121–5130. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11447194> (accessed 13/09/18).

Lourbakos A, Yuan YP, Jenkins AL, Travis J, Andrade-Gordon P, Santulli R, Potempa J and Pike RN (2001) Activation of protease-activated receptors by gingipains from *Porphyromonas gingivalis* leads to platelet aggregation: A new trait in microbial pathogenicity. *Blood. American Society of Hematology* 97(12): 3790–3797. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11389018> (accessed 12/09/16).

Lowenhaupt RW, Silberstein EB, Sperling MI and Mayfield G (1982) A quantitative method to measure human platelet chemotaxis using indium-111-oxine-labeled gel-filtered platelets. *Blood* 60(6): 1345–52. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/7139123> (accessed 09/09/16).

Ma L, Wei J, Chang J-X, Zhang C, Pei Z-X and Yang Q-H (2009) LPS Mediates the Activation of Platelet by Toll-Like Receptor 4. *Blood* 114(22). Available at: <http://www.bloodjournal.org/content/114/22/3001?sso-checked=true> (accessed 16/09/18).

Macfarlane RG (1964) An enzyme cascade in the blood clotting mechanism, and its function as a biochemical amplifier [23]. *Nature. Nature Publishing Group*, 498–499. Available at: <http://www.nature.com/doi/10.1038/202498a0> (accessed 30/11/18).

Machlus KR and Italiano JE (2013) The incredible journey: From megakaryocyte development to platelet formation. *The Journal of cell biology. Rockefeller University Press* 201(6): 785–96. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23751492> (accessed 18/05/18).

Mackman N (2009) The role of tissue factor and factor VIIa in hemostasis. *Anesthesia and Analgesia. NIH Public Access*, 1447–1452. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19372318> (accessed 30/11/18).

MacLeod RAF, Dirks WG, Reid YA, Hay RJ and Drexler HG (1997) Identity of original and late passage Dami megakaryocytes with HEL erythroleukemia cells shown by combined cytogenetics and DNA fingerprinting. *Leukemia. Nature Publishing Group* 11(12): 2032–2038. Available at: <http://www.nature.com/doi/10.1038/sj.leu.2400868> (accessed 05/10/16).

Mager DL, Ximenez-Fyvie LA, Haffajee AD and Socransky SS (2003) Distribution of selected bacterial species on intraoral surfaces. *Journal of Clinical Periodontology. Munksgaard International Publishers* 30(7): 644–654. Available at: <http://doi.wiley.com/10.1034/j.1600-051X.2003.00376.x> (accessed 03/10/16).

Mahnke YD and Roederer M (2007) Optimizing a Multicolor Immunophenotyping Assay. *Clinics in Laboratory Medicine*. Elsevier 27(3): 469–485. Available at: <https://www.sciencedirect.com/science/article/pii/S0272271207000479> (accessed 25/10/18).

Marcelino SL, Gaetti-Jardim EJ, Nakano V, Canonico LAD, Nunes FD, Lotufo RFM, Pustiglioni FE, Romito GA, Avila-Campos MJ, Canônico LAD, Nunes FD, Lotufo RFM, Pustiglioni FE, Romito GA and Avila-Campos MJ (2010) Presence of periodontopathic bacteria in coronary arteries from patients with chronic periodontitis. *Anaerobe* 16(6): 629–632. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20816998%5Cn> (accessed 07/09/16).

Marsh PD (2004) Dental plaque as a microbial biofilm. *Caries research*. Karger Publishers 38(3): 204–11. Available at: <http://www.karger.com/Article/FullText/77756> (accessed 03/01/16).

Martinez-Martinez RE, Abud-Mendoza C, Patiño-Marin N, Rizo-Rodríguez JC, Little JW and Loyola-Rodríguez JP (2009) Detection of periodontal bacterial DNA in serum and synovial fluid in refractory rheumatoid arthritis patients. *Journal of Clinical Periodontology*. Blackwell Publishing Ltd 36(12): 1004–1010. Available at: <http://doi.wiley.com/10.1111/j.1600-051X.2009.01496.x> (accessed 04/10/16).

Matsumura-Takeda K, Sogo S, Isakari Y, Harada Y, Nishioka K, Kawakami T, Ono T and Taki T (2007) CD41 + /CD45 + Cells Without Acetylcholinesterase Activity Are Immature and a Major Megakaryocytic Population in Murine Bone Marrow. *Stem Cells*. John Wiley & Sons, Ltd 25(4): 862–870. Available at: <http://doi.wiley.com/10.1634/stemcells.2006-0363> (accessed 07/12/18).

Maugeri N, Franchini S, Campana L, Baldini M, Ramirez GA, Sabbadini MG, Rovere-Querini P and Manfredi AA (2012) Circulating platelets as a source of the damage-associated molecular pattern HMGB1 in patients with systemic sclerosis. *Autoimmunity*. Taylor & Francis 45(8): 584–587. Available at: <http://www.tandfonline.com/doi/full/10.3109/08916934.2012.719946> (accessed 07/12/18).

Maynard DM, Heijnen HFG, Horne MK, White JG and Gahl WA (2007) Proteomic analysis of platelet  $\alpha$ -granules using mass spectrometry. *Journal of Thrombosis and Haemostasis* 5(9): 1945–1955. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17723134> (accessed 17/09/18).

Mayrand D and Holt SC (1988) Biology of asaccharolytic black-pigmented *Bacteroides* species. *Microbiological reviews*. American Society for Microbiology (ASM) 52(1): 134–52. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/3280965> (accessed 21/11/18).

McAlister AD, Sroka A, Fitzpatrick RE, Quinsey NS, Travis J, Potempa J and Pike RN (2009) Gingipain enzymes from *Porphyromonas gingivalis* preferentially bind immobilized extracellular proteins: a mechanism favouring colonization? *Journal of periodontal research*. NIH Public Access 44(3): 348–53. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18973544> (accessed 22/11/18).

- McCoy SA, Creamer HR, Kawanami M and Adams DF (1987) The Concentration of Lipopolysaccharide on Individual Root Surfaces at Varying Times Following in Vivo Root Planing. *Journal of Periodontology* 58(6): 393–399. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/3298609> (accessed 21/11/18).
- McEver RP, Moore KL and Cummings RD (1995) Leukocyte trafficking mediated by selectin-carbohydrate interactions. *Journal of Biological Chemistry*, 11025–11028. Available at: <http://www.jbc.org/content/270/19/11025.short> (accessed 07/12/18).
- McNicol A (2015) Bacteria-induced intracellular signalling in platelets. *Platelets*. Informa Healthcare. Available at: <http://www.tandfonline.com/doi/abs/10.3109/09537104.2015.1014470> (accessed 06/01/16).
- McNicol A and Israels SJ (2010) Mechanisms of oral bacteria-induced platelet activation. *Canadian Journal of Physiology and Pharmacology* 88(5): 510–524. Available at: <http://www.nrcresearchpress.com/doi/10.1139/Y10-029>.
- Michelson AD (2004) Platelet Function Testing in Cardiovascular Diseases. *Circulation* 110(19): e489–e493. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15533872> (accessed 02/07/18).
- Michelson AD, Barnard MR, Krueger LA, Frelinger AL and Furman MI (2000) Evaluation of platelet function by flow cytometry. *Methods (San Diego, Calif.)*. Academic Press 21(3): 259–70. Available at: <https://www.sciencedirect.com/science/article/pii/S1046202300910065> (accessed 17/11/16).
- Miklossy J (2011) Alzheimer ' s disease - a neurospirochetosis . Analysis of the evidence following Koch ' s and Hill ' s criteria. *Journal of Neuroinflammation* 8(1): 90. Available at: <http://www.jneuroinflammation.com/content/8/1/90>.
- Minors DS (2007) Haemostasis, blood platelets and coagulation. *Anaesthesia & Intensive Care Medicine*. Elsevier 8(5): 214–216. Available at: <http://linkinghub.elsevier.com/retrieve/pii/S1472029907000525> (accessed 29/11/18).
- Mishima E and Sharma A (2011) *Tannerella forsythia* invasion in oral epithelial cells requires phosphoinositide 3-Kinase activation and clathrin-mediated endocytosis. *Microbiology* 157(8): 2382–2391.
- Mitjavila-Garcia MT, Cailleret M, Godin I, Nogueira MM, Cohen-Solal K, Schiavon V, Lecluse Y, Le Pesteur F, Lagrue AH and Vainchenker W (2002) Expression of CD41 on hematopoietic progenitors derived from embryonic hematopoietic cells. *Development (Cambridge, England)* 129(8): 2003–13. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11934866> (accessed 30/01/18).
- Modderman PW, Admiraal LG, Sonnenberg A and Von dem Borne AEGK (1992) Glycoproteins V and Ib-IX form a noncovalent complex in the platelet membrane. *Journal of Biological Chemistry* 267(1): 364–369. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/1730602> (accessed 07/11/18).

Moore J, Wilson M and Kieser JB (1986) The distribution of bacterial lipopolysaccharide (endotoxin) in relation to periodontally involved root surfaces. *Journal of clinical periodontology* 13(8): 748–51. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/3464619> (accessed 21/11/18).

Morandi F, Airoidi I and Pistoia V (2014) IL-27 driven upregulation of surface HLA-e expression on monocytes inhibits IFN- $\gamma$  release by autologous NK cells. *Journal of Immunology Research*. Hindawi 2014: 938561. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24741633> (accessed 07/12/18).

Moreau T, Evans AL, Vasquez L, Tijssen MR, Yan Y, Trotter MW, Howard D, Colzani M, Arumugam M, Wu WH, Dalby A, Lampela R, Bouet G, Hobbs CM, Pask DC, Payne H, Ponomaryov T, Brill A, Soranzo N, Ouwehand WH, Pedersen RA and Ghevaert C (2016) Large-scale production of megakaryocytes from human pluripotent stem cells by chemically defined forward programming. *Nature communications*. Nature Publishing Group 7: 11208. Available at: <http://www.nature.com/ncomms/2016/160407/ncomms11208/full/ncomms11208.html> (accessed 09/04/16).

Moriarty RD, Cox A, McCall M, Smith SGJ and Cox D (2016) *Escherichia coli* induces platelet aggregation in an Fc $\gamma$ R1a-dependent manner. *Journal of Thrombosis and Haemostasis* 14(4): 797–806. Available at: <http://doi.wiley.com/10.1111/jth.13226> (accessed 12/09/16).

Muirheadi KA, Horan PK and Poste G (1985) Flow Cytometry: Present and future. *Bio/Technology*. Nature Publishing Group 3(4): 337–356. Available at: <http://www.nature.com/doi/10.1038/nbt0485-337> (accessed 25/10/18).

Murakami Y, Hasegawa Y, Nagano K and Yoshimura F (2014) Characterization of wheat germ agglutinin lectin-reactive glycosylated OmpA-like proteins derived from *Porphyromonas gingivalis*. *Infection and Immunity* 82(11): 4563–4571. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25135681> (accessed 28/11/18).

Nagano K, Read EK, Murakami Y, Masuda T, Noguchi T and Yoshimura F (2005) Trimeric structure of major outer membrane proteins homologous to OmpA in *Porphyromonas gingivalis*. *Journal of bacteriology*. American Society for Microbiology (ASM) 187(3): 902–11. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15659668> (accessed 28/11/18).

Naito M (2007) *Porphyromonas gingivalis* induced Platelet Aggregation in Human Plasma. *Journal of Oral Biosciences*. Elsevier 49(3): 173–179. Available at: <https://www.sciencedirect.com/science/article/pii/S1349007907800296> (accessed 02/07/18).

Naito M, Sakai E, Shi Y, Ideguchi H, Shoji M, Ohara N, Yamamoto K and Nakayama K (2006) *Porphyromonas gingivalis*-induced platelet aggregation in plasma depends on Hgp44 adhesin but not Rgp proteinase. *Molecular Microbiology*. Wiley/Blackwell (10.1111) 59(1): 152–167. Available at: <http://doi.wiley.com/10.1111/j.1365-2958.2005.04942.x> (accessed 25/05/18).

Nakagawa I, Amano A, Kimura RK, Nakamura T, Kawabata S and Hamada S (2000) Distribution and molecular characterization of *Porphyromonas gingivalis* carrying a new type of *fimA* gene. *Journal of clinical microbiology*. American Society for Microbiology (ASM) 38(5): 1909–14. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/10790120> (accessed 27/11/18).

Nakagawa I, Amano A, Kuboniwa M, Nakamura T, Kawabata S and Hamada S (2002) Functional differences among *FimA* variants of *Porphyromonas gingivalis* and their effects on adhesion to and invasion of human epithelial cells. *Infection and Immunity* 70(1): 277–285. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11748193> (accessed 27/11/18).

Nakajima T, Tomi N, Fukuyo Y, Ishikura H, Ohno Y, Arvind R, Arai T, Ishikawa I and Arakawa S (2006) Isolation and identification of a cytopathic activity in *Tannerella forsythia*. *Biochemical and Biophysical Research Communications* 351(1): 133–139.

Nakano K, Inaba H, Nomura R, Nemoto H, Takeda M, Yoshioka H, Matsue H, Takahashi T, Taniguchi K, Amano A and Ooshima T (2006) Detection of cariogenic *Streptococcus mutans* in extirpated heart valve and atheromatous plaque specimens. *Journal of clinical microbiology*. American Society for Microbiology (ASM) 44(9): 3313–7. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16954266> (accessed 08/09/16).

Nakano K, Inaba H, Nomura R, Nemoto H, Takeuchi H, Yoshioka H, Toda K, Taniguchi K, Amano A and Ooshima T (2008) Distribution of *Porphyromonas gingivalis fimA* genotypes in cardiovascular specimens from Japanese patients. *Oral Microbiology and Immunology*. Blackwell Publishing Ltd 23(2): 170–172. Available at: <http://doi.wiley.com/10.1111/j.1399-302X.2007.00406.x> (accessed 08/09/16).

Nakano K, Inaba H, Nomura R, Nemoto H, Tamura K, Miyamoto E, Yoshioka H, Taniguchi K, Amano A and Ooshima T (2007) Detection and serotype distribution of *Actinobacillus actinomycetemcomitans* in cardiovascular specimens from Japanese patients. *Oral microbiology and immunology* 22(2): 136–9. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17311638> (accessed 08/09/16).

Nakhjiri SF, Park Y, Yilmaz O, Chung WO, Watanabe K, El-Sabaeny A, Park K and Lamont RJ (2001) Inhibition of epithelial cell apoptosis by *Porphyromonas gingivalis*. *FEMS Microbiology Letters*. Blackwell Publishing Ltd 200(2): 145–149. Available at: <http://femsle.oxfordjournals.org/cgi/doi/10.1111/j.1574-6968.2001.tb10706.x> (accessed 02/09/16).

Nakhjiri SF, Park Y, Yilmaz O, Chung WO, Watanabe K, El-Sabaeny A, Park K and Lamont RJ (2001) Inhibition of epithelial cell apoptosis by *Porphyromonas gingivalis*. *FEMS microbiology letters* 200(2): 145–9. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11425466> (accessed 07/08/18).

Naylor KL, Widziolek M, Hunt S, Conolly M, Hicks M, Stafford P, Potempa J, Murdoch C, Douglas CWI and Stafford GP (2016) Role of *OmpA2* surface regions of *Porphyromonas gingivalis* in host-pathogen interactions with oral epithelial cells. *MicrobiologyOpen*. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/27595778> (accessed 19/09/16).

Nemerson Y (1988) Tissue factor and hemostasis. *Blood* 71(1): 1–8. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/3275472> (accessed 30/11/18).

Nesbitt WS, Giuliano S, Kulkarni S, Dopheide SM, Harper IS and Jackson SP (2003) Intercellular calcium communication regulates platelet aggregation and thrombus growth. *Journal of Cell Biology*. The Rockefeller University Press 160(7): 1151–1161. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/12668663> (accessed 11/05/18).

Nicu EA, Van der Velden U, Nieuwland R, EVERTS V and LOOS BG (2009) Elevated platelet and leukocyte response to oral bacteria in periodontitis. *Journal of thrombosis and haemostasis : JTH*. Blackwell Publishing Ltd 7(1): 162–70. Available at: <http://doi.wiley.com/10.1111/j.1538-7836.2008.03219.x> (accessed 17/05/16).

Nieuwenhuis HK, Akkerman JWN, Houdijk WPM and Sixma JJ (1985) Human blood platelets showing no response to collagen fail to express surface glycoprotein Ia. *Nature* 318(6045): 470–472. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/2933589> (accessed 05/12/18).

Njoroge T, Genco RJ, Sojar HT, Hamada N and Genco CA (1997) A role for fimbriae in *Porphyromonas gingivalis* invasion of oral epithelial cells. *Infection and immunity* 65(5): 1980–4. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/9125593> (accessed 27/11/18).

Núñez-Avellaneda D, Mosso-Pani MA, Sánchez-Torres LE, Castro-Mussot ME, Corona-De la Peña NA and Salazar MI (2018) Dengue virus induces the release of sCD40l and changes in levels of membranial CD42B and CD40L molecules in human platelets. *Viruses* 10(7): 1–13.

Nurhayati RW, Ojima Y and Taya M (2015) BMS-777607 promotes megakaryocytic differentiation and induces polyploidization in the CHR-288-11 cells. *Human Cell*. Springer Japan 28(2): 65–72. Available at: <http://link.springer.com/10.1007/s13577-014-0102-2> (accessed 29/09/16).

O'Brien-Simpson NM, Pathirana RD, Paolini RA, Chen Y-Y, Veith PD, Tam V, Ally N, Pike RN and Reynolds EC (2005) An immune response directed to proteinase and adhesin functional epitopes protects against *Porphyromonas gingivalis*-induced periodontal bone loss. *Journal of immunology (Baltimore, Md. : 1950)* 175(6): 3980–9. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16148146> (accessed 22/11/18).

Ogawa T, Uchida H and Hamada S (1994) *Porphyromonas gingivalis* fimbriae and their synthetic peptides induce proinflammatory cytokines in human peripheral blood monocyte cultures. *FEMS microbiology letters* 116(2): 237–42. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/7908651> (accessed 27/11/18).

Ogawa T and Yagi T (2010) Bioactive mechanism of *porphyromonas gingivalis* lipid A. *Periodontology 2000* 54(1): 71–77. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20712634> (accessed 21/11/18).

Olczak T, Sroka A, Potempa J and Olczak M (2008) *Porphyromonas gingivalis* HmuY and HmuR: further characterization of a novel mechanism of heme utilization. *Archives of Microbiology* 189(3): 197–210. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17922109> (accessed 27/11/18).

Olsen I and Progulsk-Fox A (2015) Invasion of Porphyromonas gingivalis strains into vascular cells and tissue. *Journal of Oral Microbiology*. Taylor & Francis, 28788. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/26329158> (accessed 04/02/19).

Overton WR (1988) Modified histogram subtraction technique for analysis of flow cytometry data. *Cytometry*. Wiley-Blackwell 9(6): 619–626. Available at: <http://doi.wiley.com/10.1002/cyto.990090617> (accessed 25/10/18).

Pallister C and Watson MS (2011) *Haematology* (2nd ed.). Banbury:Scion.

Palm E, Khalaf H and Bengtsson T (2013) Porphyromonas gingivalis downregulates the immune response of fibroblasts. *BMC microbiology*. BioMed Central 13: 155. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23841502> (accessed 16/09/18).

Palmer RJ, Gordon SM, Cisar JO and Kolenbrander PE (2003) Coaggregation-mediated interactions of streptococci and actinomyces detected in initial human dental plaque. *Journal of bacteriology* 185(11): 3400–9. Available at: <http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=155391&tool=pmcentrez&rendertype=abstract> (accessed 22/01/16).

Palta S, Saroa R and Palta A (2014) Overview of the coagulation system. *Indian Journal of Anaesthesia*. Wolters Kluwer. Medknow Publications, 515–523. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25535411> (accessed 30/11/18).

Papapanagiotou D, Nicu EA, Bizzarro S, Gerdes VEA, Meijers JC, Nieuwland R, van der Velden U and Loos BG (2009) Periodontitis is associated with platelet activation. *Atherosclerosis* 202(2): 605–611.

Papapanou PN, Sandros J, Lindberg K, Duncan MJ, Niederman R and Nannmark U (1994) Porphyromonas gingivalis may multiply and advance within stratified human junctional epithelium in vitro. *Journal of Periodontal Research*. Blackwell Publishing Ltd 29(5): 374–375. Available at: <http://doi.wiley.com/10.1111/j.1600-0765.1994.tb01237.x> (accessed 02/09/16).

Paquette DW, Brodala N and Nichols TC (2007) Cardiovascular disease, inflammation, and periodontal infection. *Periodontology 2000*. Blackwell Publishing Ltd, 113–126. Available at: <http://doi.wiley.com/10.1111/j.1600-0757.2006.00196.x> (accessed 04/10/16).

Patel SR, Hartwig JH and Italiano JE (2005) The biogenesis of platelets from megakaryocyte proplatelets. *Journal of Clinical Investigation* 115(12): 3348–3354. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16322779> (accessed 29/11/18).

Pathirana RD, O'Brien-Simpson NM, Visvanathan K, Hamilton JA and Reynolds EC (2007) Flow cytometric analysis of adherence of Porphyromonas gingivalis to oral epithelial cells. *Infection and immunity*. American Society for Microbiology (ASM) 75(5): 2484–92. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17339349> (accessed 08/11/18).

Perez-Muñoz ME, Arrieta MC, Ramer-Tait AE and Walter J (2017) A critical assessment of the 'sterile womb' and 'in utero colonization' hypotheses: Implications for research on the pioneer infant microbiome. *Microbiome*. BioMed Central, 48. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/28454555> (accessed 14/12/18).

Peters CG, Michelson AD and Flaumenhaft R (2012) Granule exocytosis is required for platelet spreading: differential sorting of  $\alpha$ -granules expressing VAMP-7. *Blood*. American Society of Hematology 120(1): 199–206. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22589474> (accessed 15/01/16).

Petersen HJ, Keane C, Jenkinson HF, Vickerman MM, Jesionowski A, Waterhouse JC, Cox D and Kerrigan SW (2010) Human Platelets Recognize a Novel Surface Protein, PadA, on *Streptococcus gordonii* through a Unique Interaction Involving Fibrinogen Receptor GPIIb/IIIa. *Infection and Immunity* 78(1): 413–422. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19884334> (accessed 17/09/18).

Pihlstrom BL, Michalowicz BS and Johnson NW (2005) Periodontal diseases. *Lancet* (London, England) 366(9499): 1809–20. Available at: <http://www.sciencedirect.com/science/article/pii/S0140673605677288> (accessed 15/09/15).

Pillitteri D, Bassus S, Boller K, Mahnel R, Scholz T, Westrup D, Wegert W and Kirchmaier CM (2007) Thrombin-induced interleukin 1  $\beta$  synthesis in platelet suspensions: Impact of contaminating leukocytes. *Platelets* 18(2): 119–127. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17365860> (accessed 16/09/18).

Pitchford S, Pan D and Welch HCE (2017) Platelets in neutrophil recruitment to sites of inflammation. *Current opinion in hematology*. Europe PMC Funders 24(1): 23–31. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/27820736> (accessed 23/04/18).

Plummer C, Wu H, Kerrigan SW, Meade G, Cox D and Ian Douglas CW (2005) A serine-rich glycoprotein of *Streptococcus sanguis* mediates adhesion to platelets via GPIb. *British Journal of Haematology* 129(1): 101–109. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15801962> (accessed 08/11/18).

Pollreisz A, Huang Y, Roth GA, Cheng B, Keschull M, Papapanou PN, Schmidt AM and Lalla E (2010) Enhanced monocyte migration and pro-inflammatory cytokine production by *Porphyromonas gingivalis* infection. *Journal of Periodontal Research*. Blackwell Publishing Ltd 45(2): 239–245. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19778327> (accessed 08/09/16).

Poole S, Singhrao SK, Kesavalu L, Curtis MA and Crean S (2013) Determining the presence of periodontopathic virulence factors in short-term postmortem Alzheimer's disease brain tissue. *Journal of Alzheimer's disease : JAD* 36(4): 665–77. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23666172> (accessed 06/09/16).

Popadiak K, Potempa J, Riesbeck K and Blom AM (2007) Biphasic effect of gingipains from *Porphyromonas gingivalis* on the human complement system. *Journal of immunology* (Baltimore, Md. : 1950) 178(11): 7242–50. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17513773> (accessed 22/11/18).

Posch G, Pabst M, Brecker L, Altmann F, Messner P and Schäffer C (2011) Characterization and scope of S-layer protein O-glycosylation in *Tannerella forsythia*. *The Journal of biological chemistry*. American Society for Biochemistry and Molecular Biology 286(44): 38714–24. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21911490> (accessed 05/10/16).

Potempa J, Pike R and Travis J (1997) Titration and Mapping of the Active Site of Cysteine Proteinases from *Porphyromonas gingivalis* (Gingipains) Using Peptidyl Chloromethanes. *Biological Chemistry* 378(3–4): 223–230. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/9165075> (accessed 22/11/18).

Pucar A, Milasin J, Lekovic V, Vukadinovic M, Ristic M, Putnik S and Kenney EB (2007) Correlation between atherosclerosis and periodontal putative pathogenic bacterial infections in coronary and internal mammary arteries. *Journal of periodontology* 78(4): 677–82. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17397315> (accessed 08/09/16).

Radley JM and Scurfield G (1980) The mechanism of platelet release. *Blood*. American Society of Hematology 56(6): 996–9. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/7437520> (accessed 08/09/16).

Rasche H (2001) Haemostasis and thrombosis: An overview. *European Heart Journal, Supplement*. Oxford University Press, Q3–Q7. Available at: [https://academic.oup.com/eurheartjsupp/article-lookup/doi/10.1016/S1520-765X\(01\)90034-3](https://academic.oup.com/eurheartjsupp/article-lookup/doi/10.1016/S1520-765X(01)90034-3) (accessed 29/11/18).

Refaai MA and Laposata M (2002) Platelet aggregation. *Platelets*. Morgan & Claypool Life Sciences, 291–296. Available at: <https://www.ncbi.nlm.nih.gov/books/NBK53449/> (accessed 05/12/18).

Reichert S, Haffner M, Keyßer G, Schäfer C, Stein JM, Schaller H-G, Wienke A, Strauss H, Heide S and Schulz S (2013) Detection of oral bacterial DNA in synovial fluid. *Journal of Clinical Periodontology* 40(6): 591–598. Available at: <http://doi.wiley.com/10.1111/jcpe.12102> (accessed 06/09/16).

Rendu F and Brohard-Bohn B (2001) The platelet release reaction: Granules' constituents, secretion and functions. *Platelets*. Taylor & Francis, 261–273. Available at: <http://www.tandfonline.com/doi/full/10.1080/09537100120068170> (accessed 17/09/18).

Reyes L, Herrera D, Kozarov E, Roldán S and Progulske-Fox A (2013) Periodontal bacterial invasion and infection: Contribution to atherosclerotic pathology. *Journal of Clinical Periodontology*, S30–S50. Available at: <http://doi.wiley.com/10.1111/jcpe.12079> (accessed 07/09/16).

Riberdy JM, Avva RR, Geuze HJ and Cresswell P (1994) Transport and intracellular distribution of MHC class II molecules and associated invariant chain in normal and antigen-processing mutant cell lines. *Journal of Cell Biology*. Rockefeller University Press 125(6): 1225–1237. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/8207055> (accessed 07/12/18).

Richardson JL, Shivdasani RA, Boers C, Hartwig JH and Italiano JE (2005) Mechanisms of organelle transport and capture along proplatelets during platelet production. *Blood*. American Society of Hematology 106(13): 4066–4075. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16118320> (accessed 09/09/16).

Rinder H, Murphy M, Mitchell J, Stocks J, Ault K and Hillman R (1991) Progressive platelet activation with storage: evidence for shortened survival of activated platelets after transfusion. *Transfusion*. Blackwell Science Ltd 31(5): 409–414. Available at: <http://doi.wiley.com/10.1046/j.1537-2995.1991.31591263195.x> (accessed 21/02/18).

Roederer M and Moody MA (2008) Polychromatic plots: Graphical display of multidimensional data. *Cytometry Part A*. Wiley-Blackwell 73A(9): 868–874. Available at: <http://doi.wiley.com/10.1002/cyto.a.20610> (accessed 25/10/18).

Roth GA, Ankersmit HJ, Brown VB, Papapanou PN, Schmidt AM and Lalla E (2007) *Porphyromonas gingivalis* infection and cell death in human aortic endothelial cells. *FEMS Microbiology Letters*. Oxford University Press 272(1): 106–113. Available at: <https://academic.oup.com/femsle/article-lookup/doi/10.1111/j.1574-6968.2007.00736.x> (accessed 07/08/18).

Roth GA, Aumayr K, Giacona MB, Papapanou PN, Schmidt AM and Lalla E (2009) *Porphyromonas gingivalis* infection and prothrombotic effects in human aortic smooth muscle cells. *Thrombosis Research*. NIH Public Access 123(5): 780–784. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18789816> (accessed 08/09/16).

Roth GA, Moser B, Roth-Walter F, Giacona MB, Harja E, Papapanou PN, Schmidt AM and Lalla E (2007) Infection with a periodontal pathogen increases mononuclear cell adhesion to human aortic endothelial cells. *Atherosclerosis* 190(2): 271–281.

Ru Y-X, Dong S-X, Liang H and Zhao S-X (2016) Platelet production of megakaryocyte: A review with original observations on human in vivo cells and bone marrow. *Ultrastructural Pathology*. Taylor & Francis 40(4): 163–170. Available at: <http://www.tandfonline.com/doi/full/10.3109/01913123.2016.1170744> (accessed 08/09/16).

Ruby J and Barbeau J (2002) The buccale puzzle: The symbiotic nature of endogenous infections of the oral cavity. *The Canadian journal of infectious diseases = Journal canadien des maladies infectieuses* 13(1): 34–41. Available at: <http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2094851&tool=pmcentrez&rendertype=abstract> (accessed 16/02/16).

Rudney JD, Chen R and Sedgewick GJ (2005) a Polymicrobial Intracellular Flora. *Imaging*. SAGE Publications 84(1): 59–63. Available at: <http://jdr.sagepub.com/cgi/doi/10.1177/154405910508400110> (accessed 02/09/16).

Ruggeri ZM (2009) Platelet adhesion under flow. *Microcirculation* (New York, N.Y. : 1994). NIH Public Access, 58–83. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19191170> (accessed 16/12/18).

Ruggeri ZM and Mendolicchio GL (2007) Adhesion mechanisms in platelet function. *Circulation Research*, 1673–1685. Available at: <https://www.ahajournals.org/doi/10.1161/01.RES.0000267878.97021.ab> (accessed 29/11/18).

Sabet M, Lee SW, Nauman RK, Sims T and Um HS (2003) The surface (S-) layer is a virulence factor of *Bacteroides forsythus*. *Microbiology* 149(12): 3617–3627.

Saboor M, Ayub Q, Ilyas S and Moinuddin (2013) Platelet receptors: An instrumental of platelet physiology. *Pakistan Journal of Medical Sciences*. Professional Medical Publications, 891–6. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24353652> (accessed 04/12/18).

Saboor M, Moinuddin M and Ilyas S (2012) Flow cytometry based chronologic analysis of surface glycoproteins of resting and stimulated platelets in normal individuals. *Pakistan Journal of Medical Sciences* 28(4): 625–629.

Sachais BS (2001) Platelet-endothelial interactions in atherosclerosis. *Current atherosclerosis reports*, 412–416. Available at: <https://link.springer.com/content/pdf/10.1007%2Fs11883-001-0080-1.pdf> (accessed 17/12/18).

Sahingur SE, Xia X-J, Alamgir S, Honma K, Sharma A and Schenkein HA (2010) DNA from *Porphyromonas gingivalis* and *Tannerella forsythia* induce cytokine production in human monocytic cell lines. *Molecular oral microbiology*. NIH Public Access 25(2): 123–35. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20331800> (accessed 08/09/16).

Saito H (1997) 3 Megakaryocytic cell lines. *Baillière's Clinical Haematology* 10(1): 47–63. Available at: [http://www.sciencedirect.com/science/article/pii/S0950353697800509%5Cnhttp://www.sciencedirect.com/science?\\_ob=MIimg&\\_imagekey=B7G7H-4KWYYTG-6-1&\\_cdi=19955&\\_user=122868&\\_pii=S0950353697800509&\\_origin=&\\_coverDate=02%2F28%2F1997&\\_sk=999899998&view=c&wchp=dGLbV](http://www.sciencedirect.com/science/article/pii/S0950353697800509%5Cnhttp://www.sciencedirect.com/science?_ob=MIimg&_imagekey=B7G7H-4KWYYTG-6-1&_cdi=19955&_user=122868&_pii=S0950353697800509&_origin=&_coverDate=02%2F28%2F1997&_sk=999899998&view=c&wchp=dGLbV).

Sakakibara J, Nagano K, Murakami Y, Higuchi N, Nakamura H, Shimozato K and Yoshimura F (2007) Loss of adherence ability to human gingival epithelial cells in S-layer protein-deficient mutants of *Tannerella forsythensis*. *Microbiology* 153(3): 866–876.

Sarratt KL, Chen H, Zutter MM, Santoro SA, Hammer DA and Kahn ML (2005) GPVI and  $\alpha 2\beta 1$  play independent critical roles during platelet adhesion and aggregate formation to collagen under flow. *Blood*. The American Society of Hematology 106(4): 1268–1277. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15886326> (accessed 16/12/18).

Savill J, Dransfield I, Hogg N and Haslett C (1990) Vitronectin receptor-mediated phagocytosis of cells undergoing apoptosis. *Nature*. Nature Publishing Group 343(6254): 170–173. Available at: <http://www.nature.com/doi/10.1038/343170a0> (accessed 01/02/18).

Scannapieco FA and Cantos A (2016) Oral inflammation and infection, and chronic medical diseases: implications for the elderly. *Periodontology 2000* 72(1): 153–175. Available at: <http://doi.wiley.com/10.1111/prd.12129> (accessed 06/09/16).

Schmitz G, Rothe G, Ruf A, Barlage S, Tschöpe D, Clemetson KJ, Goodall AH, Michelson AD, Nurden AT and Shankey TV (1998) European Working Group on Clinical Cell Analysis: Consensus protocol for the flow cytometric characterisation of platelet function. *Thrombosis and Haemostasis*, 885–896. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/9609215> (accessed 17/09/18).

Scott T and Owens MD (2008) Thrombocytes respond to lipopolysaccharide through Toll-like receptor-4, and MAP kinase and NF- $\kappa$ B pathways leading to expression of interleukin-6 and cyclooxygenase-2 with production of prostaglandin E2. *Molecular Immunology* 45(4): 1001–1008.

Sedlmayr P, Blaschitz A, Wilders-Trusching M, Tiran A and Dohr G (1995) Platelets Contain Interleukin-1 Alpha and Beta which are Detectable on the Cell Surface After Activation. *Scandinavian Journal of Immunology* 42(2): 209–214. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/7631154> (accessed 16/09/18).

Selvadurai M V. and Hamilton JR (2018) Structure and function of the open canalicular system—the platelet’s specialized internal membrane network. *Platelets*, 319–325. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/29442528> (accessed 02/12/18).

Settem RP, Honma K, Nakajima T, Phansopa C, Roy S, Stafford GP and Sharma A (2013) A bacterial glycan core linked to surface (S)-layer proteins modulates host immunity through Th17 suppression. *Mucosal immunology*. Society for Mucosal Immunology 6(2): 415–26. Available at: <http://dx.doi.org/10.1038/mi.2012.85> (accessed 18/01/16).

Shapira L, Takashiba S, Amar S and Van Dyke TE (1994) Porphyromonas gingivalis lipopolysaccharide stimulation of human monocytes: dependence on serum and CD14 receptor. *Oral microbiology and immunology* 9(2): 112–7. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/7516534> (accessed 21/11/18).

Sharma A (2010) Virulence mechanisms of tannerella forsythia. *Periodontology* 2000 54(1): 106–116.

Shattil SJ, Hoxie JA, Cunningham M and Brass LF (1985) Changes in the platelet membrane glycoprotein IIb/IIIa complex during platelet activation. *J Biol Chem* 260(20): 11107–11114. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/2411729> (accessed 01/02/18).

Sheets SM, Potempa J, Travis J, Casiano CA and Fletcher HM (2005) Gingipains from Porphyromonas gingivalis W83 induce cell adhesion molecule cleavage and apoptosis in endothelial cells. *Infection and immunity*. American Society for Microbiology (ASM) 73(3): 1543–52. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15731052> (accessed 08/09/16).

Sheets SM, Potempa J, Travis J, Fletcher HM and Casiano CA (2006) Gingipains from Porphyromonas gingivalis W83 synergistically disrupt endothelial cell adhesion and can induce caspase-independent apoptosis. *Infection and Immunity*. American Society for Microbiology 74(10): 5667–5678. Available at: <http://iai.asm.org/cgi/doi/10.1128/IAI.01140-05> (accessed 08/09/16).

Shi Y, Ratnayake DB, Okamoto K, Abe N, Yamamoto K and Nakayama K (1999) Genetic analyses of proteolysis, hemoglobin binding, and hemagglutination of *Porphyromonas gingivalis*. Construction of mutants with a combination of *rgpA*, *rgpB*, *kgp*, and *hagA*. *The Journal of biological chemistry* 274(25): 17955–60. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/10364243> (accessed 27/11/18).

Shimaoka M, Takagi J and Springer TA (2002) Conformational Regulation of Integrin Structure and Function. *Annual Review of Biophysics and Biomolecular Structure*. Annual Reviews 4139 El Camino Way, P.O. Box 10139, Palo Alto, CA 94303-0139, USA 31(1): 485–516. Available at: <http://www.annualreviews.org/doi/10.1146/annurev.biophys.31.101101.140922> (accessed 05/12/18).

Shiraki R, Inoue N, Kawasaki S, Takei A, Kadotani M, Ohnishi Y, Ejiri J, Kobayashi S, Hirata KI, Kawashima S and Yokoyama M (2004) Expression of Toll-like receptors on human platelets. *Thrombosis Research* 113(6): 379–385.

Simpson W, Olczak T and Genco CA (2004) Lysine-specific gingipain K and heme/hemoglobin receptor HmuR are involved in heme utilization in *Porphyromonas gingivalis*. *Acta biochimica Polonica* 51(1): 253–62. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15094847> (accessed 22/11/18).

Sixma JJ (1986) The role of platelet membrane glycoproteins in the adhesion of blood platelets. *Agents and actions. Supplements* 20: 15–26. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/3544740> (accessed 01/12/18).

Skoglund C, Wetterö J, Skogh T, Sjöwall C, Tengvall P and Bengtsson T (2008) C-reactive protein and C1q regulate platelet adhesion and activation on adsorbed immunoglobulin G and albumin. *Immunology and cell biology* 86(5): 466–74. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18332893> (accessed 09/09/16).

Sloan EK, Pouliot N, Stanley KL, Chia J, Moseley JM, Hards DK and Anderson RL (2006) Tumor-specific expression of alphavbeta3 integrin promotes spontaneous metastasis of breast cancer to bone. *Breast cancer research : BCR. BioMed Central* 8(2): R20. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16608535> (accessed 01/02/18).

Smalley JW, Birss AJ, Szmigielski B and Potempa J (2008) Mechanism of methaemoglobin breakdown by the lysine-specific gingipain of the periodontal pathogen *Porphyromonas gingivalis*. *Biological Chemistry* 389(9): 1235–8. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18713010> (accessed 22/11/18).

Smith SGJ, Mahon V, Lambert MA and Fagan RP (2007) A molecular Swiss army knife: OmpA structure, function and expression. *FEMS Microbiology Letters*, 1–11. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17559395> (accessed 28/11/18).

Socransky SS and Haffajee AD (2005) Periodontal microbial ecology. *Periodontology* 2000 38: 135–187.

Socransky SSS, Haffajee ADD, Cugini MA a, Smith C and Kent RL (1998) Microbial complexes in subgingival plaque. *Journal of clinical periodontology*. Blackwell Publishing Ltd 25(2): 134–144. Available at: <http://doi.wiley.com/10.1111/j.1600-051X.1998.tb02419.x> (accessed 13/07/16).

Sojar HT, Hamada N and Genco RJ (1997) Isolation and characterization of fimbriae from a sparsely fimbriated strain of *Porphyromonas gingivalis*. *Applied and Environmental Microbiology* 63(6): 2318–2323. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/9172351> (accessed 09/11/18).

Song H, Belanger M, Whitlock J, Kozarov E and Progulsk-Fox A (2005) Hemagglutinin B Is Involved in the Adherence of *Porphyromonas gingivalis* to Human Coronary Artery Endothelial Cells. *Infection and Immunity* 73(11): 7267–7273. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16239522> (accessed 27/11/18).

Sonmez O and Sonmez M (2017) Porto Biomedical Journal Rostrum Role of platelets in immune system and inflammation. *Porto Biomed. J* 2(6): 311–314. Available at: <https://ac.els-cdn.com/S2444866417300107/1-s2.0-S2444866417300107-main.pdf> (accessed 21/02/18).

Stafford G, Roy S, Honma K and Sharma a (2012) Sialic acid, periodontal pathogens and *Tannerella forsythia*: stick around and enjoy the feast! *Molecular oral microbiology* 27(1): 11–22. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22230462> (accessed 10/04/12).

Stafford P, Higham J, Pinnock A, Murdoch C, Douglas CWI, Stafford GP and Lambert DW (2013) Gingipain-dependent degradation of mammalian target of rapamycin pathway proteins by the periodontal pathogen *Porphyromonas gingivalis* during invasion. *Molecular Oral Microbiology. Europe PMC Funders* 28(5): 366–378. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23714361> (accessed 19/09/16).

Stathopoulou PG, Benakanakere MR, Galicia JC and Kinane DF (2009) The host cytokine response to *Porphyromonas gingivalis* is modified by gingipains. *Oral microbiology and immunology. NIH Public Access* 24(1): 11–7. Available at: <http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2717190&tool=pmcentrez&rendertype=abstract> (accessed 01/05/12).

Stathopoulou PG, Benakanakere MR, Galicia JC and Kinane DF (2010) Epithelial cell pro-inflammatory cytokine response differs across dental plaque bacterial species. *Journal of clinical periodontology* 37(1): 24–9. Available at: <http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2900159&tool=pmcentrez&rendertype=abstract> (accessed 18/08/11).

Stenberg PE, McEver RP, Shuman MA, Jacques Y V and Bainton DF (1985) A platelet alpha-granule membrane protein (GMP-140) is expressed on the plasma membrane after activation. *Journal of Cell Biology* 101(3): 880–886. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/2411738> (accessed 17/10/18).

Strassel C, Gachet C and Lanza F (2018) On the way to in vitro platelet production. *Transfusion Clinique et Biologique. Frontiers Media SA*, 220–227. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/30211166> (accessed 17/12/18).

Suwannakul S, Stafford GP, Whawell SA, Douglas I, Douglas CWI and Douglas I (2010) Identification of bistable populations of *Porphyromonas gingivalis* that differ in epithelial cell invasion. *Microbiology. School of Clinical Dentistry, University of Sheffield: Microbiology Society* 156(1465–2080 (Electronic)): 3052–3064. Available at: pm:20576685 (accessed 06/08/18).

Svensson L, Baumgarten M, Mörgelin M and Shannon O (2014) Platelet activation by *Streptococcus pyogenes* leads to entrapment in platelet aggregates, from which bacteria subsequently escape. *Infection and Immunity*. American Society for Microbiology (ASM) 82(10): 4307–4314. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25069984> (accessed 26/03/18).

Tada H, Sugawara S, Nemoto E, Imamura T, Potempa J, Travis J, Shimauchi H and Takada H (2003) Proteolysis of ICAM-1 on Human Oral Epithelial Cells by Gingipains. *Journal of Dental Research* 82(10): 796–801. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/14514759> (accessed 22/11/18).

Takagi J, Petre BM, Walz T and Springer TA (2002) Global conformational arrangements in integrin extracellular domains in outside-in and inside-out signaling. *Cell*. Cell Press 110(5): 599–611. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/12230977> (accessed 05/12/18).

Takahashi Y, Davey M, Yumoto H, Gibson III FC and Genco CA (2006) Fimbria-dependent activation of pro-inflammatory molecules in *Porphyromonas gingivalis* infected human aortic endothelial cells. *Cellular Microbiology*. Blackwell Publishing Ltd 8(5): 738–757. Available at: <http://doi.wiley.com/10.1111/j.1462-5822.2005.00661.x> (accessed 08/09/16).

Tanner AC, Listgarten MA, Ebersole JL and Strzempko MN (1986) *Bacteroides forsythus* sp. nov., a slow-growing, Fusiform *Bacteroides* sp. from the human oral cavity. *Int. J. Syst. Bacteriol.* 36(Apr): 213–221. Available at: [www.microbiologyresearch.org](http://www.microbiologyresearch.org) (accessed 28/11/18).

Tao Y, Zhang X, Liang X, Zang J, Mo X and Li R (2016) Structural basis for the specific inhibition of glycoprotein Iba shedding by an inhibitory antibody. *Scientific Reports*. Nature Publishing Group 6(1): 24789. Available at: <http://www.nature.com/articles/srep24789> (accessed 13/09/18).

Tervahartiala T, Pirilä E, Ceponis A, Maisi P, Salo T, Tuter G, Kallio P, Törnwall J, Srinivas R, Konttinen YT and Sorsa T (2000) The in vivo expression of the collagenolytic matrix metalloproteinases (MMP-2, -8, -13, and -14) and matrilysin (MMP-7) in adult and localized juvenile periodontitis. *Journal of dental research* 79(12): 1969–77. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11201047> (accessed 06/09/16).

Thompson H, Homer KA, Rao S, Booth V and Hosie AHF (2009) An Orthologue of *Bacteroides fragilis* NanH Is the Principal Sialidase in *Tannerella forsythia*. *Journal of Bacteriology*. American Society for Microbiology 191(11): 3623–3628. Available at: <http://jb.asm.org/cgi/doi/10.1128/JB.01618-08> (accessed 06/09/16).

Thon JN and Italiano JE (2010) Platelet Formation. *Seminars in Hematology*. NIH Public Access 47(3): 220–226. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20620432> (accessed 01/12/18).

Thon JN and Italiano JE (2012) Platelets: Production, morphology and ultrastructure. *Handbook of Experimental Pharmacology* 210(210): 3–22. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22918725> (accessed 01/12/18).

Tokuda M, Chen W, Karunakaran T and Kuramitsu HK (1998) Regulation of protease expression in *Porphyromonas gingivalis*. *Infection and immunity* 66(11): 5232–7. Available at:

<http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=108653&tool=pmcentrez&rendertype=abstract> (accessed 25/04/12).

Tomaiuolo M, Brass LF and Stalker TJ (2017) Regulation of Platelet Activation and Coagulation and Its Role in Vascular Injury and Arterial Thrombosis. *Interventional cardiology clinics. NIH Public Access* 6(1): 1–12. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/27886814> (accessed 29/11/18).

Tomer A, Harker LA and Burstein SA (1988) Flow cytometric analysis of normal human megakaryocytes. *Blood* 71(5): 1244–52. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/3359043> (accessed 29/11/18).

Tribble GD, Mao S, James CE and Lamont RJ (2006) A *Porphyromonas gingivalis* haloacid dehalogenase family phosphatase interacts with human phosphoproteins and is important for invasion. *Proceedings of the National Academy of Sciences of the United States of America. National Academy of Sciences* 103(29): 11027–32. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16832066> (accessed 02/09/16).

Tu Y, Chen Y, Zheng C and Chen H (2016) Platelet aggregation promoted by biofilms of oral bacteria and the effect of mouth rinses in vitro. *The Journal of Infection in Developing Countries* 10(07): 1–8. Available at:

<http://www.jidc.org/index.php/journal/article/view/6639>.

Tynngård N, Wallstedt M, Södergren AL, Faxälv L and Ramström S (2015) Platelet adhesion changes during storage studied with a novel method using flow cytometry and protein-coated beads. *Platelets. Informa Healthcare* 26(2): 177–185. Available at: <http://www.tandfonline.com/doi/full/10.3109/09537104.2014.891728> (accessed 07/12/18).

Uehara A, Naito M, Imamura T, Potempa J, Travis J, Nakayama K and Takada H (2008) Dual regulation of interleukin-8 production in human oral epithelial cells upon stimulation with gingipains from *Porphyromonas gingivalis*. *Journal of Medical Microbiology* 57(4): 500–507. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/18349372> (accessed 22/11/18).

Ulevitch RJ and Tobias PS (1999) Recognition of Gram-negative bacteria and endotoxin by the innate immune system. *Current Opinion in Immunology. Elsevier Current Trends*, 19–22. Available at:

<https://www.sciencedirect.com/science/article/pii/S0952791599800041?via%3Dihub> (accessed 21/11/18).

Varki A (1994) Selectin ligands. *Proceedings of the National Academy of Sciences* 91(16): 7390–7397. Available at: <http://www.pnas.org/content/91/16/7390.short> (accessed 07/12/18).

van Velzen JF, Laros-van Gorkom BAP, Pop GAM and van Heerde WL (2012) Multicolor flow cytometry for evaluation of platelet surface antigens and activation markers. *Thrombosis research* 130(1): 92–8. Available at: <http://www.sciencedirect.com/science/article/pii/S0049384812000898> (accessed 5/01/16).

Vieira-de-Abreu A, Campbell RA, Weyrich AS and Zimmerman GA (2012) Platelets: Versatile effector cells in hemostasis, inflammation, and the immune continuum. *Seminars in Immunopathology*. Springer-Verlag, 5–30. Available at: <http://link.springer.com/10.1007/s00281-011-0286-4> (accessed 12/09/18).

Vigdahl RL, Marquis NR and Tavormina PA (1969) Platelet aggregation. II. Adenyl cyclase, prostaglandin E1, and calcium. *Biochemical and biophysical research communications* 37(3): 409–15. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/4310667> (accessed 02/07/18).

Vučetić D, Ilić V, Vojvodić D, Subota V, Todorović M and Balint B (2018) Flow cytometry analysis of platelet populations: usefulness for monitoring the storage lesion in pooled buffy-coat platelet concentrates. *Blood transfusion = Trasfusione del sangue* 16(1): 83–92. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/28166864> (accessed 17/09/18).

Wade WG (2013) The oral microbiome in health and disease. *Pharmacological research : the official journal of the Italian Pharmacological Society* 69(1): 137–43. Available at: <http://www.sciencedirect.com/science/article/pii/S1043661812002277> (accessed 12/04/15).

Wagner CL, Mascelli MA, Neblock DS, Weisman HF, Coller BS and Jordan RE (1996a) Analysis of GPIIb/IIIa receptor number by quantification of 7E3 binding to human platelets. *Blood* 88(3). Available at: <http://www.bloodjournal.org/content/88/3/907.short> (accessed 15/11/18).

Wagner CL, Mascelli MA, Neblock DS, Weisman HF, Coller BS and Jordan RE (1996b) Analysis of GPIIb/IIIa receptor number by quantification of 7E3 binding to human platelets. *Blood* 88(3). Available at: <http://www.ncbi.nlm.nih.gov/pubmed/8704248> (accessed 15/11/18).

Wallén NH, Ladjevardi M, Albert J and Bröijersén A (1997) Influence of Different Anticoagulants on Platelet Aggregation in Whole Blood; A Comparison between Citrate, Low Molecular Mass Heparin and Hirudin. *Thrombosis Research*. Pergamon 87(1): 151–157. Available at: [https://www.sciencedirect.com/science/article/pii/S004938489700114X?\\_rdoc=1&\\_fmt=high&\\_origin=gateway&\\_docanchor=&md5=b8429449ccfc9c30159a5f9aeaa92ffb](https://www.sciencedirect.com/science/article/pii/S004938489700114X?_rdoc=1&_fmt=high&_origin=gateway&_docanchor=&md5=b8429449ccfc9c30159a5f9aeaa92ffb) (accessed 21/02/18).

Ware JA, Johnson PC, Smith M and Salzman EW (1986) Effect of common agonists on cytoplasmic ionized calcium concentration in platelets. Measurements with 2-methyl-6-methoxy 8-nitroquinoline (quin2) and aequorin. *Journal of Clinical Investigation* 77(3): 878–886. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/3081576> (accessed 03/12/18).

Watanabe K, Yilmaz Ö, Nakhjiri SF, Belton CM and Lamont RJ (2001) Association of mitogen-activated protein kinase pathways with gingival epithelial cell responses to *Porphyromonas gingivalis* infection. *Infection and Immunity*. American Society for Microbiology (ASM) 69(11): 6731–6737. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11598045> (accessed 02/09/16).

Watson CN, Kerrigan SW, Cox D, Henderson IR, Watson SP and Arman M (2016) Human platelet activation by *Escherichia coli*: roles for FcγRIIA and integrin αIIbβ3. *Platelets*. Taylor & Francis 27(6): 535–540. Available at: <https://www.tandfonline.com/doi/full/10.3109/09537104.2016.1148129> (accessed 27/09/18).

Watson SP, Auger JM, McCarty OJT and Pearce AC (2005) GPVI and integrin αIIbβ3 signaling in platelets. *Journal of Thrombosis and Haemostasis*, 1752–1762. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16102042> (accessed 11/12/18).

Watson SP, Morgan N V and Harrison P (2015) *The Vascular Function of Platelets*. Postgraduate Haematology. Oxford, UK: John Wiley & Sons, Ltd, 699–714. Available at: <http://doi.wiley.com/10.1002/9781118853771.ch37> (accessed 04/12/18).

Watts A, Crimmins EM and Gatz M (2008) Inflammation as a potential mediator for the association between periodontal disease and Alzheimer's disease. *Neuropsychiatric disease and treatment*. Dove Press 4(5): 865–76. Available at: <http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2626915&tool=pmcentrez&rendertype=abstract> (accessed 03/12/14).

Wegner N, Wait R, Sroka A, Eick S, Nguyen KA, Lundberg K, Kinloch A, Culshaw S, Potempa J and Venables PJ (2010) Peptidylarginine deiminase from *Porphyromonas gingivalis* citrullinates human fibrinogen and α-enolase: Implications for autoimmunity in rheumatoid Arthritis. *Arthritis and Rheumatism*. NIH Public Access 62(9): 2662–2672. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20506214> (accessed 06/09/16).

Weinberg A, Belton CM, Park Y and Lamont RJ (1997) Role of fimbriae in *Porphyromonas gingivalis* invasion of gingival epithelial cells. *Infection and immunity* 65(1): 313–6. Available at: <http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=174594&tool=pmcentrez&rendertype=abstract> (accessed 01/05/12).

Weyrich AS, Dixon DA, Pabla R, Elstad MR, McIntyre TM, Prescott SM and Zimmerman GA (1998) Signal-dependent translation of a regulatory protein, Bcl-3, in activated human platelets. *Proceedings of the National Academy of Sciences* 95(10): 5556–5561. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/9576921> (accessed 12/09/18).

White JG (1972) Interaction of membrane systems in blood platelets. *The American journal of pathology* 66(2): 295–312. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/5009975> (accessed 03/12/18).

White JG and Krumwiede M (1987) Further studies of the secretory pathway in thrombin-stimulated human platelets. *Blood* 69(4): 1196–203. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/3103715> (accessed 01/12/18).

WHO (2018) WHO | Cardiovascular diseases (CVDs). WHO. World Health Organization. Available at: [https://www.who.int/cardiovascular\\_diseases/en/](https://www.who.int/cardiovascular_diseases/en/) (accessed 16/12/18).

Wiles M V and Keller G (1991) Multiple hematopoietic lineages develop from embryonic stem (ES) cells in culture. *Development* (Cambridge, England). The Company of Biologists Ltd 111(2): 259–267. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/1893864> (accessed 30/01/18).

Wilson M and Henderson B (1995) Virulence factors of *Actinobacillus actinomycetemcomitans* relevant to the pathogenesis of inflammatory periodontal diseases. *FEMS microbiology reviews* 17(4): 365–79. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/8845187> (accessed 16/02/16).

Winkelhoff AJ, Velden U, Winkel EG and Graaff J (1986) Black-pigmented *Bacteroides* and motile organisms on oral mucosal surfaces in individuals with and without periodontal breakdown. *Journal of Periodontal Research*. Blackwell Publishing Ltd 21(4): 434–439. Available at: <http://doi.wiley.com/10.1111/j.1600-0765.1986.tb01477.x> (accessed 03/10/16).

Xia T, Takagi J, Coller BS, Wang JH and Springer TA (2004) Structural basis for allostery in integrins and binding to fibrinogen-mimetic therapeutics. *Nature*, 59–67. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15378069> (accessed 04/12/18).

Xiong J-P, Stehle T, Diefenbach B, Zhang R, Dunker R, Scott DL, Joachimiak A, Goodman SL and Arnaout MA (2001) Crystal Structure of the Extracellular Segment of Integrin alpha Vbeta 3. *Science* 294(5541): 339–345. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11546839> (accessed 04/12/18).

Xu X, He J, Xue J, Wang Y, Li K, Zhang K, Guo Q, Liu X, Zhou Y, Cheng L, Li M, Li Y, Li Y, Shi W and Zhou X (2015) Oral cavity contains distinct niches with dynamic microbial communities. *Environmental Microbiology* 17(3): 699–710. Available at: <http://doi.wiley.com/10.1111/1462-2920.12502> (accessed 02/10/16).

Yang M, Khachigian LM, Hicks C, Chesterman CN and Chong BH (1997) Identification of PDGF receptors on human megakaryocytes and megakaryocytic cell lines. *Thrombosis and haemostasis* 78(2): 892–6. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/9268191> (accessed 05/10/16).

Yang X, Pan Y, Xu X, Tong T, Yu S, Zhao Y, Lin L, Liu J, Zhang D and Li C (2018) Sialidase Deficiency in *Porphyromonas gingivalis* Increases IL-12 Secretion in Stimulated Macrophages Through Regulation of CR3, lncRNA GAS5 and miR-21. *Frontiers in cellular and infection microbiology*. *Frontiers Media SA* 8: 100. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/29675399> (accessed 24/08/18).

Yeaman MR (1997) The role of platelets in antimicrobial host defense. *Clinical infectious diseases: an official publication of the Infectious Diseases Society of America* 25(5): 951-68; quiz 969-70. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/9402338> (accessed 09/09/16).

Yeaman MR (2010a) Bacterial-platelet interactions: virulence meets host defense. *Future microbiology* 5(3): 471–506. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20210555> (accessed 09/09/16).

Yeaman MR (2010b) Platelets in defense against bacterial pathogens. *Cellular and molecular life sciences: CMLS*. Springer 67(4): 525–44. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20013024> (accessed 31/10/12).

Yilmaz O, Watanabe K and Lamont RJ (2002) Involvement of integrins in fimbriae-mediated binding and invasion by *Porphyromonas gingivalis*. *Cell Microbiol*. Department of Oral Biology, University of Washington, Seattle, WA 98195, USA. [ozlem@u.washington.edu](mailto:ozlem@u.washington.edu): Wiley/Blackwell (10.1111) 4(1462–5814 (Print)): 305–314. Available at: pm:12027958 (accessed 17/09/18).

Yilmaz O, Yao L, Maeda K, Rose TM, Lewis EL, Duman M, Lamont RJ and Ojcius DM (2008) ATP scavenging by the intracellular pathogen *Porphyromonas gingivalis* inhibits P2X7-mediated host-cell apoptosis. *Cellular microbiology*. NIH Public Access 10(4): 863–75. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18005240> (accessed 02/09/16).

Yilmaz Ö, Young PA, Lamont RJ, Kenny GE, Yilmaz O, Young PA, Lamont RJ and Kenny GE (2003) Gingival epithelial cell signalling and cytoskeletal responses to *Porphyromonas gingivalis* invasion. *Microbiology*. Microbiology Society 149(9): 2417–2426. Available at: <http://mic.microbiologyresearch.org/content/journal/micro/10.1099/mic.0.26483-0> (accessed 27/04/12).

Yoshimura F, Takahashi K, Nodasaka Y and Suzuki T (1984) Purification and characterization of a novel type of fimbriae from the oral anaerobe *Bacteroides gingivalis*. *Journal of Bacteriology* 160(3): 949–957. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/6150029> (accessed 27/11/18).

Yu K, Inoue Y, Umeda M, Terasaki H, Chen Z and Iwai T (2011) The periodontal anaerobe *Porphyromonas gingivalis* induced platelet activation and increased aggregation in whole blood by rat model. *Thrombosis Research* 127(5): 418–425. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21334044> (accessed 13/09/18).

Yun PLW, Decarlo AA, Chapple CC and Hunter N (2005) Functional implication of the hydrolysis of platelet endothelial cell adhesion molecule 1 (CD31) by gingipains of *Porphyromonas gingivalis* for the pathology of periodontal disease. *Infection and immunity* 73(3): 1386–98. Available at: <http://iai.asm.org/content/73/3/1386> (accessed 18/01/16).

Zhang G, Han J, Welch EJ, Ye RD, Voyno-Yasenetskaya TA, Malik AB, Du X and Li Z (2009) Lipopolysaccharide stimulates platelet secretion and potentiates platelet aggregation via TLR4/MyD88 and the cGMP-dependent protein kinase pathway. *Journal of immunology* (Baltimore, Md. : 1950). NIH Public Access 182(12): 7997–8004. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19494325> (accessed 08/09/16).

Zhang W, Swearingen EB, Ju J, Rigney T and Tribble GD (2010) *Porphyromonas gingivalis* invades osteoblasts and inhibits bone formation. *Microbes and Infection*. Elsevier Masson 12(11): 838–845. Available at: <https://www.sciencedirect.com/science/article/pii/S1286457910001486?via%3Dihub> (accessed 16/11/18).

Zielinski T, Wachowicz B, Saluk-Juszczak J and Kaca W (2001) The Generation of Superoxide Anion in Blood Platelets in Response to Different Forms of *Proteus mirabilis* Lipopolysaccharide: Effects of Staurosporin, Wortmannin, and Indomethacin. *Thrombosis Research*.

Zilberman-Rudenko J, Sylman JL, Garland KS, Puy C, Wong AD, Searson PC and McCarty OJT (2017) Utility of microfluidic devices to study the platelet–endothelium interface. *Platelets*. Taylor & Francis, 449–456. Available at: <https://www.tandfonline.com/doi/full/10.1080/09537104.2017.1280600> (accessed 17/12/18).

Zola H (2007) *Leukocyte and Stromal Cell Molecules: The CD Markers*. . Available at: <https://books.google.co.uk/books?hl=en&lr=&id=GNENdc2brRkC&oi=fnd&pg=PR7&dq=Zola+H,+et+al.+2007.+Leukocyte+and+Stromal+Cell+Molecules:+The+CD+Markers.&ots=OVMS1PcgnB&sig=FP6J4bpEEqgWXnHCMC-rmsqsBUs> (accessed 07/12/18).

Zucker-Franklin D (1981) Endocytosis by human platelets: Metabolic and freeze-fracture studies. *Journal of Cell Biology* 91(3 I): 706–715. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/7328117> (accessed 01/12/18).

Zucker MB and Nachmias VT (1985) Platelet Activation. *Arteriosclerosis* (February 1985): 2–18.

# Ethical approval

**Sheffield  
Hallam  
University** | Biomedical  
Research  
Centre

**Biomedical Research Centre  
Faculty of Health and Wellbeing  
Sheffield Hallam University**  
City Campus  
Howard Street  
Sheffield S1 1WB

T +44 (0)114 225 5555  
D +44 (0) 114 225 2934 / 3294  
F +44 (0)114 225 3064  
E-mail [bmrc@shu.ac.uk](mailto:bmrc@shu.ac.uk)  
[www.shu.ac.uk/bmrc](http://www.shu.ac.uk/bmrc)  
Head of Research Centre:  
**Professor Nicola Woodroffe**

21<sup>st</sup> May 2015

Dr P Stafford  
Biomedical Research Centre  
Sheffield Hallam University  
City Campus  
Sheffield S1 1WB

Dear Dr Stafford

**Ethics Application No. HWB-BIO-03**

Thank you second version of your project entitled: Oral pathogens and cardiovascular disease: can oral pathogens contribute to cardiovascular disease by altering platelet behaviour and function. Following re-review we are delighted to give you ethics permission to undertake the project.

Yours sincerely



 Dr N Jordan-Mahy  
Chair of the Bioscience and Chemistry Ethics Committee



## Copyright licences

License Number	4486380241929
License date	Dec 12, 2018
Licensed Content Publisher	Springer Nature
Licensed Content Publication	Nature Reviews Immunology
Licensed Content Title	Periodontitis: from microbial immune subversion to systemic inflammation
Licensed Content Author	George Hajishengallis
Licensed Content Date	Dec 23, 2014
Licensed Content Volume	15
Licensed Content Issue	1
Type of Use	Thesis/Dissertation
Requestor type	academic/university or research institute
Format	electronic
Portion	figures/tables/illustrations
Number of figures/tables/illustrations	1
High-res required	no
Will you be translating?	no
Circulation/distribution	<501
Author of this Springer Nature content	no
Title	Effects of the Periodontal Pathogens Porphyromonas gingivalis and Tannerella forsythia on Platelets
Institution name	Sheffield Hallam University
Expected presentation date	Dec 2018
Portions	Figure 1.3
Requestor Location	Sheffield Hallam University Howard Street Sheffield, S11WB United Kingdom
Billing Type	Invoice
Billing address	Sheffield Hallam University Howard Street Sheffield, United Kingdom S11WB
License Number	4486381492372

License date	Dec 12, 2018
Licensed Content Publisher	Wolters Kluwer Health, Inc.
Licensed Content Publication	Circulation Research
Licensed Content Title	Integrin $\alpha$ IIb $\beta$ 3
Licensed Content Author	Kamila Bledzka, Susan S. Smyth, Edward F. Plow
Licensed Content Date	Apr 12, 2013
Licensed Content Volume	112
Licensed Content Issue	8
Type of Use	Dissertation/Thesis
Requestor type	Individual
Portion	Figures/table/illustration
Number of figures/tables/illustrations	1
Figures/tables/illustrations used	Figure
Author of this Wolters Kluwer article	No
Title of your thesis / dissertation	Effects of the Periodontal Pathogens Porphyromonas gingivalis and Tannerella forsythia on Platelets
Expected completion date	Dec 2018
Estimated size(pages)	1
Requestor Location	Sheffield Hallam University Howard Street Sheffield, S11WB United Kingdom
Publisher Tax ID	EU826013006
Billing Type	Invoice
Billing address	Sheffield Hallam University Howard Street Sheffield, United Kingdom S11WB